
    
<!DOCTYPE html>




<html lang="en" >
<head >
    <meta charset="UTF-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">

    <!-- Mobile properties -->
    <meta name="HandheldFriendly" content="True">
    <meta name="MobileOptimized" content="320">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">

  
    <!-- Stylesheets -->
    <link rel="stylesheet" href="/pmc/static/CACHE/css/output.cc84172e9e16.css" type="text/css">
  
  <link rel="stylesheet" href="/pmc/static/CACHE/css/output.b634933a977d.css" type="text/css"><link rel="stylesheet" href="/pmc/static/CACHE/css/output.913c7dcab8ff.css" type="text/css"><link rel="stylesheet" href="/pmc/static/CACHE/css/output.3766d7ad0d2d.css" type="text/css"><link rel="stylesheet" href="/pmc/static/CACHE/css/output.e3c3c2c84eb3.css" type="text/css">

  
    <link rel="stylesheet" href="https://maxcdn.bootstrapcdn.com/font-awesome/4.7.0/css/font-awesome.min.css"/>
  
<link type="text/css" href="/pmc/static/bundles/base/base.a2ef7ca69e4b20dff539.css" rel="stylesheet" />


    <link rel="stylesheet" href="/corehtml/pmc/css/fonts/stix/stixfonts.css" type="text/css" /><link rel="stylesheet" href="/corehtml/pmc/css/3.18/pmcrefs1.min.css" type="text/css" /><link rel="stylesheet" href="/corehtml/pmc/css/pmc2020_1.1/ncbi_web.min.css?_=a" type="text/css" /><style type="text/css">.pmc-wm {background:transparent repeat-y top left;background-image:url(/corehtml/pmc/pmcgifs/wm-journal.gif);background-size: auto, contain}</style><style type="text/css">.print-view{display:block}</style>

    <link type="text/css" href="/pmc/static/bundles/article/article.3c5d12ff2e4beea20136.css" rel="stylesheet" />
    <link type="text/css" href="/pmc/static/django_pmc_cite_box/lib/cite-box.css" rel="stylesheet" />


    <title>Soluble form of the MDA5 protein in human sera - PMC</title>

  
  <!-- Favicons -->
  <link rel="shortcut icon" type="image/ico" href="https://www.ncbi.nlm.nih.gov/coreutils/nwds/img/favicons/favicon.ico" />
  <link rel="icon" type="image/png" href="https://www.ncbi.nlm.nih.gov/coreutils/nwds/img/favicons/favicon.png" />

  <!-- 192x192, as recommended for Android
  http://updates.html5rocks.com/2014/11/Support-for-theme-color-in-Chrome-39-for-Android
  -->
  <link rel="icon" type="image/png" sizes="192x192" href="https://www.ncbi.nlm.nih.gov/coreutils/nwds/img/favicons/favicon-192.png" />

  <!-- 57x57 (precomposed) for iPhone 3GS, pre-2011 iPod Touch and older Android devices -->
  <link rel="apple-touch-icon-precomposed" href="https://www.ncbi.nlm.nih.gov/coreutils/nwds/img/favicons/favicon-57.png">
  <!-- 72x72 (precomposed) for 1st generation iPad, iPad 2 and iPad mini -->
  <link rel="apple-touch-icon-precomposed" sizes="72x72" href="https://www.ncbi.nlm.nih.gov/coreutils/nwds/img/favicons/favicon-72.png">
  <!-- 114x114 (precomposed) for iPhone 4, 4S, 5 and post-2011 iPod Touch -->
  <link rel="apple-touch-icon-precomposed" sizes="114x114" href="https://www.ncbi.nlm.nih.gov/coreutils/nwds/img/favicons/favicon-114.png">
  <!-- 144x144 (precomposed) for iPad 3rd and 4th generation -->
  <link rel="apple-touch-icon-precomposed" sizes="144x144" href="https://www.ncbi.nlm.nih.gov/coreutils/nwds/img/favicons/favicon-144.png">



    
        <!-- Logging params: Pinger defaults -->

<meta name="ncbi_app" content="pmc-frontend" />

<meta name="ncbi_db" content="pmc" />

<meta name="ncbi_phid" content="D0BD41E4AC192A4500004E82341CB980.1.m_2" />


        <!-- Logging params: Pinger custom -->

<meta name="ncbi_pdid" content="article" />

<meta name="ncbi_op" content="retrieved" />

<meta name="ncbi_app_version" content="0.0" />

<meta name="ncbi_domain" content="heliyon" />

<meta name="ncbi_type" content="fulltext" />

<meta name="ncbi_pcid" content="/articles/PMC11153190/" />


    


    <script>
        
            var ncbiBaseUrl = "https://www.ncbi.nlm.nih.gov";
        
        var useOfficialGovtHeader = true;
    </script>


    <meta name="robots" content="INDEX,NOFOLLOW,NOARCHIVE" /><link rel="canonical" href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11153190/" /><link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /><meta name="citation_journal_title" content="Heliyon" /><meta name="citation_title" content="Soluble form of the MDA5 protein in human sera" /><meta name="citation_author" content="Masaki Okamoto" /><meta name="citation_author_institution" content="Division of Respirology, Neurology, and Rheumatology, Department of Medicine, Kurume University School of Medicine, 67 Asahi-machi, Kurume, Fukuoka, 830-0011, Japan" /><meta name="citation_author" content="Yoshiaki Zaizen" /><meta name="citation_author_institution" content="Division of Respirology, Neurology, and Rheumatology, Department of Medicine, Kurume University School of Medicine, 67 Asahi-machi, Kurume, Fukuoka, 830-0011, Japan" /><meta name="citation_author" content="Shinjiro Kaieda" /><meta name="citation_author_institution" content="Division of Respirology, Neurology, and Rheumatology, Department of Medicine, Kurume University School of Medicine, 67 Asahi-machi, Kurume, Fukuoka, 830-0011, Japan" /><meta name="citation_author" content="Takashi Nouno" /><meta name="citation_author_institution" content="Division of Respirology, Neurology, and Rheumatology, Department of Medicine, Kurume University School of Medicine, 67 Asahi-machi, Kurume, Fukuoka, 830-0011, Japan" /><meta name="citation_author" content="Takuma Koga" /><meta name="citation_author_institution" content="Division of Respirology, Neurology, and Rheumatology, Department of Medicine, Kurume University School of Medicine, 67 Asahi-machi, Kurume, Fukuoka, 830-0011, Japan" /><meta name="citation_author" content="Goushi Matama" /><meta name="citation_author_institution" content="Division of Respirology, Neurology, and Rheumatology, Department of Medicine, Kurume University School of Medicine, 67 Asahi-machi, Kurume, Fukuoka, 830-0011, Japan" /><meta name="citation_author" content="Masahiro Mitsuoka" /><meta name="citation_author_institution" content="Department of Surgery, Kurume University School of Medicine, 67 Asahi-machi, Kurume, Fukuoka, 830-0011, Japan" /><meta name="citation_author" content="Jun Akiba" /><meta name="citation_author_institution" content="Department of Pathology, Kurume University School of Medicine, 67 Asahi-machi, Kurume, Fukuoka, 830-0011, Japan" /><meta name="citation_author" content="Shintaro Yamada" /><meta name="citation_author_institution" content="Institute of Cardiovascular Immunology, University Hospital Bonn, University of Bonn, Venusberg-Campus 1, 53127, Bonn, Germany" /><meta name="citation_author" content="Hiroki Kato" /><meta name="citation_author_institution" content="Institute of Cardiovascular Immunology, University Hospital Bonn, University of Bonn, Venusberg-Campus 1, 53127, Bonn, Germany" /><meta name="citation_author" content="Tomoaki Hoshino" /><meta name="citation_author_institution" content="Division of Respirology, Neurology, and Rheumatology, Department of Medicine, Kurume University School of Medicine, 67 Asahi-machi, Kurume, Fukuoka, 830-0011, Japan" /><meta name="citation_author_institution" content="National Cancer Institute (NCI) &#x02013; Frederick, 1050 Boyles St, Frederick, MD, 21702, USA" /><meta name="citation_publication_date" content="2024/06/06" /><meta name="citation_issue" content="11" /><meta name="citation_volume" content="10" /><meta name="citation_doi" content="10.1016/j.heliyon.2024.e31727" /><meta name="citation_abstract_html_url" content="/pmc/articles/PMC11153190/?report=abstract" /><meta name="citation_fulltext_html_url" content="/pmc/articles/PMC11153190/" /><meta name="citation_pmid" content="38845920" /><meta name="DC.Title" content="Soluble form of the MDA5 protein in human sera" /><meta name="DC.Type" content="Text" /><meta name="DC.Publisher" content="Elsevier" /><meta name="DC.Contributor" content="Masaki Okamoto" /><meta name="DC.Contributor" content="Yoshiaki Zaizen" /><meta name="DC.Contributor" content="Shinjiro Kaieda" /><meta name="DC.Contributor" content="Takashi Nouno" /><meta name="DC.Contributor" content="Takuma Koga" /><meta name="DC.Contributor" content="Goushi Matama" /><meta name="DC.Contributor" content="Masahiro Mitsuoka" /><meta name="DC.Contributor" content="Jun Akiba" /><meta name="DC.Contributor" content="Shintaro Yamada" /><meta name="DC.Contributor" content="Hiroki Kato" /><meta name="DC.Contributor" content="Tomoaki Hoshino" /><meta name="DC.Date" content="2024 Jun 15" /><meta name="DC.Identifier" content="10.1016/j.heliyon.2024.e31727" /><meta name="DC.Language" content="en" /><meta property="og:title" content="Soluble form of the MDA5 protein in human sera" /><meta property="og:type" content="article" /><meta property="og:description" content="Viral double-stranded RNA (dsRNA) is sensed by toll-like receptor 3 (TLR3) and retinoic acid-inducible gene I (RIG-I)-like receptors (RLRs), including melanoma differentiation-associated gene 5 (MDA5). MDA5 recognizes the genome of dsRNA viruses and replication ..." /><meta property="og:url" content="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11153190/" /><meta property="og:site_name" content="PubMed Central (PMC)" /><meta property="og:image" content="https://www.ncbi.nlm.nih.gov/corehtml/pmc/pmcgifs/pmc-card-share.jpg?_=0" /><meta name="twitter:card" content="summary_large_image" /><meta name="twitter:site" content="@ncbi" /><meta name="ncbi_feature" content="associated_data" />


</head>
<body >

   
    
        <button
          class="back-to-top back-to-top--bottom"
          data-ga-category="pagination"
          data-ga-action="back_to_top">
          Back to Top
        </button>
    

    <a class="usa-skipnav" href="#main-content">Skip to main content</a>
    <!-- ========== BEGIN HEADER ========== -->
<section class="usa-banner" style="display: none;">
  <div class="usa-accordion">
    <header class="usa-banner-header">
      <div class="usa-grid usa-banner-inner">
        <img src="https://www.ncbi.nlm.nih.gov/coreutils/uswds/img/favicons/favicon-57.png" alt="U.S. flag" />
        <p>An official website of the United States government</p>
        <button
          class="usa-accordion-button usa-banner-button"
          aria-expanded="false"
          aria-controls="gov-banner-top"
        >
          <span class="usa-banner-button-text">Here's how you know</span>
        </button>
      </div>
    </header>
    <div
      class="usa-banner-content usa-grid usa-accordion-content"
      id="gov-banner-top"
    >
      <div class="usa-banner-guidance-gov usa-width-one-half">
        <img
          class="usa-banner-icon usa-media_block-img"
          src="https://www.ncbi.nlm.nih.gov/coreutils/uswds/img/icon-dot-gov.svg"
          alt="Dot gov"
        />
        <div class="usa-media_block-body">
          <p>
            <strong>The .gov means it’s official.</strong>
            <br />
            Federal government websites often end in .gov or .mil. Before
            sharing sensitive information, make sure you’re on a federal
            government site.
          </p>
        </div>
      </div>
      <div class="usa-banner-guidance-ssl usa-width-one-half">
        <img
          class="usa-banner-icon usa-media_block-img"
          src="https://www.ncbi.nlm.nih.gov/coreutils/uswds/img/icon-https.svg"
          alt="Https"
        />
        <div class="usa-media_block-body">
          <p>
            <strong>The site is secure.</strong>
            <br />
            The <strong>https://</strong> ensures that you are connecting to the
            official website and that any information you provide is encrypted
            and transmitted securely.
          </p>
        </div>
      </div>
    </div>
  </div>
</section>
<div class="usa-overlay"></div>
<header class="ncbi-header" role="banner" data-section="Header">

	<div class="usa-grid">
		<div class="usa-width-one-whole">

            <div class="ncbi-header__logo">
                <a href="https://www.ncbi.nlm.nih.gov/" class="logo" aria-label="NCBI Logo" data-ga-action="click_image" data-ga-label="NIH NLM Logo">
                  <img src="https://www.ncbi.nlm.nih.gov/coreutils/nwds/img/logos/AgencyLogo.svg" alt="NIH NLM Logo" />
                </a>
            </div>

			<div class="ncbi-header__account">
				<a id="account_login" href="https://account.ncbi.nlm.nih.gov" class="usa-button header-button" style="display:none" data-ga-action="open_menu" data-ga-label="account_menu">Log in</a>
				<button id="account_info" class="header-button" style="display:none"
						aria-controls="account_popup">
					<span class="fa fa-user" aria-hidden="true"></span>
					<span class="username desktop-only" aria-hidden="true" id="uname_short"></span>
					<span class="sr-only">Show account info</span>
				</button>
			</div>

			<div class="ncbi-popup-anchor">
				<div class="ncbi-popup account-popup" id="account_popup" aria-hidden="true">
					<div class="ncbi-popup-head">
						<button class="ncbi-close-button" data-ga-action="close_menu" data-ga-label="account_menu"><span class="fa fa-times"></span><span class="usa-sr-only">Close</span></button>
						<h4>Account</h4>
					</div>
					<div class="account-user-info">
						Logged in as:<br/>
						<b><span class="username" id="uname_long">username</span></b>
					</div>
					<div class="account-links">
						<ul class="usa-unstyled-list">
							<li><a id="account_myncbi" href="/myncbi/" class="set-base-url" data-ga-action="click_menu_item" data-ga-label="account_myncbi">Dashboard</a></li>
							<li><a id="account_pubs" href="/myncbi/collections/bibliography/" class="set-base-url" data-ga-action="click_menu_item" data-ga-label="account_pubs">Publications</a></li>
							<li><a id="account_settings" href="/account/settings/" class="set-base-url" data-ga-action="click_menu_item" data-ga-label="account_settings">Account settings</a></li>
							<li><a id="account_logout" href="/account/signout/" class="set-base-url" data-ga-action="click_menu_item" data-ga-label="account_logout">Log out</a></li>
						</ul>
					</div>
				</div>
			</div>

		</div>
	</div>
</header>
<div role="navigation" aria-label="access keys">
<a id="nws_header_accesskey_0" href="https://www.ncbi.nlm.nih.gov/guide/browsers/#ncbi_accesskeys" class="usa-sr-only" accesskey="0" tabindex="-1">Access keys</a>
<a id="nws_header_accesskey_1" href="https://www.ncbi.nlm.nih.gov" class="usa-sr-only" accesskey="1" tabindex="-1">NCBI Homepage</a>
<a id="nws_header_accesskey_2" href="/myncbi/" class="set-base-url usa-sr-only" accesskey="2" tabindex="-1">MyNCBI Homepage</a>
<a id="nws_header_accesskey_3" href="#maincontent" class="usa-sr-only" accesskey="3" tabindex="-1">Main Content</a>
<a id="nws_header_accesskey_4" href="#" class="usa-sr-only" accesskey="4" tabindex="-1">Main Navigation</a>
</div>
<section data-section="Alerts">
	<div class="ncbi-alerts-placeholder"></div>
</section>
<!-- ========== END HEADER ========== -->

    
    


    
        

<section class="pmc-alerts">
    
    <div role="alert" class="pmc-alert pmc-alert--info" role="region" aria-label="Alert" aria-hidden="false"  data-key="pmc-alert-welcome">
        <div class="pmc-alert__body pmc-alert--ncbi-icon">
            <div class="pmc-alert__content">
                <p>
                    <strong>
                        Preview improvements coming to the PMC website in October 2024.
                        <a href="https://ncbiinsights.ncbi.nlm.nih.gov/2024/03/14/preview-pmc-improvements/" data-ga-category="cloud_beta_banner" data-ga-label="learn_more" data-ga-action="on_pmc2020">Learn More</a> or
                        <a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC11153190/" data-ga-category="cloud_beta_banner" data-ga-action="on_pmc2020" data-ga-label="go_to_cloud">Try it out now</a>.
                    </strong>
                </p>
            </div>
        </div>
    </div>
    
</section>
    

    
    
        
        <header class="pmc-header usa-header-extended" role="banner">
    <div class="pmc-header__bar">
        <div class="pmc-header__control usa-accordion">
            
                <button class="usa-menu-btn pmc-header--button pmc-header--left">
                    <i class="fa fa-ellipsis-v" aria-hidden="true"></i>
                </button>
            

            <div class="usa-logo pmc-header__logo pmc-header--stretch
                
               " id="extended-mega-logo">
                <div class="usa-logo-text">
                    <a href="/pmc/" title="Home" aria-label="Home" ></a>
                </div>
            </div>
            <button class="usa-accordion-button pmc-header--right pmc-header--button pmc-header__search--control pmc-header--right" aria-expanded="false" aria-controls="a1">
                <i class="fa fa-search" aria-hidden="true"></i>
                <i class="fa fa-times" aria-hidden="true"></i>
            </button>
        </div>
        <div class="pmc-header__search usa-accordion-content" id="a1">
            <div role="search"  class="pmc-header--stretch"  >
    <form class="usa-search " autocomplete="off">
        <div>
              <label class="usa-sr-only" for="pmc-search">Search PMC Full-Text Archive</label>
              <span class="clearable">
                <input
                  required="required"
                  autocomplete-url="/pmc/autocomplete/pmc/"
                  placeholder="Search PMC Full-Text Archive"
                  id="pmc-search" type="search" name="term"/>
                  <i class="clear-btn" ></i>
              </span>
              <button type="submit" formaction="/pmc/">
                <span class="usa-search-submit-text">Search in PMC</span>
              </button>
        </div>
    </form>
</div>


            <ul class="usa-unstyled-list usa-nav-secondary-links pmc-header--offset-two">
                    <li>
                        <a href="https://www.ncbi.nlm.nih.gov/pmc/advanced" data-ga-action="featured_link" data-ga-label="advanced_search">
                            Advanced Search
                        </a>
                    </li>
                    <li>
                        <a  href="/pmc/about/userguide/" data-ga-action="featured_link"
                        data-ga-label="user guide">
                            User Guide
                        </a>
                    </li>
            </ul>
        </div>
    </div>
     <nav role="navigation" class="usa-nav ">
        <button class="usa-nav-close">
            <i class="fa fa-times" aria-hidden="true"></i>
        </button>
        <div class="usa-breadcrumb usa-breadcrumb--wrap usa-breadcrumb--hack">
             
    <ul class="usa-breadcrumb__list">
            
                <li class="usa-breadcrumb__list-item"
                    >
                    <a href="/pmc/journals/" class="navlink">Journal List</a>
                </li>
            
                <li class="usa-breadcrumb__list-item"
                    >
                    <a class="navlink" href="/pmc/journals/2992/">Heliyon</a>
                </li>
            
                <li class="usa-breadcrumb__list-item"
                    >
                    <a class="navlink" href="/pmc/issues/463821/">v.10(11); 2024 Jun 15</a>
                </li>
            
                <li class="usa-breadcrumb__list-item"
                     aria-current="page" >
                    PMC11153190
                </li>
            
    </ul>
 

        </div>
        
        
            <div class="pmc-sidebar pmc-sidebar-hack">
                

<div class="scroller">

    
        <section>
                <h6>Other Formats</h6>
                <ul class="pmc-sidebar__formats">
                  <li class="pdf-link other_item"><a href="/pmc/articles/PMC11153190/pdf/main.pdf" class="int-view">PDF (2.4M)</a></li>
                </ul>
        </section>
    
    <section>
        <h6>Actions</h6>
        <ul class="pmc-sidebar__actions">
            <li>
                <button role="button" class="citation-button citation-dialog-trigger ctxp"
                        aria-label="Open dialog with citation text in different styles" data-ga-category="save_share" data-ga-action="cite" data-ga-label="open"
                        data-all-citations-url="/pmc/resources/citations/11153190/"
                        data-citation-style="nlm"
                        data-download-format-link="/pmc/resources/citations/11153190/export/"
                >
                    <span class="button-label">Cite</span>
                </button>
            </li>
            <li>
                
                    

<link type="text/css" href="ncbi-overlay-block/src/overlay-block.css">
<div class="collections-button-container" data-article-id="11153190" data-article-db="pmc">
  <button class="collections-button collections-dialog-trigger"
          aria-label="Save article in MyNCBI collections."
          data-ga-category="collections_button"
          data-ga-action="click"
          data-ga-label="collections_button"
          data-collections-open-dialog-enabled="false"
          data-collections-open-dialog-url="https://www.ncbi.nlm.nih.gov/account?back_url=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC11153190%2F%23open-collections-dialog"
          data-in-collections="false">
      <span class="button-label">Collections</span>
  </button>
  <div class="overlay" role="dialog">
  <div id="collections-action-dialog"
       class="dialog collections-dialog"
       aria-hidden="true">
    <div class="title">Add to Collections</div>
    <div class="collections-action-panel action-panel">
      


<form id="collections-action-dialog-form"
      class="collections-action-panel-form action-panel-content action-form action-panel-smaller-selectors"
      data-existing-collections-url="/pmc/list-existing-collections/"
      data-add-to-existing-collection-url="/pmc/add-to-existing-collection/"
      data-create-and-add-to-new-collection-url="/pmc/create-and-add-to-new-collection/"
      data-myncbi-max-collection-name-length="100"
      data-collections-root-url="https://www.ncbi.nlm.nih.gov/myncbi/collections/">

  <input type="hidden" name="csrfmiddlewaretoken" value="Laczk6AT4j30cAiQ07AQK7KgStPTVzUHWkgtA8DZWPNUBOJn4IZi9UvdKwpf3sXw">

  

  <div class="choice-group" role="radiogroup">
    <ul class="radio-group-items">
      <li>
        <input type="radio"
               id="collections-action-dialog-new-header "
               class="collections-new"
               name="collections"
               value="new"
               data-ga-category="collections_button"
               data-ga-action="click"
               data-ga-label="collections_radio_new">
        <label for="collections-action-dialog-new-header ">Create a new collection</label>
      </li>
      <li>
        <input type="radio"
               id="collections-action-dialog-existing-header "
               class="collections-existing"
               name="collections"
               value="existing"
               checked="true"
               data-ga-category="collections_button"
               data-ga-action="click"
               data-ga-label="collections_radio_existing">
        <label for="collections-action-dialog-existing-header ">Add to an existing collection</label>
      </li>
    </ul>
  </div>

  <div class="controls-wrapper">
    <div class="action-panel-control-wrap new-collections-controls">
      <label for="collections-action-dialog-add-to-new" class="action-panel-label required-field-asterisk">
        Name your collection:
      </label>
      <input
        type="text"
        name="add-to-new-collection"
        id="collections-action-dialog-add-to-new"
        class="collections-action-add-to-new"
        pattern="[^&quot;&amp;=&lt;&gt;/]*" title="The following characters are not allowed in the Name field: &quot;&amp;=&lt;&gt;/"
        maxlength=""
        data-ga-category="collections_button"
        data-ga-action="create_collection"
        data-ga-label="non_favorties_collection">
      <div class="collections-new-name-too-long usa-input-error-message selection-validation-message">
        Name must be less than  characters
      </div>
    </div>
    <div class="action-panel-control-wrap existing-collections-controls">
      <label for="collections-action-dialog-add-to-existing" class="action-panel-label">
        Choose a collection:
      </label>
      <select id="collections-action-dialog-add-to-existing"
              class="action-panel-selector collections-action-add-to-existing"
              data-ga-category="collections_button"
              data-ga-action="select_collection"
              data-ga-label="($('.collections-action-add-to-existing').val() === 'Favorites') ? 'Favorites' : 'non_favorites_collection'">
      </select>
      <div class="collections-retry-load-on-error usa-input-error-message selection-validation-message">
        Unable to load your collection due to an error<br>
        <a href="#">Please try again</a>
      </div>
    </div>
  </div>

  <div class="action-panel-actions">
    <button class="action-panel-submit"
            type="submit"
            data-loading-label="Adding..."
            data-pinger-ignore
            data-ga-category="collections_button"
            data-ga-action="click"
            data-ga-label="add">
      Add
    </button>
    <button class="action-panel-cancel"
            aria-label="Close 'Add to Collections' panel"
            ref="linksrc=close_collections_panel"
            aria-controls="collections-action-panel"
            aria-expanded="false"
            data-ga-category="collections_button"
            data-ga-action="click"
            data-ga-label="cancel">
      Cancel
    </button>
  </div>
</form>
    </div>
  </div>
</div>
</div>
                
            </li>

        </ul>
    </section>
    
        <section class="social-sharing">
            <h6>Share</h6>
            <ul class="pmc-sidebar__share">
                <li><a class="fa-stack fa-lg" target="_blank" rel="noopener noreferrer" role="button" href="https://twitter.com/intent/tweet?url=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC11153190%2F&amp;text=Soluble%20form%20of%20the%20MDA5%20protein%20in%20human%20sera" alt="Share on Twitter"><i class="fa fa-twitter fa-stack-1x">&#160;</i></a></li> 
<li><a class="fa-stack fa-lg" target="_blank" rel="noopener noreferrer" role="button" href="https://www.facebook.com/sharer/sharer.php?u=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC11153190%2F" alt="Share on Facebook"><i class="fa fa-facebook fa-stack-1x">&#160;</i></a></li>
                <li>
                    <div class="share-permalink">
                        <button class="trigger"  alt="Show article permalink" aria-expanded="false" aria-haspopup="true">
                            <i class="fa-stack fa-lg" >
                                <i class="fa fa-link fa-stack-1x">&nbsp;</i>
                            </i>
                        </button>
                        <div class="dropdown dropdown-container" hidden>
                              <div class="title">
                                Permalink
                              </div>
                              <div class="content">
                                  <input type="text" class="permalink-text" value="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11153190/" aria-label="Article permalink"><button class="permalink-copy-button usa-button-primary" title="Copy article permalink" data-ga-category="save_share" data-ga-action="link" data-ga-label="copy_link">
                                      <span class="button-title">Copy</span>
                                  </button>
                              </div>
                        </div>
                    </div>
                </li>
            </ul>
        </section>
    
    <section>
        <h6>RESOURCES</h6>
        <ul class="pmc-sidebar__resources">
        
            <li>
                <div class="usa-accordion">
                    <button
                            data-ga-category="resources_accordion"
                            data-ga-action="open_similar_articles"
                            data-ga-label="/pmc/articles/PMC11153190/"
                            class="usa-accordion-button"
                            aria-controls="similar-articles-accordion-header"
                            aria-expanded="false"
                            data-action-open="open_similar_articles"
                            data-action-close="close_similar_articles"
                    >
                        Similar articles
                    </button>
                    <div
                            
                                data-source-url="/pmc/resources/similar-article-links/38845920/"
                            

                         class="usa-accordion-content pmc-sidebar__resources--citations" id="similar-articles-accordion-header" aria-hidden="true">
                        
                    </div>
                </div>
            </li>
            <li>
                <div class="usa-accordion">
                    <button
                            data-ga-category="resources_accordion"
                            data-ga-action="open_cited_by"
                            data-ga-label="/pmc/articles/PMC11153190/"
                            class="usa-accordion-button"
                            aria-controls="cited-by-accordion-header"
                            aria-expanded="false"
                            data-action-open="open_cited_by"
                            data-action-close="close_cited_by"
                    >
                        Cited by other articles
                    </button>
                    <div
                            
                                data-source-url="/pmc/resources/cited-by-links/38845920/"
                            
                            class="usa-accordion-content pmc-sidebar__resources--citations"
                            id="cited-by-accordion-header"
                            aria-hidden="true"
                    >
                        
                    </div>
                </div>
            </li>
            <li>
                <div class="usa-accordion">
                    <button
                            data-ga-category="resources_accordion"
                            data-ga-action="open_NCBI_links"
                            data-ga-label="/pmc/articles/PMC11153190/"
                            class="usa-accordion-button"
                            aria-controls="links-accordion-header"
                            aria-expanded="false"
                            data-action-open="open_NCBI_links"
                            data-action-close="close_NCBI_link"
                    >
                        Links to NCBI Databases
                    </button>
                    <div data-source-url="/pmc/resources/db-links/11153190/" class="usa-accordion-content" id="links-accordion-header" aria-hidden="true"></div>
                </div>
            </li>

            
        
        </ul>
    </section>

 </div>
            </div>
        

    </nav>

</header>

    
    

    <div class="usa-overlay"></div>
    
<main id="main-content" class="usa-grid usa-layout-docs pmc-main">
    <article class="usa-width-three-fourths usa-layout-docs-main_content pmc-article">
        <section class="usa-breadcrumb usa-breadcrumb--wrap">
         
    <ul class="usa-breadcrumb__list">
            
                <li class="usa-breadcrumb__list-item"
                    >
                    <a href="/pmc/journals/" class="navlink">Journal List</a>
                </li>
            
                <li class="usa-breadcrumb__list-item"
                    >
                    <a class="navlink" href="/pmc/journals/2992/">Heliyon</a>
                </li>
            
                <li class="usa-breadcrumb__list-item"
                    >
                    <a class="navlink" href="/pmc/issues/463821/">v.10(11); 2024 Jun 15</a>
                </li>
            
                <li class="usa-breadcrumb__list-item"
                     aria-current="page" >
                    PMC11153190
                </li>
            
    </ul>
 

        </section>
        
  <div class="pmc-article__disclaimer" role="complementary" aria-label="Disclaimer note">
    As a library, NLM provides access to scientific literature. Inclusion in an NLM database does not imply endorsement of, or agreement with,
    the contents by NLM or the National Institutes of Health.<br/>
    Learn more:
    <a data-ga-category="Link click" data-ga-action="Disclaimer" data-ga-label="New disclaimer box" href="/pmc/about/disclaimer/">PMC Disclaimer</a>
    |
    <a data-ga-category="Link click" data-ga-action="PMC Copyright Notice" data-ga-label="New disclaimer box" href="/pmc/about/copyright/">
        PMC Copyright Notice
    </a>
</div>

        <section class="pmc-page-banner" role="banner">
            
                
                    <div><img src="/corehtml/pmc/pmcgifs/logo-heliyon.png" alt="Logo of heliyon" usemap="#logo-imagemap" /><map id="logo-imagemap" name="logo-imagemap"><area alt="Link to Publisher's site" title="Link to Publisher's site" shape="default" coords="0,0,499,74" href="http://www.journals.elsevier.com/heliyon" target="_blank" rel="noopener noreferrer" ref="reftype=publisher&amp;article-id=11153190&amp;issue-id=463821&amp;journal-id=2992&amp;FROM=Article%7CBanner&amp;TO=Publisher%7COther%7CN/A" /></map></div> 
                
            
        </section>
        <section  role="document">
            
                <div id="mc" class=" article lit-style content pmc-wm slang-all page-box"><!--main-content--><div class="jig-ncbiinpagenav" data-jigconfig="smoothScroll: false, allHeadingLevels: ['h2'], headingExclude: ':hidden,.nomenu'"><div class="fm-sec half_rhythm no_top_margin"><div class="fm-flexbox"><div class="fm-citation"><div class="citation-default"><div class="part1"><span id="pmcmata">Heliyon.</span> 2024 Jun 15; 10(11): e31727. </div><div class="part2"><span class="fm-vol-iss-date">Published online 2024 May 24. </span>  <span class="doi"><span>doi: </span><a href="//doi.org/10.1016%2Fj.heliyon.2024.e31727" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=11153190&amp;issue-id=463821&amp;journal-id=2992&amp;FROM=Article%7CFront%20Matter&amp;TO=Content%20Provider%7CCrosslink%7CDOI">10.1016/j.heliyon.2024.e31727</a></span></div></div></div><div class="fm-ids"><div class="fm-citation-pmcid"><span class="fm-citation-ids-label">PMCID: </span><span>PMC11153190</span></div><div class="fm-citation-pmid">PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/38845920">38845920</a></div></div></div><h1 class="content-title">Soluble form of the MDA5 protein in human sera</h1><div class="half_rhythm"><div class="contrib-group fm-author"><a href="https://pubmed.ncbi.nlm.nih.gov/?term=Okamoto%20M%5BAuthor%5D" id="au1" class="affpopup" co-rid="_co_idm139914624849248" co-class="co-affbox">Masaki Okamoto</a>,<sup>a</sup> <a href="https://pubmed.ncbi.nlm.nih.gov/?term=Zaizen%20Y%5BAuthor%5D" id="au2" class="affpopup" co-rid="_co_idm139914626039168" co-class="co-affbox">Yoshiaki Zaizen</a>,<sup>a</sup> <a href="https://pubmed.ncbi.nlm.nih.gov/?term=Kaieda%20S%5BAuthor%5D" id="au3" class="affpopup" co-rid="_co_idm139914665089248" co-class="co-affbox">Shinjiro Kaieda</a>,<sup>a</sup> <a href="https://pubmed.ncbi.nlm.nih.gov/?term=Nouno%20T%5BAuthor%5D" id="au4" class="affpopup" co-rid="_co_idm139914665087136" co-class="co-affbox">Takashi Nouno</a>,<sup>a</sup> <a href="https://pubmed.ncbi.nlm.nih.gov/?term=Koga%20T%5BAuthor%5D" id="au5" class="affpopup" co-rid="_co_idm139914613965248" co-class="co-affbox">Takuma Koga</a>,<sup>a</sup> <a href="https://pubmed.ncbi.nlm.nih.gov/?term=Matama%20G%5BAuthor%5D" id="au6" class="affpopup" co-rid="_co_idm139914613963024" co-class="co-affbox">Goushi Matama</a>,<sup>a</sup> <a href="https://pubmed.ncbi.nlm.nih.gov/?term=Mitsuoka%20M%5BAuthor%5D" id="au7" class="affpopup" co-rid="_co_idm139914619513488" co-class="co-affbox">Masahiro Mitsuoka</a>,<sup>b</sup> <a href="https://pubmed.ncbi.nlm.nih.gov/?term=Akiba%20J%5BAuthor%5D" id="au8" class="affpopup" co-rid="_co_idm139914619511264" co-class="co-affbox">Jun Akiba</a>,<sup>c</sup> <a href="https://pubmed.ncbi.nlm.nih.gov/?term=Yamada%20S%5BAuthor%5D" id="au9" class="affpopup" co-rid="_co_idm139914619366048" co-class="co-affbox">Shintaro Yamada</a>,<sup>d</sup> <a href="https://pubmed.ncbi.nlm.nih.gov/?term=Kato%20H%5BAuthor%5D" id="au10" class="affpopup" co-rid="_co_idm139914619363824" co-class="co-affbox">Hiroki Kato</a>,<sup>d</sup> and  <a href="https://pubmed.ncbi.nlm.nih.gov/?term=Hoshino%20T%5BAuthor%5D" id="au11" class="affpopup" co-rid="_co_idm139914623177152" co-class="co-affbox">Tomoaki Hoshino</a><sup>a,</sup><sup>e,</sup><sup>&#x0204e;</sup></div><div style="display:none" class="contrib-group aff-tip"><div id="_co_idm139914624849248"><h3 class="no_margin">Masaki Okamoto</h3><p><sup>a</sup>Division of Respirology, Neurology, and Rheumatology, Department of Medicine, Kurume University School of Medicine, 67 Asahi-machi, Kurume, Fukuoka, 830-0011, Japan</p><div>Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=Okamoto%20M%5BAuthor%5D">Masaki Okamoto</a></div></div><div id="_co_idm139914626039168"><h3 class="no_margin">Yoshiaki Zaizen</h3><p><sup>a</sup>Division of Respirology, Neurology, and Rheumatology, Department of Medicine, Kurume University School of Medicine, 67 Asahi-machi, Kurume, Fukuoka, 830-0011, Japan</p><div>Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=Zaizen%20Y%5BAuthor%5D">Yoshiaki Zaizen</a></div></div><div id="_co_idm139914665089248"><h3 class="no_margin">Shinjiro Kaieda</h3><p><sup>a</sup>Division of Respirology, Neurology, and Rheumatology, Department of Medicine, Kurume University School of Medicine, 67 Asahi-machi, Kurume, Fukuoka, 830-0011, Japan</p><div>Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=Kaieda%20S%5BAuthor%5D">Shinjiro Kaieda</a></div></div><div id="_co_idm139914665087136"><h3 class="no_margin">Takashi Nouno</h3><p><sup>a</sup>Division of Respirology, Neurology, and Rheumatology, Department of Medicine, Kurume University School of Medicine, 67 Asahi-machi, Kurume, Fukuoka, 830-0011, Japan</p><div>Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=Nouno%20T%5BAuthor%5D">Takashi Nouno</a></div></div><div id="_co_idm139914613965248"><h3 class="no_margin">Takuma Koga</h3><p><sup>a</sup>Division of Respirology, Neurology, and Rheumatology, Department of Medicine, Kurume University School of Medicine, 67 Asahi-machi, Kurume, Fukuoka, 830-0011, Japan</p><div>Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=Koga%20T%5BAuthor%5D">Takuma Koga</a></div></div><div id="_co_idm139914613963024"><h3 class="no_margin">Goushi Matama</h3><p><sup>a</sup>Division of Respirology, Neurology, and Rheumatology, Department of Medicine, Kurume University School of Medicine, 67 Asahi-machi, Kurume, Fukuoka, 830-0011, Japan</p><div>Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=Matama%20G%5BAuthor%5D">Goushi Matama</a></div></div><div id="_co_idm139914619513488"><h3 class="no_margin">Masahiro Mitsuoka</h3><p><sup>b</sup>Department of Surgery, Kurume University School of Medicine, 67 Asahi-machi, Kurume, Fukuoka, 830-0011, Japan</p><div>Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=Mitsuoka%20M%5BAuthor%5D">Masahiro Mitsuoka</a></div></div><div id="_co_idm139914619511264"><h3 class="no_margin">Jun Akiba</h3><p><sup>c</sup>Department of Pathology, Kurume University School of Medicine, 67 Asahi-machi, Kurume, Fukuoka, 830-0011, Japan</p><div>Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=Akiba%20J%5BAuthor%5D">Jun Akiba</a></div></div><div id="_co_idm139914619366048"><h3 class="no_margin">Shintaro Yamada</h3><p><sup>d</sup>Institute of Cardiovascular Immunology, University Hospital Bonn, University of Bonn, Venusberg-Campus 1, 53127, Bonn, Germany</p><div>Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=Yamada%20S%5BAuthor%5D">Shintaro Yamada</a></div></div><div id="_co_idm139914619363824"><h3 class="no_margin">Hiroki Kato</h3><p><sup>d</sup>Institute of Cardiovascular Immunology, University Hospital Bonn, University of Bonn, Venusberg-Campus 1, 53127, Bonn, Germany</p><div>Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=Kato%20H%5BAuthor%5D">Hiroki Kato</a></div></div><div id="_co_idm139914623177152"><h3 class="no_margin">Tomoaki Hoshino</h3><p><sup>a</sup>Division of Respirology, Neurology, and Rheumatology, Department of Medicine, Kurume University School of Medicine, 67 Asahi-machi, Kurume, Fukuoka, 830-0011, Japan</p><p><sup>e</sup>National Cancer Institute (NCI) &#x02013; Frederick, 1050 Boyles St, Frederick, MD, 21702, USA</p><div>Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=Hoshino%20T%5BAuthor%5D">Tomoaki Hoshino</a></div></div></div></div><div class="half_rhythm"><div class="togglers fm-copyright-license"><a href="#" class="pmctoggle" rid="idm139914614512848_ai">Author information</a> <a href="#" class="pmctoggle" rid="idm139914614512848_an">Article notes</a> <a href="#" class="pmctoggle" rid="idm139914614512848_cpl">Copyright and License information</a> <a href="/pmc/about/disclaimer/" style="margin-left: 1em">PMC Disclaimer</a></div><div class="fm-authors-info hide half_rhythm" id="idm139914614512848_ai" style="display:none"><div class="fm-affl" id="aff1"><sup>a</sup>Division of Respirology, Neurology, and Rheumatology, Department of Medicine, Kurume University School of Medicine, 67 Asahi-machi, Kurume, Fukuoka, 830-0011, Japan</div><div class="fm-affl" id="aff2"><sup>b</sup>Department of Surgery, Kurume University School of Medicine, 67 Asahi-machi, Kurume, Fukuoka, 830-0011, Japan</div><div class="fm-affl" id="aff3"><sup>c</sup>Department of Pathology, Kurume University School of Medicine, 67 Asahi-machi, Kurume, Fukuoka, 830-0011, Japan</div><div class="fm-affl" id="aff4"><sup>d</sup>Institute of Cardiovascular Immunology, University Hospital Bonn, University of Bonn, Venusberg-Campus 1, 53127, Bonn, Germany</div><div class="fm-affl" id="aff5"><sup>e</sup>National Cancer Institute (NCI) &#x02013; Frederick, 1050 Boyles St, Frederick, MD, 21702, USA</div><div><span class="contrib-email" id="au11">Tomoaki Hoshino: <a href="mailto:dev@null" data-email="pj.ca.u-emuruk.dem@onihsoh" class="oemail">pj.ca.u-emuruk.dem@onihsoh</a></span> </div><div id="cor1"><sup>&#x0204e;</sup>Corresponding author. Division of Respirology, Neurology, and Rheumatology, Department of Medicine, Kurume University School of Medicine, 67 Asahimachi, Kurume, Fukuoka, 830-0011, Japan. <a href="mailto:dev@null" data-email="pj.ca.u-emuruk.dem@onihsoh" class="oemail">pj.ca.u-emuruk.dem@onihsoh</a></div></div><div class="fm-article-notes hide half_rhythm" id="idm139914614512848_an" style="display:none"><div class="fm-pubdate half_rhythm">Received 2022 Oct 15; Revised 2024 May 20; Accepted 2024 May 21.</div></div><div class="permissions half_rhythm hide" id="idm139914614512848_cpl" style="display:none"><div class="fm-copyright half_rhythm"><a href="/pmc/about/copyright/">Copyright</a> Published by Elsevier Ltd.</div><div class="license half_rhythm">This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).</div></div></div><div id="pmclinksbox" class="links-box whole_rhythm hidden" role="complementary" aria-label="Related or updated information about this article."></div></div><div class="sec"></div><div id="ass-data" class="tsec fm-sec whole_rhythm" data-section="Featured_PMC_Datacitation"><h2 class="nomenu">Associated Data</h2><dl data-length="216" class="box-data-avail whole_rhythm no_bottom_margin"><dt><a href="#" rid="data-avl-stmnt" data-ga-action="click_feat_toggler" data-ga-label="Data Availability Statement" class="pmctoggle">Data Availability Statement</a></dt><dd id="data-avl-stmnt" style="display: none;"><p class="p p-first-last">The authors declare that the data supporting the findings of this study are available within the paper. A request for more detailed data should be sent to the corresponding authors with the permission of all authors.</p></dd></dl></div><div id="abs0010" lang="en" class="tsec sec"><h2 class="head no_bottom_margin" id="abs0010title">Abstract</h2><!--article-meta--><div><p class="p p-first-last">Viral double-stranded RNA (dsRNA) is sensed by toll-like receptor 3 (TLR3) and retinoic acid-inducible gene I (RIG-I)-like receptors (RLRs), including melanoma differentiation-associated gene 5 (MDA5). MDA5 recognizes the genome of dsRNA viruses and replication intermediates of single-stranded RNA viruses. MDA5 also plays an important role in the development of autoimmune diseases, such as Aicardi-Goutieres syndrome and type I diabetes. Patients with dermatomyositis with serum MDA5 autoantibodies (anti-CADM-140) are known to have a high risk of developing rapidly progressive interstitial lung disease and poor prognosis. However, there have been no reports on the soluble form of MDA5 in human serum. In the present study, we generated in-house monoclonal antibodies (mAbs) against human MDA5. We then performed immunohistochemical analysis and sensitive sandwich immunoassays to detect the MDA5 protein using two different mAbs (clones H27 and H46). As per the immunohistochemical analysis, the MDA5 protein was moderately expressed in the alveolar epithelia of normal lungs and was strongly expressed in the cytoplasm of lymphoid cells in the tonsils and acinar cells of the pancreas. Interestingly, soluble MDA5 protein was detectable in the serum, but not in the urine, of healthy donors. Soluble MDA5 protein was also detectable in the serum of patients with dermatomyositis. Immunoblot analysis showed that human cells expressed a 120&#x000a0;kDa MDA5 protein, while the 60&#x000a0;kDa MDA5 protein increased in the supernatant of peripheral mononuclear cells within 15&#x000a0;min after MDA5 agonist/double-strand RNA stimulation. Hydrogen deuterium exchange mass spectrometry revealed that an anti-MDA5 mAb (clone H46) bound to the epitope (415QILENSLLNL424) derived from the helicase domain of MDA5. These results indicate that a soluble MDA5 protein containing the helicase domain of MDA5 could be rapidly released from the cytoplasm of tissues after RNA stimulation.</p></div><div class="sec"><strong class="kwd-title">Keywords: </strong><span class="kwd-text">MDA5, RNA virus, Soluble form, RNA sensor</span></div></div><div id="abs0015" lang="en" class="tsec sec"><h2 class="head no_bottom_margin" id="abs0015title">Highlights</h2><!--article-meta--><div><ul class="simple" style="list-style-type:none" id="ulist0010"><li class="a_label" id="u0010"><div class="inline_block a_label">&#x02022;</div><div id="p0010">In this study, we established five in-house mAbs against human MDA5.</div></li><li class="a_label" id="u0015"><div class="inline_block a_label">&#x02022;</div><div id="p0015">We performed immunohistochemical analysis and developed a sensitive sandwich immunoassay system to detect soluble MDA5 protein in sera.</div></li><li class="a_label" id="u0020"><div class="inline_block a_label">&#x02022;</div><div id="p0020">MDA5 protein was detectable in the sera, but not in the urine of healthy donors. The MDA5 protein was also detected in the sera of patients with dermatomyositis.</div></li><li class="a_label" id="u0025"><div class="inline_block a_label">&#x02022;</div><div id="p0025">In addition, levels of the 60&#x000a0;kDa MDA5 protein increased in the supernatant of peripheral mononuclear cells within 15&#x000a0;min of dsRNA stimulation.</div></li></ul><p></p></div></div><div id="nomen0010" class="tsec sec"><h2 class="head no_bottom_margin" id="nomen0010title">Abbreviations</h2><div class="def-list"><dl class="labeled-list"><dt id="d0010">RNAs</dt><dd>ribonucleic acids</dd><dt id="d0015">DNA</dt><dd>deoxyribonucleic acid</dd><dt id="d0020">ssRNA</dt><dd>single-stranded RNA</dd><dt id="d0025">dsRNA</dt><dd>double strand RNA</dd><dt id="d0030">RIG-I</dt><dd>retinoic acid-inducible gene I</dd><dt id="d0035">RLRs</dt><dd>RIG-I-like receptors</dd><dt id="d0040">MDA5</dt><dd>melanoma differentiation-associated gene 5</dd><dt id="d0045">mAbs</dt><dd>monoclonal antibodies</dd><dt id="d0050">CARD</dt><dd>caspase recruitment domains</dd><dt id="d0055">IRF</dt><dd>interferon-regulatory factor</dd><dt id="d0060">PBS</dt><dd>phosphate-buffered saline</dd><dt id="d0065">AGS</dt><dd>Aicardi-Goutieres syndrome</dd><dt id="d0070">DM</dt><dd>dermatomyositis</dd><dt id="d0075">CADM</dt><dd>clinically amyopathic dermatomyositis</dd><dt id="d0080">TLRs</dt><dd>toll-like receptors</dd></dl></div></div><div id="sec1" class="tsec sec"><h2 class="head no_bottom_margin" id="sec1title">1. Introduction</h2><p id="p0105" class="p p-first">Viral double-stranded RNA (dsRNA) is sensed by toll-like receptor 3 (TLR3), RIG-I-like receptors (RLRs), a family comprising RIG-I (DDX58), laboratory of genetics and physiology 2 (LGP2; DHX58), and melanoma differentiation-associated gene 5 (MDA5; IFIH1). All three RLRs are expressed in the cytoplasm (reviewed in Ref. [<a href="#bib1" rid="bib1" class=" bibr popnode">1</a>]). MDA5 is activated upon infection with picornaviruses, including polio-and encephalomyocarditis viruses, as well as by long double-stranded RNA (dsRNA) [<a href="#bib2" rid="bib2" class=" bibr popnode">2</a>]. MDA5 can also recognize single-stranded RNA (ssRNA) viruses of the murine coronavirus, mouse hepatitis virus, calicivirus, flavivirus families, and SARS-CoV-2 [<a href="#bib3" rid="bib3" class=" bibr popnode">3</a>,<a href="#bib4" rid="bib4" class=" bibr popnode">4</a>]. RIG-I and MDA5 contain two caspase recruitment domains (CARD) a DExD/H-box helicase domain composed of helicase domains 1 (Hel1) and 2 (Hel2), and a helicase insertion domain (Hel2i) [<a href="#bib1" rid="bib1" class=" bibr popnode">1</a>]. MDA5 recognizes viral RNA and activates NF-&#x003ba;B and interferon-regulatory factor (IRF) through mitochondrial antiviral signaling, also known as IPS-1/VISA/Cardif, leading to the production of cytokines including type I and III interferons (IFNs) [<a href="#bib5" rid="bib5" class=" bibr popnode">5</a>]. A previous study reported the case of a patient with a homozygous missense mutation in the Hel1 domain of MDA5 (K365E). This patient had a history of life-threatening recurrent respiratory tract infections caused by ssRNA viruses (including human rhinovirus, influenza virus, respiratory syncytial virus, and coronavirus), adenovirus, and bacteria, such as <em>Haemophilus influenza, Mycoplasma pneumoniae,</em> and <em>Staphylococcus aureus</em> [<a href="#bib6" rid="bib6" class=" bibr popnode">6</a>]. Taken together, these observations indicate that MDA5 plays an important role in defense against dsRNA viruses, ssRNA viruses, deoxyribonucleic acid (DNA) viruses, and bacteria.</p><p id="p0110">MDA5 is also associated with autoimmune diseases. A gain-of-function mutation in mouse MDA5 (G821S) following exposure to N-ethyl-N-nitrosourea (ENU) induces autoimmune disorders observed in interferonopathy patients, including Aicardi-Goutieres syndrome (AGS)-like encephalitis and lupus-like nephritis [<a href="#bib7" rid="bib7" class=" bibr popnode">7</a>,<a href="#bib8" rid="bib8" class=" bibr popnode">8</a>]. A genome-wide association study showed that single nucleotide polymorphisms (SNPs) in IFIH1 (E627* and I923V), which are loss-of-function mutations [<a href="#bib9" rid="bib9" class=" bibr popnode">9</a>], are significantly associated with resistance to type 1 diabetes mellitus [<a href="#bib10" rid="bib10" class=" bibr popnode">10</a>]. Six gain-of-function mutations (rare SNPs) in MDA5 have been identified in AGS in patients [<a href="#bib11" rid="bib11" class=" bibr popnode">11</a>,<a href="#bib12" rid="bib12" class=" bibr popnode">12</a>]. These results suggested that MDA5 plays an important role in the development of autoimmune diseases.</p><p id="p0115">Dermatomyositis (DM) is an autoimmune disease characterized by the shared features of proximal skeletal muscle weakness and inflammation. Some patients with DM have definite cutaneous manifestations of DM but no clinically significant myopathy, which is defined as clinically amyopathic dermatomyositis (CADM) [<a href="#bib13" rid="bib13" class=" bibr popnode">13</a>]. An anti-CADM 140 antibody has been reported to be highly expressed in patients with CADM. Patients with CADM have a high risk of developing rapidly progressive interstitial lung disease (ILD) and poor prognosis due to poor therapeutic response [<a href="#bib14" rid="bib14" class=" bibr popnode">14</a>]. In 2005, an anti-CADM 140 antibody present in the sera of patients with CADM was reported to react with human MDA5 protein [<a href="#bib15" rid="bib15" class=" bibr popnode">15</a>]. We previously reported anti-MDA5 antibodies as biomarkers of DM-ILD and demonstrated that the presence and titer of anti-MDA5 antibodies are associated with mortality in the early phase and/or response to immunosuppressive therapy [<a href="#bib16" rid="bib16" class=" bibr popnode">16</a>,<a href="#bib17" rid="bib17" class=" bibr popnode">17</a>]. A recent meta-analysis showed that anti-MDA5 antibodies could be used as biomarkers for the clinical diagnosis of DM and that the presence of anti-MDA5 antibodies is associated with poor survival [<a href="#bib18" rid="bib18" class=" bibr popnode">18</a>].</p><p id="p0120">As mentioned previously, MDA5 expression is highly correlated with various systemic diseases. Toll-like receptors (TLRs), which are related to innate immunity, such as MDA5, the presence of soluble forms has been reported for TLR2 and TLR4 [<a href="#bib19" rid="bib19" class=" bibr popnode">19</a>,<a href="#bib20" rid="bib20" class=" bibr popnode">20</a>]. We hypothesized that a soluble form of MDA5 and the presence of soluble MDA5 may influence many systemic diseases.</p><p id="p0125" class="p p-last">In the present study, we developed five in-house monoclonal antibodies against human MDA5. We performed immunohistochemical analysis and developed a sensitive sandwich immunoassay system to detect soluble MDA5 protein in sera. Soluble MDA5 protein was detected in the sera of 14 of the 32 healthy donors. Soluble MDA5 protein was also detected in the sera of 26 of 31 patients with DM. In addition, levels of the 60&#x000a0;kDa MDA5 protein increased in the supernatant of peripheral mononuclear cells within 15&#x000a0;min of dsRNA stimulation. Our <em>in vitro</em> study suggests that soluble MDA5 is rapidly released from the cytoplasm of tissues after RNA stimulation. The possible physiological role of the soluble MDA5 protein in viral infections and autoimmune diseases is also discussed.</p></div><div id="sec2" class="tsec sec"><h2 class="head no_bottom_margin" id="sec2title">2. Materials and methods</h2><div id="sec2.1" class="sec sec-first"><h3 id="sec2.1title">2.1. Human participants</h3><p id="p0130" class="p p-first-last">Normal lung tissues were obtained from two patients with squamous carcinoma of the lung who underwent lobectomy at the Kurume University Hospital. Donor 1 was a 67-year-old male and donor 2 was a 71-year-old male. Serum and/or urine samples were obtained from 32 healthy donors (23 males and 9 females, aged 28&#x02013;58 years). Formalin-fixed, paraffin-embedded tissues of the tonsils (4-year-old female) and pancreas (51-year-old female) were purchased from Bio-Options, Inc. (Brea, CA, USA). The present study also included 31 patients diagnosed with DM (9 males and 22 females, aged 12&#x02013;87 years) at our institution between 2014 and 2019. The patients met the diagnostic criteria for polymyositis and dermatomyositis, as reported by Bohan and Peter [<a href="#bib21" rid="bib21" class=" bibr popnode">21</a>] and recently by us [<a href="#bib22" rid="bib22" class=" bibr popnode">22</a>]. Twelve of 31 patients showed seropositive for anti-MDA5 antibodies.</p></div><div id="sec2.2" class="sec"><h3 id="sec2.2title">2.2. Recombinant full-length human MDA5 protein</h3><p id="p0135" class="p p-first-last">Recombinant full-length human MDA5 protein was made as previously reported [<a href="#bib23" rid="bib23" class=" bibr popnode">23</a>].</p></div><div id="sec2.3" class="sec"><h3 id="sec2.3title">2.3. Establishment of an anti-human MDA5 monoclonal antibody (mAb)</h3><p id="p0140" class="p p-first-last">Mouse anti-human MDA5 mAbs were established, and purified anti-human MDA5 mAb was generated as described previously [<a href="#bib23" rid="bib23" class=" bibr popnode">23</a>,<a href="#bib24" rid="bib24" class=" bibr popnode">24</a>].</p></div><div id="sec2.4" class="sec"><h3 id="sec2.4title">2.4. Immunoprecipitation and western blotting analysis</h3><p id="p0145" class="p p-first-last">HEK293T cells were transfected with pEF-Flag-human MDA5 or pEF-Flag-mouse MDA5 using the pEF-BOS-EX vector [<a href="#bib25" rid="bib25" class=" bibr popnode">25</a>] as previously reported [<a href="#bib26" rid="bib26" class=" bibr popnode">26</a>]. At 18&#x02013;48&#x000a0;h post-transfection, the cells were harvested and lysed with Nonidet P-40 (NP-40) lysis buffer (50&#x000a0;mM Tris-HCl pH 8.0, 150&#x000a0;mM NaCl, and 1&#x000a0;% NP-40) supplemented with 1&#x000a0;mM phenylmethylsulfonyl fluoride (PMSF), 1&#x000a0;mM sodium orthovanadate, and 2&#x000a0;&#x003bc;g/mL leupeptin. Subsequently, 500&#x000a0;&#x003bc;L of lysates were incubated with 1&#x000a0;&#x003bc;g of monoclonal anti-MDA5 antibodies and anti-Flag M2 (catalog no.: F3165, Sigma-Aldrich, Germany) or normal mouse IgG (catalog no.: sc-2025, Santa Cruz Biotechnology, Germany) for 30&#x000a0;min on ice, followed by further incubation with Dynabeads Protein G (catalog no.: 10-003-D, Invitrogen, Germany) at 4&#x000a0;&#x000b0;C overnight. The beads were eluted with 1&#x000a0;&#x000d7;&#x000a0;SDS sample buffer (62.5&#x000a0;mM Tris-HCl pH 6.8, 5&#x000a0;% 2-mercaptoethanol, 2&#x000a0;% SDS, 10&#x000a0;% glycerol, and 0.005&#x000a0;% bromophenol blue) and heated for 5&#x000a0;min at 95&#x000a0;&#x000b0;C. Diluted (1&#x000a0;%) lysates of Flag-human MDA5 overexpressing HEK293T cells or Flag-mouse MDA5 overexpressing HEK293T cells were used as positive controls. The eluted proteins were analyzed using western blotting. Western blotting was performed using NuPAGE&#x000ae; 4&#x02013;20&#x000a0;% Tris-Glycine Mini Gels or 7&#x000a0;% Tris-Acetate Midi Gel (Thermo Fisher Scientific, Tokyo, Japan) according to the manufacturer's protocol. In this study, an anti-human MDA5 mAb clone H27 and anti-&#x003b2;-action mAb (clone AC-15, Sigma, Tokyo, Japan) were used for western blotting.</p></div><div id="sec2.5" class="sec"><h3 id="sec2.5title">2.5. Real-time quantitative-PCR (RT-qPCR)</h3><p id="p0150" class="p p-first-last">cDNAs isolated from normal human tissues (lungs, spleen, pancreas, muscle, and placenta) were purchased from BioChain (Newark, CA, USA). RT-qPCR was performed twice with SYBR Green Mastermix (Qiagen, Tokyo, Japan) using primers for human &#x003b2;-actin and MDA5 (Qiagen) on an Mx3000p PCR machine (Stratagene, La Jolla, CA). Relative mRNA expression of MDA5 per &#x003b2;-actin was calculated using the comparative threshold cycle (Ct) method, using the delta delta Ct (&#x00394;&#x00394;Ct) method. Fold gene expression&#x000a0;=&#x000a0;2^-(&#x00394;&#x00394;Ct), as previously reported [<a href="#bib27" rid="bib27" class=" bibr popnode">27</a>,<a href="#bib28" rid="bib28" class=" bibr popnode">28</a>].</p></div><div id="sec2.6" class="sec"><h3 id="sec2.6title">2.6. Immunohistochemical staining</h3><p id="p0155" class="p p-first-last">Immunohistochemical staining was performed using as reported [<a href="#bib24" rid="bib24" class=" bibr popnode">24</a>,<a href="#bib29" rid="bib29" class=" bibr popnode">29</a>]. We used an in-house mouse anti-human MDA5 mAb (H27 [mouse IgG1], 1&#x02013;2&#x000a0;&#x003bc;g/mL). Mouse IgG1 (BioLegend, Tokyo, Japan) was used as control.</p></div><div id="sec2.7" class="sec"><h3 id="sec2.7title">2.7. PBMC isolation and <em>in vitro</em> stimulation by polyinosinic-polycytidylic acid sodium salt (poly I:C)</h3><p id="p0160" class="p p-first-last">Peripheral blood mononuclear cells (PBMCs) were isolated from the peripheral blood of three healthy donors using Lymphoprep&#x02122; (STEMCELL TECHNOLOGIES, Vancouver, Canada). The cells were washed twice with cold phosphate-buffered saline (PBS) and suspended in cold PBS or RPMI-1640 (Sigma) at a density of 2&#x000a0;&#x000d7;&#x000a0;10<sup>6</sup>&#x000a0;cells/mL. Cells were stimulated with 250&#x000a0;&#x003bc;g/mL poly I:C (catalog no.: P1530, Merk, Tokyo, Japan) at 37&#x000a0;&#x000b0;C. Supernatants and cells were harvested at various time points.</p></div><div id="sec2.8" class="sec"><h3 id="sec2.8title">2.8. Establishing human MDA5 sandwich immunoassay system</h3><p id="p0165" class="p p-first-last">The human MDA5 sandwich immunoassay system was established using electrochemiluminescence in a MESOSCALE DISCOVERY &#x000ae; assay system (Meso Scale Japan, Tokyo, Japan). Briefly, mouse anti-human MDA5 mAb (clone H46) was used as the primary mAb, dissolved at 2&#x000a0;&#x003bc;g/mL in PBS, dispensed into plates in aliquots of 25 &#x003bc;L/well, and left undisturbed overnight at 4&#x000a0;&#x000b0;C. The plates were then washed three times with 150&#x000a0;&#x003bc;L Quantikine Wash Buffer 1 (R&#x00026;D Systems, Minneapolis, MN, USA). Block Ace blocking solution (100 &#x003bc;L/well; Nacalai Tesque, Kyoto, Japan) was added and incubated for at least 1&#x000a0;h at 20&#x000a0;&#x000b0;C to prevent nonspecific adhesion of the secondary antibody to the plates. The plates were then washed three times. The samples were aliquoted at 25 &#x003bc;L/well. Recombinant human MDA5 protein diluted to 50, 10, 2, 400, 80, 16, and 3.2&#x000a0;pg/mL was used as the standard. After incubation for 1&#x000a0;h at 20&#x000a0;&#x000b0;C, each well was washed three times. Next, 2&#x000a0;&#x003bc;g/mL biotin-labeled mouse anti-human MDA5 secondary mAb (clone H27) was added at 25 &#x003bc;L/well, followed by incubation for 1&#x000a0;h at 20&#x000a0;&#x000b0;C after which each well was washed three times. This was followed by the addition of 50&#x000a0;&#x003bc;L of 0.5&#x000a0;&#x003bc;g/mL MSD SULFO-TAG&#x02122; labeled streptavidin to each well, and the plates were left for 30&#x000a0;min at 20&#x000a0;&#x000b0;C. Each well was washed three times. The amount of human MDA5 protein was measured using a MESO QuickPlex SQ 120, according to the manufacturer's protocol.</p></div><div id="sec2.9" class="sec"><h3 id="sec2.9title">2.9. Hydrogen deuterium exchange mass spectrometry</h3><p id="p0170" class="p p-first">Hydrogen deuterium exchange mass spectrometry experiments were performed using Waters HDX with a LEAP system (Waters, Tokyo, Japan), as previously reported [<a href="#bib30" rid="bib30" class=" bibr popnode">30</a>]. The antigen (recombinant human MDA5) and antibody (anti-human MDA5 monoclonal antibody clone H46) complexes (hereby antigen&#x000a0;+&#x000a0;antibody complex) were prepared by mixing equal amounts of 160&#x000a0;&#x003bc;M antigen solution and 160&#x000a0;&#x003bc;M antibody solution suspended in 50&#x000a0;mM Tris-HCl, 150&#x000a0;mM NaCl, 1&#x000a0;mM EDTA, 0.01&#x000a0;% CHAPS, and 1&#x000a0;mM TCEP (pH 8.0). Moreover, 80&#x000a0;&#x003bc;M protein solutions (antigen, antigen&#x000a0;+&#x000a0;antibody complex) was diluted 20-fold with 50&#x000a0;mM Tris-HCl, 150&#x000a0;mM NaCl, 1&#x000a0;mM EDTA, 0.01&#x000a0;% CHAPS, and 1&#x000a0;mM TCEP (pH 8.0) and incubated at 20&#x000a0;&#x000b0;C for various hydrogen/deuterium exchange time points (0.5, 1, 10, 60, and 240&#x000a0;min). The exchange reaction was quenched by dropping the pH to 2.4 with mixing equal volume of 100&#x000a0;mM phosphate, 4&#x000a0;M guanidinium chloride, 0.5&#x000a0;M TCEP (pH 2.3). The quenched samples (100&#x000a0;pmol) were immediately injected, desalted, and separated online using a Waters UPLC system based on the NanoACQUITY &#x02122; platform. The online digestion was performed for over 6&#x000a0;min in water containing 0.05&#x000a0;% formic acid at 4&#x000a0;&#x000b0;C at a flow rate of 50&#x000a0;&#x003bc;L/min. The digested peptides were trapped on an ACQUITY UPLC BEH C18 1.7&#x000a0;&#x003bc;m peptide trap (Waters) maintained at 0&#x000a0;&#x000b0;C and desalted with water and 0.1&#x000a0;% formic acid. Flow was diverted by a switching valve, and the trapped peptide fragments were eluted at 40&#x000a0;&#x003bc;L/min onto a column of 1&#x000a0;&#x000d7;&#x000a0;100&#x000a0;mm (C18 1.7&#x000a0;&#x003bc;m, ACQUITY UPLC BEH, Waters) held at 0&#x000a0;&#x000b0;C, with a 9&#x000a0;min linear acetonitrile gradient (8&#x02013;40&#x000a0;%) containing 0.1&#x000a0;% formic acid. The eluate was directed into a mass spectrometer (Synapt HD, Waters) with electrospray ionization and lock mass correction (using glu-fibrinogen peptide B). Mass spectra were transformed using MassLynx (Waters) and acquired over an <em>m</em>/<em>z</em> range of 100&#x02013;2000. Pepsin fragments were identified using a combination of exact mass and MS/MS, aided by the ProteinLynx Global SERVER (PLGS, Waters). Peptide deuterium levels were determined using DynamX 3.0 (Waters). Peptides that were significantly different between the antigen and antigen&#x000a0;+&#x000a0;antibody complexes were evaluated by creating volcano plots with 99&#x000a0;% confidence intervals (CIs) for the degree of deuterium exchange, using Welch's <em>t</em>-test. The mass difference in hydrogen-deuterium exchange (&#x00394;<em>HX</em>) for each peptide at each deuterium exchange time is calculated as follows.</p><div class="disp-formula" id="ufd1"><div class="f"><math xmlns:mml="http://www.w3.org/1998/Math/MathML" display="block" id="M1" altimg="si1.svg"><mrow><mo>&#x00394;</mo><mi>H</mi><mi>X</mi><mo linebreak="badbreak">=</mo><msub><mi mathvariant="normal">m</mi><mrow><mtext>sample</mtext><mn>1</mn></mrow></msub><mspace width="0.25em"></mspace><mo>&#x02013;</mo><mspace width="0.25em"></mspace><msub><mi mathvariant="normal">m</mi><mrow><mtext>sample</mtext><mn>2</mn></mrow></msub></mrow></math></div></div><p></p><p id="p0175" class="p p-last">Sample 1 shows the antigen&#x000a0;+&#x000a0;antibody (recombinant human MDA5 and anti-human MDA5 monoclonal antibody clone H46) complex and sample 2 shows the antigen (recombinant human MDA5) protein.</p></div><div id="sec2.10" class="sec"><h3 id="sec2.10title">2.10. Surface antigen and intracellular analysis by flow cytometry</h3><p id="p0180" class="p p-first-last">Purified anti-human MDA5 mAbs (clones H5 and H27) were conjugated with fluorescein using a Fluorescein Labeling Kit-NH<sub>2</sub> &#x000ae; (Dojindo, Kumamoto, Japan). Flow cytometric analysis was performed using BD FACSLyric&#x02122; (BD, Tokyo, Japan). Four-color analysis was performed for surface and intracellular analyses. Isolated PBMCs were stimulated with or without poly I:C as described above. For intracellular cellular analysis, the cells were treated with 1&#x000a0;% paraformaldehyde and 0.1&#x000a0;% saponin. Cells were stained with fluorescein conjugated anti-human MDA5 mAbs (clones H5 or H27), PE/Cy7-anti-human CD4 mAb (clone OKT4, Biolegend, Tokyo, Japan), APC- anti-human CD8a mAb (Clone RPA-T8, Biolegend), PE-anti-human CD16 mAb (clone 3G8, Biolegend), anti-human CD19 (clone HIB19, Biolegend), and/or control isotype matched mouse Immunoglobulin (Biolegend), as we have reported previously [<a href="#bib31" rid="bib31" class=" bibr popnode">31</a>,<a href="#bib32" rid="bib32" class=" bibr popnode">32</a>]. The lymphocyte population was gated for analysis.</p></div><div id="sec2.11" class="sec"><h3 id="sec2.11title">2.11. Statistical analysis</h3><p id="p0185" class="p p-first-last">Results are expressed as means&#x000a0;&#x000b1;&#x000a0;standard error of the mean (SEM). Non-parametric tests (Wilcoxon/Kruskal&#x02013;Wallis test) were used to compare the differences between groups. Correlations were analyzed using simple regression. Statistical significance was set at P&#x000a0;&#x0003c;&#x000a0;0.05. significance. All analyses were performed using the JMP Pro software (version 17.0.0; SAS Institute, Cary, NC, USA).</p></div><div id="sec2.12" class="sec sec-last"><h3 id="sec2.12title">2.12. Ethical issues</h3><p id="p0190" class="p p-first-last">This study was approved by the Institutional Review Board of Kurume University Hospital (approval date: July 31, 2019; approval number:19090) and performed in accordance with the 2013 Declaration of Helsinki. Informed consent for participation in this study was obtained from all participants. All animal procedures were approved by the Committee on the Ethics of Animal Experiments at Kurume University (Approval No. 2022-083, 2022-084, 2022-085). Animal care was performed in accordance with the procedures outlined in the &#x0201c;Principles of Laboratory Animal Care (National Institutes of Health Publication 86-23, revised 1985). All efforts were made to minimize suffering of the animals used in this study.</p></div></div><div id="sec3" class="tsec sec"><h2 class="head no_bottom_margin" id="sec3title">3. Results</h2><div id="sec3.1" class="sec sec-first"><h3 id="sec3.1title">3.1. Anti-human MDA5 mAb (H46) recognizes a peptide derived from the helicase domain of human MDA5</h3><p id="p0195" class="p p-first">We established five anti-human MDA5 monoclonal antibodies (clones H5 [mouse IgG1], H27 [mouse IgG1], H46 [mouse IgG2b], H77 [mouse IgG2b], and H85 [mouse IgG1]). Anti-human MDA5 mAbs (clones H5 and H27) were used for western blotting and intracellular flow cytometric staining. Western blot analysis showed that HEK293T cells strongly expressed the approximately 120&#x000a0;kDa MDA5 protein (data not shown). HEK293T cells were transfected with pEF-Flag-human MDA5 or pEF-Flag-mouse MDA5 vectors. Human MDA5 was immunoprecipitated using all anti-MDA5 mAb clones and an anti-FLAG M2 antibody but not with normal mouse IgG. In contrast, mouse MDA5 was not immunoprecipitated by the anti-MDA5 mAb clones (<a href="/pmc/articles/PMC11153190/figure/fig1/" target="figure" class="fig-table-link figpopup" rid-figpopup="fig1" rid-ob="ob-fig1" co-legend-rid="lgnd_fig1"><span>Fig. 1</span></a>), demonstrating the specificity of the anti-human MDA5 clones.</p><!--fig ft0--><!--fig mode=article f1--><div class="fig iconblock whole_rhythm" id="fig1" co-legend-rid="lgnd_fig1"><a href="/pmc/articles/PMC11153190/figure/fig1/" target="figure" rid-figpopup="fig1" rid-ob="ob-fig1"><!--fig/graphic|fig/alternatives/graphic mode="anchored" m1--><div class="figure" data-largeobj="" data-largeobj-link-rid="largeobj_idm139914624426960"><a class="inline_block ts_canvas" href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=11153190_gr1.jpg" target="tileshopwindow" rel="noopener"><div class="ts_bar small" title="Click on image to zoom"></div><img loading="lazy" alt="Fig. 1" title="Click on image to zoom" class="tileshop" src="/pmc/articles/PMC11153190/bin/gr1.jpg" /></a></div><div class="largeobj-link align_right" id="largeobj_idm139914624426960"><a target="object" rel="noopener" href="/pmc/articles/PMC11153190/figure/fig1/?report=objectonly">Open in a separate window</a></div></a><div class="icnblk_cntnt" id="lgnd_fig1"><div><a class="figpopup" href="/pmc/articles/PMC11153190/figure/fig1/" target="figure" rid-figpopup="fig1" rid-ob="ob-fig1">Fig. 1</a></div><!--caption a7--><div class="caption"><p>Immunoprecipitation shows anti-human MDA5 monoclonal antibodies (mAbs) recognize human but not mouse MDA5 protein. The HEK293T cells were transfected with Flag-human MDA5 cDNA (left panel). HEK293T cells were transfected with Flag-mouse MDA5 cDNA (right panel). Diluted whole-cell extract of Flag-human MDA5 overexpressing HEK293T cells (line 1, left) or Flag-mouse MDA5 overexpressing HEK293T cells (line 1, right) were used as positive controls. Immunoprecipitation was performed using four different anti-human MDA5 mAbs (clones H27 [no. 2], H46 [no. 3], H77 [no. 4], and H85 [no. 5]), anti-Flag M2 antibody [no. 6], and control normal mouse IgG [no. 7]. Western blotting was performed using anti-Flag M2 antibody.</p></div></div></div><p id="p0200" class="p p-last">We performed hydrogen deuterium exchange mass spectrometry to examine the antigen (recombinant human MDA5) and antibody (anti-human MDA5 monoclonal antibody clone H46) complexes, as previously reported [<a href="#bib30" rid="bib30" class=" bibr popnode">30</a>]. In this study, we analyzed 425 peptides, covering 96.7&#x000a0;% of human MDA5 (<a href="/pmc/articles/PMC11153190/table/tbl1/" target="table" class="fig-table-link figpopup" rid-figpopup="tbl1" rid-ob="ob-tbl1" co-legend-rid=""><span>Table 1</span></a>). Statistical analysis using a volcano plot is shown in <a href="/pmc/articles/PMC11153190/figure/fig2/" target="figure" class="fig-table-link figpopup" rid-figpopup="fig2" rid-ob="ob-fig2" co-legend-rid="lgnd_fig2"><span>Fig. 2</span></a>. A positive &#x00394;HX plot indicates a decrease in deuterium exchange degree with the addition of antibody, i.e., interaction sites, while a negative &#x00394;HX plot indicates an increase in the deuterium exchange degree with the addition of the antibody, as reported [<a href="#bib30" rid="bib30" class=" bibr popnode">30</a>]. Five plots in the region enclosed by the red dotted line (&#x00394;HX&#x000a0;&#x0003c;&#x000a0;&#x02212;0.4978 or &#x00394;HX&#x0003c;0.4978 and p-value &#x0003c;0.01) are those with significant differences at the 99&#x000a0;% confidence interval. <a href="/pmc/articles/PMC11153190/table/tbl2/" target="table" class="fig-table-link figpopup" rid-figpopup="tbl2" rid-ob="ob-tbl2" co-legend-rid=""><span>Table 2</span></a> shows the list of 5 peptides, the deuterium exchange times, &#x00394;HX, and <em>p-</em>value with significant differences at the 99&#x000a0;% confidence interval, as described above. The peptide with a start point of 417(Q) and an end point of 426(L) (sequence QILENSLLNL) was considered the region where the degree of deuterium exchange decreased the most because of the addition of the anti-MDA5 monoclonal antibody clone H46 (<a href="/pmc/articles/PMC11153190/table/tbl1/" target="table" class="fig-table-link figpopup" rid-figpopup="tbl1" rid-ob="ob-tbl1" co-legend-rid=""><span>Table 1</span></a>). Taken together, hydrogen deuterium exchange mass spectrometry showed that clone H46 bound to the peptide (415QILENSLLNL424) derived from the helicase domain of human MDA5 (GenBank accession no. <a id="__tag_1150213701" class="tag_hotlink" href="/nuccore/AF095844" ref="/nuccore/AF095844"><span class="tag-json" style="display:none">{"type":"entrez-nucleotide","attrs":{"text":"AF095844","term_id":"11344593","term_text":"AF095844"}}</span>AF095844</a>).</p><!--table ft1--><!--table-wrap mode="anchored" t5--><div class="table-wrap anchored whole_rhythm" id="tbl1"><h3>Table 1</h3><!--caption a7--><div class="caption"><p>We analyzed 425 peptides, covering 96.7&#x000a0;% of human MDA5 by hydrogen deuterium exchange mass spectrometry. The peptide with a start point of 417(Q) and an end point of 426(L) (no. 169, sequence QILENSLLNL) is shown in bold.</p></div><div class="xtable"><table frame="hsides" rules="groups" class="rendered small default_table"><thead><tr><th rowspan="1" colspan="1">Sequence</th><th rowspan="1" colspan="1">Start</th><th rowspan="1" colspan="1">End</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">1. YSTDENF</td><td align="left" rowspan="1" colspan="1">7</td><td align="left" rowspan="1" colspan="1">13</td></tr><tr><td align="left" rowspan="1" colspan="1">2. FRYLISCFRARVK</td><td align="left" rowspan="1" colspan="1">13</td><td align="left" rowspan="1" colspan="1">25</td></tr><tr><td align="left" rowspan="1" colspan="1">3. RYLISCFRARV</td><td align="left" rowspan="1" colspan="1">14</td><td align="left" rowspan="1" colspan="1">24</td></tr><tr><td align="left" rowspan="1" colspan="1">4. YIQVEPVL</td><td align="left" rowspan="1" colspan="1">27</td><td align="left" rowspan="1" colspan="1">34</td></tr><tr><td align="left" rowspan="1" colspan="1">5. YIQVEPVLDYLTFL</td><td align="left" rowspan="1" colspan="1">27</td><td align="left" rowspan="1" colspan="1">40</td></tr><tr><td align="left" rowspan="1" colspan="1">6. IQVEPVLDYLTFL</td><td align="left" rowspan="1" colspan="1">28</td><td align="left" rowspan="1" colspan="1">40</td></tr><tr><td align="left" rowspan="1" colspan="1">7. PVLDYL</td><td align="left" rowspan="1" colspan="1">32</td><td align="left" rowspan="1" colspan="1">37</td></tr><tr><td align="left" rowspan="1" colspan="1">8. PVLDYLTFLP</td><td align="left" rowspan="1" colspan="1">32</td><td align="left" rowspan="1" colspan="1">41</td></tr><tr><td align="left" rowspan="1" colspan="1">9. LDYLTF</td><td align="left" rowspan="1" colspan="1">34</td><td align="left" rowspan="1" colspan="1">39</td></tr><tr><td align="left" rowspan="1" colspan="1">10. DYLTFLPAEVKEQIQRTV</td><td align="left" rowspan="1" colspan="1">35</td><td align="left" rowspan="1" colspan="1">52</td></tr><tr><td align="left" rowspan="1" colspan="1">11. YLTFLPAE</td><td align="left" rowspan="1" colspan="1">36</td><td align="left" rowspan="1" colspan="1">43</td></tr><tr><td align="left" rowspan="1" colspan="1">12. YLTFLPAEVK</td><td align="left" rowspan="1" colspan="1">36</td><td align="left" rowspan="1" colspan="1">45</td></tr><tr><td align="left" rowspan="1" colspan="1">13. TFLPAEVKEQIQRTVATSGNMQA</td><td align="left" rowspan="1" colspan="1">38</td><td align="left" rowspan="1" colspan="1">60</td></tr><tr><td align="left" rowspan="1" colspan="1">14. PAEVKEQIQRT</td><td align="left" rowspan="1" colspan="1">41</td><td align="left" rowspan="1" colspan="1">51</td></tr><tr><td align="left" rowspan="1" colspan="1">15. PAEVKEQIQRTVA</td><td align="left" rowspan="1" colspan="1">41</td><td align="left" rowspan="1" colspan="1">53</td></tr><tr><td align="left" rowspan="1" colspan="1">16. PAEVKEQIQRTVATSGNMQA</td><td align="left" rowspan="1" colspan="1">41</td><td align="left" rowspan="1" colspan="1">60</td></tr><tr><td align="left" rowspan="1" colspan="1">17. VKEQIQRTVATSGNM</td><td align="left" rowspan="1" colspan="1">44</td><td align="left" rowspan="1" colspan="1">58</td></tr><tr><td align="left" rowspan="1" colspan="1">18. VKEQIQRTVATSGNMQA</td><td align="left" rowspan="1" colspan="1">44</td><td align="left" rowspan="1" colspan="1">60</td></tr><tr><td align="left" rowspan="1" colspan="1">19. KEQIQRTVATSGNMQAVELLLSTLEK</td><td align="left" rowspan="1" colspan="1">45</td><td align="left" rowspan="1" colspan="1">70</td></tr><tr><td align="left" rowspan="1" colspan="1">20. QIQRTVATSGNM</td><td align="left" rowspan="1" colspan="1">47</td><td align="left" rowspan="1" colspan="1">58</td></tr><tr><td align="left" rowspan="1" colspan="1">21. IQRTVATSGN</td><td align="left" rowspan="1" colspan="1">48</td><td align="left" rowspan="1" colspan="1">57</td></tr><tr><td align="left" rowspan="1" colspan="1">22. QRTVATSGNM</td><td align="left" rowspan="1" colspan="1">49</td><td align="left" rowspan="1" colspan="1">58</td></tr><tr><td align="left" rowspan="1" colspan="1">23. VATSGN</td><td align="left" rowspan="1" colspan="1">52</td><td align="left" rowspan="1" colspan="1">57</td></tr><tr><td align="left" rowspan="1" colspan="1">24. ATSGNMQAVELL</td><td align="left" rowspan="1" colspan="1">53</td><td align="left" rowspan="1" colspan="1">64</td></tr><tr><td align="left" rowspan="1" colspan="1">25. GNMQAVELLLSTLEKGVWH</td><td align="left" rowspan="1" colspan="1">56</td><td align="left" rowspan="1" colspan="1">74</td></tr><tr><td align="left" rowspan="1" colspan="1">26. LLSTLEKGVWHLGWTRE</td><td align="left" rowspan="1" colspan="1">64</td><td align="left" rowspan="1" colspan="1">80</td></tr><tr><td align="left" rowspan="1" colspan="1">27. LSTLEKGVWHLGWTRE</td><td align="left" rowspan="1" colspan="1">65</td><td align="left" rowspan="1" colspan="1">80</td></tr><tr><td align="left" rowspan="1" colspan="1">28. STLEKGVWHLGWTRE</td><td align="left" rowspan="1" colspan="1">66</td><td align="left" rowspan="1" colspan="1">80</td></tr><tr><td align="left" rowspan="1" colspan="1">29. TLEKGVWHLGWTR</td><td align="left" rowspan="1" colspan="1">67</td><td align="left" rowspan="1" colspan="1">79</td></tr><tr><td align="left" rowspan="1" colspan="1">30. LEKGVWHLGW</td><td align="left" rowspan="1" colspan="1">68</td><td align="left" rowspan="1" colspan="1">77</td></tr><tr><td align="left" rowspan="1" colspan="1">31. LEKGVWHLGWTR</td><td align="left" rowspan="1" colspan="1">68</td><td align="left" rowspan="1" colspan="1">79</td></tr><tr><td align="left" rowspan="1" colspan="1">32. LEKGVWHLGWTRE</td><td align="left" rowspan="1" colspan="1">68</td><td align="left" rowspan="1" colspan="1">80</td></tr><tr><td align="left" rowspan="1" colspan="1">33. EKGVWHLGWTRE</td><td align="left" rowspan="1" colspan="1">69</td><td align="left" rowspan="1" colspan="1">80</td></tr><tr><td align="left" rowspan="1" colspan="1">34. GVWHLGWTRE</td><td align="left" rowspan="1" colspan="1">71</td><td align="left" rowspan="1" colspan="1">80</td></tr><tr><td align="left" rowspan="1" colspan="1">35. VWHLGWTREFVE</td><td align="left" rowspan="1" colspan="1">72</td><td align="left" rowspan="1" colspan="1">83</td></tr><tr><td align="left" rowspan="1" colspan="1">36. EFVEALR</td><td align="left" rowspan="1" colspan="1">80</td><td align="left" rowspan="1" colspan="1">86</td></tr><tr><td align="left" rowspan="1" colspan="1">37. EFVEALRR</td><td align="left" rowspan="1" colspan="1">80</td><td align="left" rowspan="1" colspan="1">87</td></tr><tr><td align="left" rowspan="1" colspan="1">38. FVEALRRT</td><td align="left" rowspan="1" colspan="1">81</td><td align="left" rowspan="1" colspan="1">88</td></tr><tr><td align="left" rowspan="1" colspan="1">39. VEALRRTGSP</td><td align="left" rowspan="1" colspan="1">82</td><td align="left" rowspan="1" colspan="1">91</td></tr><tr><td align="left" rowspan="1" colspan="1">40. ALRRTGSPLA</td><td align="left" rowspan="1" colspan="1">84</td><td align="left" rowspan="1" colspan="1">93</td></tr><tr><td align="left" rowspan="1" colspan="1">41. LRRTGSPLAA</td><td align="left" rowspan="1" colspan="1">85</td><td align="left" rowspan="1" colspan="1">94</td></tr><tr><td align="left" rowspan="1" colspan="1">42. RRTGSPLAARY</td><td align="left" rowspan="1" colspan="1">86</td><td align="left" rowspan="1" colspan="1">96</td></tr><tr><td align="left" rowspan="1" colspan="1">43. RRTGSPLAARYMNPEL</td><td align="left" rowspan="1" colspan="1">86</td><td align="left" rowspan="1" colspan="1">101</td></tr><tr><td align="left" rowspan="1" colspan="1">44. TGSPLAARYM</td><td align="left" rowspan="1" colspan="1">88</td><td align="left" rowspan="1" colspan="1">97</td></tr><tr><td align="left" rowspan="1" colspan="1">45. GSPLAA</td><td align="left" rowspan="1" colspan="1">89</td><td align="left" rowspan="1" colspan="1">94</td></tr><tr><td align="left" rowspan="1" colspan="1">46. GSPLAAR</td><td align="left" rowspan="1" colspan="1">89</td><td align="left" rowspan="1" colspan="1">95</td></tr><tr><td align="left" rowspan="1" colspan="1">47. TDLPSP</td><td align="left" rowspan="1" colspan="1">102</td><td align="left" rowspan="1" colspan="1">107</td></tr><tr><td align="left" rowspan="1" colspan="1">48. TDLPSPSF</td><td align="left" rowspan="1" colspan="1">102</td><td align="left" rowspan="1" colspan="1">109</td></tr><tr><td align="left" rowspan="1" colspan="1">49. TDLPSPSFE</td><td align="left" rowspan="1" colspan="1">102</td><td align="left" rowspan="1" colspan="1">110</td></tr><tr><td align="left" rowspan="1" colspan="1">50. LPSPSF</td><td align="left" rowspan="1" colspan="1">104</td><td align="left" rowspan="1" colspan="1">109</td></tr><tr><td align="left" rowspan="1" colspan="1">51. ENAHDEY</td><td align="left" rowspan="1" colspan="1">110</td><td align="left" rowspan="1" colspan="1">116</td></tr><tr><td align="left" rowspan="1" colspan="1">52. NAHDEY</td><td align="left" rowspan="1" colspan="1">111</td><td align="left" rowspan="1" colspan="1">116</td></tr><tr><td align="left" rowspan="1" colspan="1">53. AHDEYLQLLNLLQPT</td><td align="left" rowspan="1" colspan="1">112</td><td align="left" rowspan="1" colspan="1">126</td></tr><tr><td align="left" rowspan="1" colspan="1">54. HDEYLQLLNLLQ</td><td align="left" rowspan="1" colspan="1">113</td><td align="left" rowspan="1" colspan="1">124</td></tr><tr><td align="left" rowspan="1" colspan="1">55. QLLNLLQPTLV</td><td align="left" rowspan="1" colspan="1">118</td><td align="left" rowspan="1" colspan="1">128</td></tr><tr><td align="left" rowspan="1" colspan="1">56. LLNLLQPTLVD</td><td align="left" rowspan="1" colspan="1">119</td><td align="left" rowspan="1" colspan="1">129</td></tr><tr><td align="left" rowspan="1" colspan="1">57. LNLLQPTL</td><td align="left" rowspan="1" colspan="1">120</td><td align="left" rowspan="1" colspan="1">127</td></tr><tr><td align="left" rowspan="1" colspan="1">58. LNLLQPTLVD</td><td align="left" rowspan="1" colspan="1">120</td><td align="left" rowspan="1" colspan="1">129</td></tr><tr><td align="left" rowspan="1" colspan="1">59. NLLQPTL</td><td align="left" rowspan="1" colspan="1">121</td><td align="left" rowspan="1" colspan="1">127</td></tr><tr><td align="left" rowspan="1" colspan="1">60. LVRDVL</td><td align="left" rowspan="1" colspan="1">132</td><td align="left" rowspan="1" colspan="1">137</td></tr><tr><td align="left" rowspan="1" colspan="1">61. RDVLDKCMEEEL</td><td align="left" rowspan="1" colspan="1">134</td><td align="left" rowspan="1" colspan="1">145</td></tr><tr><td align="left" rowspan="1" colspan="1">62. EEELLTIEDRNRI</td><td align="left" rowspan="1" colspan="1">142</td><td align="left" rowspan="1" colspan="1">154</td></tr><tr><td align="left" rowspan="1" colspan="1">63. LTIEDRNRIAAAENNGNESG</td><td align="left" rowspan="1" colspan="1">146</td><td align="left" rowspan="1" colspan="1">165</td></tr><tr><td align="left" rowspan="1" colspan="1">64. LTIEDRNRIAAAENNGNESGVRELL</td><td align="left" rowspan="1" colspan="1">146</td><td align="left" rowspan="1" colspan="1">170</td></tr><tr><td align="left" rowspan="1" colspan="1">65. DRNRIAAAEN</td><td align="left" rowspan="1" colspan="1">150</td><td align="left" rowspan="1" colspan="1">159</td></tr><tr><td align="left" rowspan="1" colspan="1">66. DRNRIAAAENNGNESGVRE</td><td align="left" rowspan="1" colspan="1">150</td><td align="left" rowspan="1" colspan="1">168</td></tr><tr><td align="left" rowspan="1" colspan="1">67. AENNGNESGVRELL</td><td align="left" rowspan="1" colspan="1">157</td><td align="left" rowspan="1" colspan="1">170</td></tr><tr><td align="left" rowspan="1" colspan="1">68. LLKRIVQKENW</td><td align="left" rowspan="1" colspan="1">169</td><td align="left" rowspan="1" colspan="1">179</td></tr><tr><td align="left" rowspan="1" colspan="1">69. KENWFSAFLNVL</td><td align="left" rowspan="1" colspan="1">176</td><td align="left" rowspan="1" colspan="1">187</td></tr><tr><td align="left" rowspan="1" colspan="1">70. FSAFLN</td><td align="left" rowspan="1" colspan="1">180</td><td align="left" rowspan="1" colspan="1">185</td></tr><tr><td align="left" rowspan="1" colspan="1">71. FSAFLNVLRQTGNNE</td><td align="left" rowspan="1" colspan="1">180</td><td align="left" rowspan="1" colspan="1">194</td></tr><tr><td align="left" rowspan="1" colspan="1">72. FLNVLRQTGNN</td><td align="left" rowspan="1" colspan="1">183</td><td align="left" rowspan="1" colspan="1">193</td></tr><tr><td align="left" rowspan="1" colspan="1">73. FLNVLRQTGNNELV</td><td align="left" rowspan="1" colspan="1">183</td><td align="left" rowspan="1" colspan="1">196</td></tr><tr><td align="left" rowspan="1" colspan="1">74. LNVLRQTGNN</td><td align="left" rowspan="1" colspan="1">184</td><td align="left" rowspan="1" colspan="1">193</td></tr><tr><td align="left" rowspan="1" colspan="1">75. LNVLRQTGNNEL</td><td align="left" rowspan="1" colspan="1">184</td><td align="left" rowspan="1" colspan="1">195</td></tr><tr><td align="left" rowspan="1" colspan="1">76. VLRQTGNNELVQEL</td><td align="left" rowspan="1" colspan="1">186</td><td align="left" rowspan="1" colspan="1">199</td></tr><tr><td align="left" rowspan="1" colspan="1">77. LRQTGNNELVQ</td><td align="left" rowspan="1" colspan="1">187</td><td align="left" rowspan="1" colspan="1">197</td></tr><tr><td align="left" rowspan="1" colspan="1">78. RQTGNNEL</td><td align="left" rowspan="1" colspan="1">188</td><td align="left" rowspan="1" colspan="1">195</td></tr><tr><td align="left" rowspan="1" colspan="1">79. LVQELT</td><td align="left" rowspan="1" colspan="1">195</td><td align="left" rowspan="1" colspan="1">200</td></tr><tr><td align="left" rowspan="1" colspan="1">80. VQELTGSD</td><td align="left" rowspan="1" colspan="1">196</td><td align="left" rowspan="1" colspan="1">203</td></tr><tr><td align="left" rowspan="1" colspan="1">81. VQELTGSDCSESNA</td><td align="left" rowspan="1" colspan="1">196</td><td align="left" rowspan="1" colspan="1">209</td></tr><tr><td align="left" rowspan="1" colspan="1">82. SNAEIENLSQVD</td><td align="left" rowspan="1" colspan="1">207</td><td align="left" rowspan="1" colspan="1">218</td></tr><tr><td align="left" rowspan="1" colspan="1">83. IENLSQVDGPQVEEQLLSTTVQPNL</td><td align="left" rowspan="1" colspan="1">211</td><td align="left" rowspan="1" colspan="1">235</td></tr><tr><td align="left" rowspan="1" colspan="1">84. SQVDGP</td><td align="left" rowspan="1" colspan="1">215</td><td align="left" rowspan="1" colspan="1">220</td></tr><tr><td align="left" rowspan="1" colspan="1">85. SQVDGPQVE</td><td align="left" rowspan="1" colspan="1">215</td><td align="left" rowspan="1" colspan="1">223</td></tr><tr><td align="left" rowspan="1" colspan="1">86. SQVDGPQVEE</td><td align="left" rowspan="1" colspan="1">215</td><td align="left" rowspan="1" colspan="1">224</td></tr><tr><td align="left" rowspan="1" colspan="1">87. SQVDGPQVEEQL</td><td align="left" rowspan="1" colspan="1">215</td><td align="left" rowspan="1" colspan="1">226</td></tr><tr><td align="left" rowspan="1" colspan="1">88. SQVDGPQVEEQLL</td><td align="left" rowspan="1" colspan="1">215</td><td align="left" rowspan="1" colspan="1">227</td></tr><tr><td align="left" rowspan="1" colspan="1">89. VDGPQVE</td><td align="left" rowspan="1" colspan="1">217</td><td align="left" rowspan="1" colspan="1">223</td></tr><tr><td align="left" rowspan="1" colspan="1">90. VDGPQVEEQL</td><td align="left" rowspan="1" colspan="1">217</td><td align="left" rowspan="1" colspan="1">226</td></tr><tr><td align="left" rowspan="1" colspan="1">91. DGPQVE</td><td align="left" rowspan="1" colspan="1">218</td><td align="left" rowspan="1" colspan="1">223</td></tr><tr><td align="left" rowspan="1" colspan="1">92. GPQVEEQL</td><td align="left" rowspan="1" colspan="1">219</td><td align="left" rowspan="1" colspan="1">226</td></tr><tr><td align="left" rowspan="1" colspan="1">93. VEEQLLSTTVQPNL</td><td align="left" rowspan="1" colspan="1">222</td><td align="left" rowspan="1" colspan="1">235</td></tr><tr><td align="left" rowspan="1" colspan="1">94. EQLLSTTVQPNLEK</td><td align="left" rowspan="1" colspan="1">224</td><td align="left" rowspan="1" colspan="1">237</td></tr><tr><td align="left" rowspan="1" colspan="1">95. LSTTVQPNL</td><td align="left" rowspan="1" colspan="1">227</td><td align="left" rowspan="1" colspan="1">235</td></tr><tr><td align="left" rowspan="1" colspan="1">96. LSTTVQPNLE</td><td align="left" rowspan="1" colspan="1">227</td><td align="left" rowspan="1" colspan="1">236</td></tr><tr><td align="left" rowspan="1" colspan="1">97. STTVQPNL</td><td align="left" rowspan="1" colspan="1">228</td><td align="left" rowspan="1" colspan="1">235</td></tr><tr><td align="left" rowspan="1" colspan="1">98. TVQPNLE</td><td align="left" rowspan="1" colspan="1">230</td><td align="left" rowspan="1" colspan="1">236</td></tr><tr><td align="left" rowspan="1" colspan="1">99. EKEVWGMENNSSESSF</td><td align="left" rowspan="1" colspan="1">236</td><td align="left" rowspan="1" colspan="1">251</td></tr><tr><td align="left" rowspan="1" colspan="1">100. FADSSV</td><td align="left" rowspan="1" colspan="1">251</td><td align="left" rowspan="1" colspan="1">256</td></tr><tr><td align="left" rowspan="1" colspan="1">101. ADSSVVSE</td><td align="left" rowspan="1" colspan="1">252</td><td align="left" rowspan="1" colspan="1">259</td></tr><tr><td align="left" rowspan="1" colspan="1">102. SVVSESDTSL</td><td align="left" rowspan="1" colspan="1">255</td><td align="left" rowspan="1" colspan="1">264</td></tr><tr><td align="left" rowspan="1" colspan="1">103. VSESDTSL</td><td align="left" rowspan="1" colspan="1">257</td><td align="left" rowspan="1" colspan="1">264</td></tr><tr><td align="left" rowspan="1" colspan="1">104. SESDTSL</td><td align="left" rowspan="1" colspan="1">258</td><td align="left" rowspan="1" colspan="1">264</td></tr><tr><td align="left" rowspan="1" colspan="1">105. TSLAEGSVS</td><td align="left" rowspan="1" colspan="1">262</td><td align="left" rowspan="1" colspan="1">270</td></tr><tr><td align="left" rowspan="1" colspan="1">106. TSLAEGSVSCL</td><td align="left" rowspan="1" colspan="1">262</td><td align="left" rowspan="1" colspan="1">272</td></tr><tr><td align="left" rowspan="1" colspan="1">107. LAEGSV</td><td align="left" rowspan="1" colspan="1">264</td><td align="left" rowspan="1" colspan="1">269</td></tr><tr><td align="left" rowspan="1" colspan="1">108. AEGSVSC</td><td align="left" rowspan="1" colspan="1">265</td><td align="left" rowspan="1" colspan="1">271</td></tr><tr><td align="left" rowspan="1" colspan="1">109. AEGSVSCL</td><td align="left" rowspan="1" colspan="1">265</td><td align="left" rowspan="1" colspan="1">272</td></tr><tr><td align="left" rowspan="1" colspan="1">110. VSCLDES</td><td align="left" rowspan="1" colspan="1">269</td><td align="left" rowspan="1" colspan="1">275</td></tr><tr><td align="left" rowspan="1" colspan="1">111. LDESLG</td><td align="left" rowspan="1" colspan="1">272</td><td align="left" rowspan="1" colspan="1">277</td></tr><tr><td align="left" rowspan="1" colspan="1">112. DESLGHNSNMG</td><td align="left" rowspan="1" colspan="1">273</td><td align="left" rowspan="1" colspan="1">283</td></tr><tr><td align="left" rowspan="1" colspan="1">113. SLGHNSNMGS</td><td align="left" rowspan="1" colspan="1">275</td><td align="left" rowspan="1" colspan="1">284</td></tr><tr><td align="left" rowspan="1" colspan="1">114. ENVAARASP</td><td align="left" rowspan="1" colspan="1">296</td><td align="left" rowspan="1" colspan="1">304</td></tr><tr><td align="left" rowspan="1" colspan="1">115. NVAARA</td><td align="left" rowspan="1" colspan="1">297</td><td align="left" rowspan="1" colspan="1">302</td></tr><tr><td align="left" rowspan="1" colspan="1">116. AARASP</td><td align="left" rowspan="1" colspan="1">299</td><td align="left" rowspan="1" colspan="1">304</td></tr><tr><td align="left" rowspan="1" colspan="1">117. ARASPEPEL</td><td align="left" rowspan="1" colspan="1">300</td><td align="left" rowspan="1" colspan="1">308</td></tr><tr><td align="left" rowspan="1" colspan="1">118. PELQLRPYQMEVAQP</td><td align="left" rowspan="1" colspan="1">306</td><td align="left" rowspan="1" colspan="1">320</td></tr><tr><td align="left" rowspan="1" colspan="1">119. ELQLRPYQME</td><td align="left" rowspan="1" colspan="1">307</td><td align="left" rowspan="1" colspan="1">316</td></tr><tr><td align="left" rowspan="1" colspan="1">120. ELQLRPYQMEVAQPALE</td><td align="left" rowspan="1" colspan="1">307</td><td align="left" rowspan="1" colspan="1">323</td></tr><tr><td align="left" rowspan="1" colspan="1">121. QMEVAQPALE</td><td align="left" rowspan="1" colspan="1">314</td><td align="left" rowspan="1" colspan="1">323</td></tr><tr><td align="left" rowspan="1" colspan="1">122. MEVAQP</td><td align="left" rowspan="1" colspan="1">315</td><td align="left" rowspan="1" colspan="1">320</td></tr><tr><td align="left" rowspan="1" colspan="1">123. MEVAQPALEGKNII</td><td align="left" rowspan="1" colspan="1">315</td><td align="left" rowspan="1" colspan="1">328</td></tr><tr><td align="left" rowspan="1" colspan="1">124. EVAQPAL</td><td align="left" rowspan="1" colspan="1">316</td><td align="left" rowspan="1" colspan="1">322</td></tr><tr><td align="left" rowspan="1" colspan="1">125. EVAQPALEGKN</td><td align="left" rowspan="1" colspan="1">316</td><td align="left" rowspan="1" colspan="1">326</td></tr><tr><td align="left" rowspan="1" colspan="1">126. EVAQPALEGKNII</td><td align="left" rowspan="1" colspan="1">316</td><td align="left" rowspan="1" colspan="1">328</td></tr><tr><td align="left" rowspan="1" colspan="1">127. VAQPAL</td><td align="left" rowspan="1" colspan="1">317</td><td align="left" rowspan="1" colspan="1">322</td></tr><tr><td align="left" rowspan="1" colspan="1">128. VAQPALEGKN</td><td align="left" rowspan="1" colspan="1">317</td><td align="left" rowspan="1" colspan="1">326</td></tr><tr><td align="left" rowspan="1" colspan="1">129. VAQPALEGKNIIIC</td><td align="left" rowspan="1" colspan="1">317</td><td align="left" rowspan="1" colspan="1">330</td></tr><tr><td align="left" rowspan="1" colspan="1">130. PALEGKN</td><td align="left" rowspan="1" colspan="1">320</td><td align="left" rowspan="1" colspan="1">326</td></tr><tr><td align="left" rowspan="1" colspan="1">131. ALEGKNIIICLP</td><td align="left" rowspan="1" colspan="1">321</td><td align="left" rowspan="1" colspan="1">332</td></tr><tr><td align="left" rowspan="1" colspan="1">132. IIICLPTGSGKTRVAV</td><td align="left" rowspan="1" colspan="1">327</td><td align="left" rowspan="1" colspan="1">342</td></tr><tr><td align="left" rowspan="1" colspan="1">133. IICLPTGSGKT</td><td align="left" rowspan="1" colspan="1">328</td><td align="left" rowspan="1" colspan="1">338</td></tr><tr><td align="left" rowspan="1" colspan="1">134. CLPTGSGKTRVAV</td><td align="left" rowspan="1" colspan="1">330</td><td align="left" rowspan="1" colspan="1">342</td></tr><tr><td align="left" rowspan="1" colspan="1">135. LPTGSGKTRVAV</td><td align="left" rowspan="1" colspan="1">331</td><td align="left" rowspan="1" colspan="1">342</td></tr><tr><td align="left" rowspan="1" colspan="1">136. PTGSGKTRVAV</td><td align="left" rowspan="1" colspan="1">332</td><td align="left" rowspan="1" colspan="1">342</td></tr><tr><td align="left" rowspan="1" colspan="1">137. PTGSGKTRVAVY</td><td align="left" rowspan="1" colspan="1">332</td><td align="left" rowspan="1" colspan="1">343</td></tr><tr><td align="left" rowspan="1" colspan="1">138. TGSGKTRVAVY</td><td align="left" rowspan="1" colspan="1">333</td><td align="left" rowspan="1" colspan="1">343</td></tr><tr><td align="left" rowspan="1" colspan="1">139. TGSGKTRVAVYI</td><td align="left" rowspan="1" colspan="1">333</td><td align="left" rowspan="1" colspan="1">344</td></tr><tr><td align="left" rowspan="1" colspan="1">140. SGKTRV</td><td align="left" rowspan="1" colspan="1">335</td><td align="left" rowspan="1" colspan="1">340</td></tr><tr><td align="left" rowspan="1" colspan="1">141. GKTRVA</td><td align="left" rowspan="1" colspan="1">336</td><td align="left" rowspan="1" colspan="1">341</td></tr><tr><td align="left" rowspan="1" colspan="1">142. VAVYIA</td><td align="left" rowspan="1" colspan="1">340</td><td align="left" rowspan="1" colspan="1">345</td></tr><tr><td align="left" rowspan="1" colspan="1">143. YIAKDHLDKKKKASEPGKVIVL</td><td align="left" rowspan="1" colspan="1">343</td><td align="left" rowspan="1" colspan="1">364</td></tr><tr><td align="left" rowspan="1" colspan="1">144. IAKDHLDKKKKASEPGKVIVL</td><td align="left" rowspan="1" colspan="1">344</td><td align="left" rowspan="1" colspan="1">364</td></tr><tr><td align="left" rowspan="1" colspan="1">145. DKKKKASEPGKVIVL</td><td align="left" rowspan="1" colspan="1">350</td><td align="left" rowspan="1" colspan="1">364</td></tr><tr><td align="left" rowspan="1" colspan="1">146. VNKVLL</td><td align="left" rowspan="1" colspan="1">365</td><td align="left" rowspan="1" colspan="1">370</td></tr><tr><td align="left" rowspan="1" colspan="1">147. VNKVLLVEQLFRKEFQP</td><td align="left" rowspan="1" colspan="1">365</td><td align="left" rowspan="1" colspan="1">381</td></tr><tr><td align="left" rowspan="1" colspan="1">148. LFRKEFQPFL</td><td align="left" rowspan="1" colspan="1">374</td><td align="left" rowspan="1" colspan="1">383</td></tr><tr><td align="left" rowspan="1" colspan="1">149. FRKEFQPFL</td><td align="left" rowspan="1" colspan="1">375</td><td align="left" rowspan="1" colspan="1">383</td></tr><tr><td align="left" rowspan="1" colspan="1">150. FRKEFQPFLKK</td><td align="left" rowspan="1" colspan="1">375</td><td align="left" rowspan="1" colspan="1">385</td></tr><tr><td align="left" rowspan="1" colspan="1">151. FRKEFQPFLKKWYRVIG</td><td align="left" rowspan="1" colspan="1">375</td><td align="left" rowspan="1" colspan="1">391</td></tr><tr><td align="left" rowspan="1" colspan="1">152. FRKEFQPFLKKWYRVIGL</td><td align="left" rowspan="1" colspan="1">375</td><td align="left" rowspan="1" colspan="1">392</td></tr><tr><td align="left" rowspan="1" colspan="1">153. KKWYRVIGLSGDTQL</td><td align="left" rowspan="1" colspan="1">384</td><td align="left" rowspan="1" colspan="1">398</td></tr><tr><td align="left" rowspan="1" colspan="1">154. KKWYRVIGLSGDTQLK</td><td align="left" rowspan="1" colspan="1">384</td><td align="left" rowspan="1" colspan="1">399</td></tr><tr><td align="left" rowspan="1" colspan="1">155. WYRVIGLSGDTQL</td><td align="left" rowspan="1" colspan="1">386</td><td align="left" rowspan="1" colspan="1">398</td></tr><tr><td align="left" rowspan="1" colspan="1">156. YRVIGLSGDTQL</td><td align="left" rowspan="1" colspan="1">387</td><td align="left" rowspan="1" colspan="1">398</td></tr><tr><td align="left" rowspan="1" colspan="1">157. RVIGLSGDTQ</td><td align="left" rowspan="1" colspan="1">388</td><td align="left" rowspan="1" colspan="1">397</td></tr><tr><td align="left" rowspan="1" colspan="1">158. IGLSGDTQLKI</td><td align="left" rowspan="1" colspan="1">390</td><td align="left" rowspan="1" colspan="1">400</td></tr><tr><td align="left" rowspan="1" colspan="1">159. GLSGDTQLKI</td><td align="left" rowspan="1" colspan="1">391</td><td align="left" rowspan="1" colspan="1">400</td></tr><tr><td align="left" rowspan="1" colspan="1">160. SGDTQL</td><td align="left" rowspan="1" colspan="1">393</td><td align="left" rowspan="1" colspan="1">398</td></tr><tr><td align="left" rowspan="1" colspan="1">161. LKISFPEVVKSCDIII</td><td align="left" rowspan="1" colspan="1">398</td><td align="left" rowspan="1" colspan="1">413</td></tr><tr><td align="left" rowspan="1" colspan="1">162. KISFPE</td><td align="left" rowspan="1" colspan="1">399</td><td align="left" rowspan="1" colspan="1">404</td></tr><tr><td align="left" rowspan="1" colspan="1">163. ISFPEVVKSC</td><td align="left" rowspan="1" colspan="1">400</td><td align="left" rowspan="1" colspan="1">409</td></tr><tr><td align="left" rowspan="1" colspan="1">164. ISFPEVVKSCD</td><td align="left" rowspan="1" colspan="1">400</td><td align="left" rowspan="1" colspan="1">410</td></tr><tr><td align="left" rowspan="1" colspan="1">165. PEVVKSCD</td><td align="left" rowspan="1" colspan="1">403</td><td align="left" rowspan="1" colspan="1">410</td></tr><tr><td align="left" rowspan="1" colspan="1">166. PEVVKSCDIIISTA</td><td align="left" rowspan="1" colspan="1">403</td><td align="left" rowspan="1" colspan="1">416</td></tr><tr><td align="left" rowspan="1" colspan="1">167. EVVKSCD</td><td align="left" rowspan="1" colspan="1">404</td><td align="left" rowspan="1" colspan="1">410</td></tr><tr><td align="left" rowspan="1" colspan="1">168. VKSCDIIISTAQ</td><td align="left" rowspan="1" colspan="1">406</td><td align="left" rowspan="1" colspan="1">417</td></tr><tr><td align="left" rowspan="1" colspan="1"><strong>169. QILENSLLNL</strong></td><td align="left" rowspan="1" colspan="1"><strong>417</strong></td><td align="left" rowspan="1" colspan="1"><strong>426</strong></td></tr><tr><td align="left" rowspan="1" colspan="1">170. LLNLEN</td><td align="left" rowspan="1" colspan="1">423</td><td align="left" rowspan="1" colspan="1">428</td></tr><tr><td align="left" rowspan="1" colspan="1">171. LNLENGEDAG</td><td align="left" rowspan="1" colspan="1">424</td><td align="left" rowspan="1" colspan="1">433</td></tr><tr><td align="left" rowspan="1" colspan="1">172. LNLENGEDAGVQ</td><td align="left" rowspan="1" colspan="1">424</td><td align="left" rowspan="1" colspan="1">435</td></tr><tr><td align="left" rowspan="1" colspan="1">173. NLENGEDAGVQ</td><td align="left" rowspan="1" colspan="1">425</td><td align="left" rowspan="1" colspan="1">435</td></tr><tr><td align="left" rowspan="1" colspan="1">174. ENGEDAGVQL</td><td align="left" rowspan="1" colspan="1">427</td><td align="left" rowspan="1" colspan="1">436</td></tr><tr><td align="left" rowspan="1" colspan="1">175. DAGVQL</td><td align="left" rowspan="1" colspan="1">431</td><td align="left" rowspan="1" colspan="1">436</td></tr><tr><td align="left" rowspan="1" colspan="1">176. DAGVQLSDFSLI</td><td align="left" rowspan="1" colspan="1">431</td><td align="left" rowspan="1" colspan="1">442</td></tr><tr><td align="left" rowspan="1" colspan="1">177. DAGVQLSDFSLIIID</td><td align="left" rowspan="1" colspan="1">431</td><td align="left" rowspan="1" colspan="1">445</td></tr><tr><td align="left" rowspan="1" colspan="1">178. AGVQLSD</td><td align="left" rowspan="1" colspan="1">432</td><td align="left" rowspan="1" colspan="1">438</td></tr><tr><td align="left" rowspan="1" colspan="1">179. AGVQLSDFSLIIID</td><td align="left" rowspan="1" colspan="1">432</td><td align="left" rowspan="1" colspan="1">445</td></tr><tr><td align="left" rowspan="1" colspan="1">180. GVQLSDFSLIIIDECHHTNKEAVYN</td><td align="left" rowspan="1" colspan="1">433</td><td align="left" rowspan="1" colspan="1">457</td></tr><tr><td align="left" rowspan="1" colspan="1">181. LSDFSLIIIDEC</td><td align="left" rowspan="1" colspan="1">436</td><td align="left" rowspan="1" colspan="1">447</td></tr><tr><td align="left" rowspan="1" colspan="1">182. SDFSLIIID</td><td align="left" rowspan="1" colspan="1">437</td><td align="left" rowspan="1" colspan="1">445</td></tr><tr><td align="left" rowspan="1" colspan="1">183. DFSLII</td><td align="left" rowspan="1" colspan="1">438</td><td align="left" rowspan="1" colspan="1">443</td></tr><tr><td align="left" rowspan="1" colspan="1">184. IIIDECHHTNKEAV</td><td align="left" rowspan="1" colspan="1">442</td><td align="left" rowspan="1" colspan="1">455</td></tr><tr><td align="left" rowspan="1" colspan="1">185. IIIDECHHTNKEAVYNN</td><td align="left" rowspan="1" colspan="1">442</td><td align="left" rowspan="1" colspan="1">458</td></tr><tr><td align="left" rowspan="1" colspan="1">186. IIIDECHHTNKEAVYNNIMRH</td><td align="left" rowspan="1" colspan="1">442</td><td align="left" rowspan="1" colspan="1">462</td></tr><tr><td align="left" rowspan="1" colspan="1">187. IDECHHTNKEAV</td><td align="left" rowspan="1" colspan="1">444</td><td align="left" rowspan="1" colspan="1">455</td></tr><tr><td align="left" rowspan="1" colspan="1">188. IDECHHTNKEAVYNNIMRHYLMQ</td><td align="left" rowspan="1" colspan="1">444</td><td align="left" rowspan="1" colspan="1">466</td></tr><tr><td align="left" rowspan="1" colspan="1">189. TNKEAVYN</td><td align="left" rowspan="1" colspan="1">450</td><td align="left" rowspan="1" colspan="1">457</td></tr><tr><td align="left" rowspan="1" colspan="1">190. NKEAVYNNIMR</td><td align="left" rowspan="1" colspan="1">451</td><td align="left" rowspan="1" colspan="1">461</td></tr><tr><td align="left" rowspan="1" colspan="1">191. YNNIMRHYLM</td><td align="left" rowspan="1" colspan="1">456</td><td align="left" rowspan="1" colspan="1">465</td></tr><tr><td align="left" rowspan="1" colspan="1">192. IMRHYLMQKLKNNRL</td><td align="left" rowspan="1" colspan="1">459</td><td align="left" rowspan="1" colspan="1">473</td></tr><tr><td align="left" rowspan="1" colspan="1">193. IMRHYLMQKLKNNRLKKENKPVIPLPQILGL</td><td align="left" rowspan="1" colspan="1">459</td><td align="left" rowspan="1" colspan="1">489</td></tr><tr><td align="left" rowspan="1" colspan="1">194. MQKLKNNRLKKENKPVIPLPQILGL</td><td align="left" rowspan="1" colspan="1">465</td><td align="left" rowspan="1" colspan="1">489</td></tr><tr><td align="left" rowspan="1" colspan="1">195. QKLKNNRLKKENKPVIPLPQILGL</td><td align="left" rowspan="1" colspan="1">466</td><td align="left" rowspan="1" colspan="1">489</td></tr><tr><td align="left" rowspan="1" colspan="1">196. KLKNNRLKKENKPVIPLPQILGL</td><td align="left" rowspan="1" colspan="1">467</td><td align="left" rowspan="1" colspan="1">489</td></tr><tr><td align="left" rowspan="1" colspan="1">197. LKKENKPVIPLPQILGLTASP</td><td align="left" rowspan="1" colspan="1">473</td><td align="left" rowspan="1" colspan="1">493</td></tr><tr><td align="left" rowspan="1" colspan="1">198. KKENKPVIPLPQILGL</td><td align="left" rowspan="1" colspan="1">474</td><td align="left" rowspan="1" colspan="1">489</td></tr><tr><td align="left" rowspan="1" colspan="1">199. ENKPVIPLPQI</td><td align="left" rowspan="1" colspan="1">476</td><td align="left" rowspan="1" colspan="1">486</td></tr><tr><td align="left" rowspan="1" colspan="1">200. PQILGL</td><td align="left" rowspan="1" colspan="1">484</td><td align="left" rowspan="1" colspan="1">489</td></tr><tr><td align="left" rowspan="1" colspan="1">201. PQILGLTA</td><td align="left" rowspan="1" colspan="1">484</td><td align="left" rowspan="1" colspan="1">491</td></tr><tr><td align="left" rowspan="1" colspan="1">202. PQILGLTASP</td><td align="left" rowspan="1" colspan="1">484</td><td align="left" rowspan="1" colspan="1">493</td></tr><tr><td align="left" rowspan="1" colspan="1">203. LGLTASPGVGGATKQAKAE</td><td align="left" rowspan="1" colspan="1">487</td><td align="left" rowspan="1" colspan="1">505</td></tr><tr><td align="left" rowspan="1" colspan="1">204. GLTASPG</td><td align="left" rowspan="1" colspan="1">488</td><td align="left" rowspan="1" colspan="1">494</td></tr><tr><td align="left" rowspan="1" colspan="1">205. GLTASPGVGG</td><td align="left" rowspan="1" colspan="1">488</td><td align="left" rowspan="1" colspan="1">497</td></tr><tr><td align="left" rowspan="1" colspan="1">206. LTASPGVGGA</td><td align="left" rowspan="1" colspan="1">489</td><td align="left" rowspan="1" colspan="1">498</td></tr><tr><td align="left" rowspan="1" colspan="1">207. TASPGVGGAT</td><td align="left" rowspan="1" colspan="1">490</td><td align="left" rowspan="1" colspan="1">499</td></tr><tr><td align="left" rowspan="1" colspan="1">208. TASPGVGGATKQAKAEE</td><td align="left" rowspan="1" colspan="1">490</td><td align="left" rowspan="1" colspan="1">506</td></tr><tr><td align="left" rowspan="1" colspan="1">209. TASPGVGGATKQAKAEEHILKL</td><td align="left" rowspan="1" colspan="1">490</td><td align="left" rowspan="1" colspan="1">511</td></tr><tr><td align="left" rowspan="1" colspan="1">210. SPGVGGATKQ</td><td align="left" rowspan="1" colspan="1">492</td><td align="left" rowspan="1" colspan="1">501</td></tr><tr><td align="left" rowspan="1" colspan="1">211. SPGVGGATKQAKAEE</td><td align="left" rowspan="1" colspan="1">492</td><td align="left" rowspan="1" colspan="1">506</td></tr><tr><td align="left" rowspan="1" colspan="1">212. SPGVGGATKQAKAEEHILKL</td><td align="left" rowspan="1" colspan="1">492</td><td align="left" rowspan="1" colspan="1">511</td></tr><tr><td align="left" rowspan="1" colspan="1">213. PGVGGAT</td><td align="left" rowspan="1" colspan="1">493</td><td align="left" rowspan="1" colspan="1">499</td></tr><tr><td align="left" rowspan="1" colspan="1">214. PGVGGATKQAKAEE</td><td align="left" rowspan="1" colspan="1">493</td><td align="left" rowspan="1" colspan="1">506</td></tr><tr><td align="left" rowspan="1" colspan="1">215. PGVGGATKQAKAEEH</td><td align="left" rowspan="1" colspan="1">493</td><td align="left" rowspan="1" colspan="1">507</td></tr><tr><td align="left" rowspan="1" colspan="1">216. PGVGGATKQAKAEEHILKL</td><td align="left" rowspan="1" colspan="1">493</td><td align="left" rowspan="1" colspan="1">511</td></tr><tr><td align="left" rowspan="1" colspan="1">217. GVGGATKQAKAEEH</td><td align="left" rowspan="1" colspan="1">494</td><td align="left" rowspan="1" colspan="1">507</td></tr><tr><td align="left" rowspan="1" colspan="1">218. GGATKQAKAEEHILKL</td><td align="left" rowspan="1" colspan="1">496</td><td align="left" rowspan="1" colspan="1">511</td></tr><tr><td align="left" rowspan="1" colspan="1">219. TKQAKAEEHILKLCANL</td><td align="left" rowspan="1" colspan="1">499</td><td align="left" rowspan="1" colspan="1">515</td></tr><tr><td align="left" rowspan="1" colspan="1">220. AKAEEHILKLCANLDAFTIKTV</td><td align="left" rowspan="1" colspan="1">502</td><td align="left" rowspan="1" colspan="1">523</td></tr><tr><td align="left" rowspan="1" colspan="1">221. KAEEHILKLCANLD</td><td align="left" rowspan="1" colspan="1">503</td><td align="left" rowspan="1" colspan="1">516</td></tr><tr><td align="left" rowspan="1" colspan="1">222. EEHILKL</td><td align="left" rowspan="1" colspan="1">505</td><td align="left" rowspan="1" colspan="1">511</td></tr><tr><td align="left" rowspan="1" colspan="1">223. KLCANLDAFT</td><td align="left" rowspan="1" colspan="1">510</td><td align="left" rowspan="1" colspan="1">519</td></tr><tr><td align="left" rowspan="1" colspan="1">224. CANLDA</td><td align="left" rowspan="1" colspan="1">512</td><td align="left" rowspan="1" colspan="1">517</td></tr><tr><td align="left" rowspan="1" colspan="1">225. FTIKTVKENL</td><td align="left" rowspan="1" colspan="1">518</td><td align="left" rowspan="1" colspan="1">527</td></tr><tr><td align="left" rowspan="1" colspan="1">226. FTIKTVKENLDQL</td><td align="left" rowspan="1" colspan="1">518</td><td align="left" rowspan="1" colspan="1">530</td></tr><tr><td align="left" rowspan="1" colspan="1">227. TIKTVKENL</td><td align="left" rowspan="1" colspan="1">519</td><td align="left" rowspan="1" colspan="1">527</td></tr><tr><td align="left" rowspan="1" colspan="1">228. TVKENLDQLKNQ</td><td align="left" rowspan="1" colspan="1">522</td><td align="left" rowspan="1" colspan="1">533</td></tr><tr><td align="left" rowspan="1" colspan="1">229. NLDQLKNQIQEPCKKFAIA</td><td align="left" rowspan="1" colspan="1">526</td><td align="left" rowspan="1" colspan="1">544</td></tr><tr><td align="left" rowspan="1" colspan="1">230. DQLKNQIQEPCKKFAIADATREDPFKEKL</td><td align="left" rowspan="1" colspan="1">528</td><td align="left" rowspan="1" colspan="1">556</td></tr><tr><td align="left" rowspan="1" colspan="1">231. EPCKKFA</td><td align="left" rowspan="1" colspan="1">536</td><td align="left" rowspan="1" colspan="1">542</td></tr><tr><td align="left" rowspan="1" colspan="1">232. PCKKFAIADAT</td><td align="left" rowspan="1" colspan="1">537</td><td align="left" rowspan="1" colspan="1">547</td></tr><tr><td align="left" rowspan="1" colspan="1">233. AIADAT</td><td align="left" rowspan="1" colspan="1">542</td><td align="left" rowspan="1" colspan="1">547</td></tr><tr><td align="left" rowspan="1" colspan="1">234. DATREDPFKEKL</td><td align="left" rowspan="1" colspan="1">545</td><td align="left" rowspan="1" colspan="1">556</td></tr><tr><td align="left" rowspan="1" colspan="1">235. ATREDPFKEKL</td><td align="left" rowspan="1" colspan="1">546</td><td align="left" rowspan="1" colspan="1">556</td></tr><tr><td align="left" rowspan="1" colspan="1">236. ATREDPFKEKLLE</td><td align="left" rowspan="1" colspan="1">546</td><td align="left" rowspan="1" colspan="1">558</td></tr><tr><td align="left" rowspan="1" colspan="1">237. TREDPFKEKL</td><td align="left" rowspan="1" colspan="1">547</td><td align="left" rowspan="1" colspan="1">556</td></tr><tr><td align="left" rowspan="1" colspan="1">238. IMTRIQT</td><td align="left" rowspan="1" colspan="1">559</td><td align="left" rowspan="1" colspan="1">565</td></tr><tr><td align="left" rowspan="1" colspan="1">239. MTRIQTYCQMSPMSDFGTQPY</td><td align="left" rowspan="1" colspan="1">560</td><td align="left" rowspan="1" colspan="1">580</td></tr><tr><td align="left" rowspan="1" colspan="1">240. MTRIQTYCQMSPMSDFGTQPYE</td><td align="left" rowspan="1" colspan="1">560</td><td align="left" rowspan="1" colspan="1">581</td></tr><tr><td align="left" rowspan="1" colspan="1">241. RIQTYC</td><td align="left" rowspan="1" colspan="1">562</td><td align="left" rowspan="1" colspan="1">567</td></tr><tr><td align="left" rowspan="1" colspan="1">242. YCQMSPMSD</td><td align="left" rowspan="1" colspan="1">566</td><td align="left" rowspan="1" colspan="1">574</td></tr><tr><td align="left" rowspan="1" colspan="1">243. YCQMSPMSDF</td><td align="left" rowspan="1" colspan="1">566</td><td align="left" rowspan="1" colspan="1">575</td></tr><tr><td align="left" rowspan="1" colspan="1">244. CQMSPMSD</td><td align="left" rowspan="1" colspan="1">567</td><td align="left" rowspan="1" colspan="1">574</td></tr><tr><td align="left" rowspan="1" colspan="1">245. CQMSPMSDF</td><td align="left" rowspan="1" colspan="1">567</td><td align="left" rowspan="1" colspan="1">575</td></tr><tr><td align="left" rowspan="1" colspan="1">246. MSPMSDF</td><td align="left" rowspan="1" colspan="1">569</td><td align="left" rowspan="1" colspan="1">575</td></tr><tr><td align="left" rowspan="1" colspan="1">247. SPMSDF</td><td align="left" rowspan="1" colspan="1">570</td><td align="left" rowspan="1" colspan="1">575</td></tr><tr><td align="left" rowspan="1" colspan="1">248. SPMSDFGTQPYEQW</td><td align="left" rowspan="1" colspan="1">570</td><td align="left" rowspan="1" colspan="1">583</td></tr><tr><td align="left" rowspan="1" colspan="1">249. FGTQPYEQ</td><td align="left" rowspan="1" colspan="1">575</td><td align="left" rowspan="1" colspan="1">582</td></tr><tr><td align="left" rowspan="1" colspan="1">250. GTQPYEQ</td><td align="left" rowspan="1" colspan="1">576</td><td align="left" rowspan="1" colspan="1">582</td></tr><tr><td align="left" rowspan="1" colspan="1">251. GTQPYEQW</td><td align="left" rowspan="1" colspan="1">576</td><td align="left" rowspan="1" colspan="1">583</td></tr><tr><td align="left" rowspan="1" colspan="1">252. TQPYEQW</td><td align="left" rowspan="1" colspan="1">577</td><td align="left" rowspan="1" colspan="1">583</td></tr><tr><td align="left" rowspan="1" colspan="1">253. PYEQWAIQMEKKA</td><td align="left" rowspan="1" colspan="1">579</td><td align="left" rowspan="1" colspan="1">591</td></tr><tr><td align="left" rowspan="1" colspan="1">254. AIQMEKKAAKKG</td><td align="left" rowspan="1" colspan="1">584</td><td align="left" rowspan="1" colspan="1">595</td></tr><tr><td align="left" rowspan="1" colspan="1">255. EKKAAK</td><td align="left" rowspan="1" colspan="1">588</td><td align="left" rowspan="1" colspan="1">593</td></tr><tr><td align="left" rowspan="1" colspan="1">256. ERVCAEHLRKYNEALQIND</td><td align="left" rowspan="1" colspan="1">599</td><td align="left" rowspan="1" colspan="1">617</td></tr><tr><td align="left" rowspan="1" colspan="1">257. AEHLRKYNEALQINDT</td><td align="left" rowspan="1" colspan="1">603</td><td align="left" rowspan="1" colspan="1">618</td></tr><tr><td align="left" rowspan="1" colspan="1">258. HLRKYNEALQIN</td><td align="left" rowspan="1" colspan="1">605</td><td align="left" rowspan="1" colspan="1">616</td></tr><tr><td align="left" rowspan="1" colspan="1">259. HLRKYNEALQIND</td><td align="left" rowspan="1" colspan="1">605</td><td align="left" rowspan="1" colspan="1">617</td></tr><tr><td align="left" rowspan="1" colspan="1">260. RMIDAY</td><td align="left" rowspan="1" colspan="1">620</td><td align="left" rowspan="1" colspan="1">625</td></tr><tr><td align="left" rowspan="1" colspan="1">261. YTHLET</td><td align="left" rowspan="1" colspan="1">625</td><td align="left" rowspan="1" colspan="1">630</td></tr><tr><td align="left" rowspan="1" colspan="1">262. FYNEEKDK</td><td align="left" rowspan="1" colspan="1">631</td><td align="left" rowspan="1" colspan="1">638</td></tr><tr><td align="left" rowspan="1" colspan="1">263. FYNEEKDKKF</td><td align="left" rowspan="1" colspan="1">631</td><td align="left" rowspan="1" colspan="1">640</td></tr><tr><td align="left" rowspan="1" colspan="1">264. YNEEKDKKFAVIEDDSDEGGDDE</td><td align="left" rowspan="1" colspan="1">632</td><td align="left" rowspan="1" colspan="1">654</td></tr><tr><td align="left" rowspan="1" colspan="1">265. NEEKDKKFAVIEDDSDEGGDDEY</td><td align="left" rowspan="1" colspan="1">633</td><td align="left" rowspan="1" colspan="1">655</td></tr><tr><td align="left" rowspan="1" colspan="1">266. KDKKFA</td><td align="left" rowspan="1" colspan="1">636</td><td align="left" rowspan="1" colspan="1">641</td></tr><tr><td align="left" rowspan="1" colspan="1">267. DDEYCDGDEDEDDLKKPLKLDETDR</td><td align="left" rowspan="1" colspan="1">652</td><td align="left" rowspan="1" colspan="1">676</td></tr><tr><td align="left" rowspan="1" colspan="1">268. YCDGDEDEDDLKKPLKL</td><td align="left" rowspan="1" colspan="1">655</td><td align="left" rowspan="1" colspan="1">671</td></tr><tr><td align="left" rowspan="1" colspan="1">269. YCDGDEDEDDLKKPLKLDETDRF</td><td align="left" rowspan="1" colspan="1">655</td><td align="left" rowspan="1" colspan="1">677</td></tr><tr><td align="left" rowspan="1" colspan="1">270. DEDEDDLKKPLKL</td><td align="left" rowspan="1" colspan="1">659</td><td align="left" rowspan="1" colspan="1">671</td></tr><tr><td align="left" rowspan="1" colspan="1">271. EDEDDLKKPLK</td><td align="left" rowspan="1" colspan="1">660</td><td align="left" rowspan="1" colspan="1">670</td></tr><tr><td align="left" rowspan="1" colspan="1">272. DEDDLKKPLKL</td><td align="left" rowspan="1" colspan="1">661</td><td align="left" rowspan="1" colspan="1">671</td></tr><tr><td align="left" rowspan="1" colspan="1">273. DEDDLKKPLKLDE</td><td align="left" rowspan="1" colspan="1">661</td><td align="left" rowspan="1" colspan="1">673</td></tr><tr><td align="left" rowspan="1" colspan="1">274. DDLKKPLKL</td><td align="left" rowspan="1" colspan="1">663</td><td align="left" rowspan="1" colspan="1">671</td></tr><tr><td align="left" rowspan="1" colspan="1">275. DLKKPLKL</td><td align="left" rowspan="1" colspan="1">664</td><td align="left" rowspan="1" colspan="1">671</td></tr><tr><td align="left" rowspan="1" colspan="1">276. LKKPLKL</td><td align="left" rowspan="1" colspan="1">665</td><td align="left" rowspan="1" colspan="1">671</td></tr><tr><td align="left" rowspan="1" colspan="1">277. DETDRF</td><td align="left" rowspan="1" colspan="1">672</td><td align="left" rowspan="1" colspan="1">677</td></tr><tr><td align="left" rowspan="1" colspan="1">278. TDRFLM</td><td align="left" rowspan="1" colspan="1">674</td><td align="left" rowspan="1" colspan="1">679</td></tr><tr><td align="left" rowspan="1" colspan="1">279. DRFLMTLF</td><td align="left" rowspan="1" colspan="1">675</td><td align="left" rowspan="1" colspan="1">682</td></tr><tr><td align="left" rowspan="1" colspan="1">280. DRFLMTLFFENNKMLKRLAENPEYENEKLT</td><td align="left" rowspan="1" colspan="1">675</td><td align="left" rowspan="1" colspan="1">704</td></tr><tr><td align="left" rowspan="1" colspan="1">281. MTLFFE</td><td align="left" rowspan="1" colspan="1">679</td><td align="left" rowspan="1" colspan="1">684</td></tr><tr><td align="left" rowspan="1" colspan="1">282. LFFENNKM</td><td align="left" rowspan="1" colspan="1">681</td><td align="left" rowspan="1" colspan="1">688</td></tr><tr><td align="left" rowspan="1" colspan="1">283. LFFENNKMLKRLAENPEYE</td><td align="left" rowspan="1" colspan="1">681</td><td align="left" rowspan="1" colspan="1">699</td></tr><tr><td align="left" rowspan="1" colspan="1">284. FFENNKM</td><td align="left" rowspan="1" colspan="1">682</td><td align="left" rowspan="1" colspan="1">688</td></tr><tr><td align="left" rowspan="1" colspan="1">285. FFENNKMLKRLAENPEYE</td><td align="left" rowspan="1" colspan="1">682</td><td align="left" rowspan="1" colspan="1">699</td></tr><tr><td align="left" rowspan="1" colspan="1">286. FFENNKMLKRLAENPEYENEKL</td><td align="left" rowspan="1" colspan="1">682</td><td align="left" rowspan="1" colspan="1">703</td></tr><tr><td align="left" rowspan="1" colspan="1">287. FFENNKMLKRLAENPEYENEKLTKLRNTIM</td><td align="left" rowspan="1" colspan="1">682</td><td align="left" rowspan="1" colspan="1">711</td></tr><tr><td align="left" rowspan="1" colspan="1">288. FENNKMLKRLAENPEYENEKL</td><td align="left" rowspan="1" colspan="1">683</td><td align="left" rowspan="1" colspan="1">703</td></tr><tr><td align="left" rowspan="1" colspan="1">289. FENNKMLKRLAENPEYENEKLTKLRNTIM</td><td align="left" rowspan="1" colspan="1">683</td><td align="left" rowspan="1" colspan="1">711</td></tr><tr><td align="left" rowspan="1" colspan="1">290. LKRLAENPEYENEKL</td><td align="left" rowspan="1" colspan="1">689</td><td align="left" rowspan="1" colspan="1">703</td></tr><tr><td align="left" rowspan="1" colspan="1">291. LAENPEYENEKL</td><td align="left" rowspan="1" colspan="1">692</td><td align="left" rowspan="1" colspan="1">703</td></tr><tr><td align="left" rowspan="1" colspan="1">292. LAENPEYENEKLTKLRNTIMEQYTRTE</td><td align="left" rowspan="1" colspan="1">692</td><td align="left" rowspan="1" colspan="1">718</td></tr><tr><td align="left" rowspan="1" colspan="1">293. ENPEYENEKLTK</td><td align="left" rowspan="1" colspan="1">694</td><td align="left" rowspan="1" colspan="1">705</td></tr><tr><td align="left" rowspan="1" colspan="1">294. TKLRNTIM</td><td align="left" rowspan="1" colspan="1">704</td><td align="left" rowspan="1" colspan="1">711</td></tr><tr><td align="left" rowspan="1" colspan="1">295. TKLRNTIMEQ</td><td align="left" rowspan="1" colspan="1">704</td><td align="left" rowspan="1" colspan="1">713</td></tr><tr><td align="left" rowspan="1" colspan="1">296. TKLRNTIMEQYT</td><td align="left" rowspan="1" colspan="1">704</td><td align="left" rowspan="1" colspan="1">715</td></tr><tr><td align="left" rowspan="1" colspan="1">297. IMEQYTRTEESAR</td><td align="left" rowspan="1" colspan="1">710</td><td align="left" rowspan="1" colspan="1">722</td></tr><tr><td align="left" rowspan="1" colspan="1">298. EQYTRTEESARG</td><td align="left" rowspan="1" colspan="1">712</td><td align="left" rowspan="1" colspan="1">723</td></tr><tr><td align="left" rowspan="1" colspan="1">299. QYTRTEESARGIIF</td><td align="left" rowspan="1" colspan="1">713</td><td align="left" rowspan="1" colspan="1">726</td></tr><tr><td align="left" rowspan="1" colspan="1">300. TRTEESARGI</td><td align="left" rowspan="1" colspan="1">715</td><td align="left" rowspan="1" colspan="1">724</td></tr><tr><td align="left" rowspan="1" colspan="1">301. ESARGIIFTKTRQ</td><td align="left" rowspan="1" colspan="1">719</td><td align="left" rowspan="1" colspan="1">731</td></tr><tr><td align="left" rowspan="1" colspan="1">302. SARGII</td><td align="left" rowspan="1" colspan="1">720</td><td align="left" rowspan="1" colspan="1">725</td></tr><tr><td align="left" rowspan="1" colspan="1">303. SARGIIF</td><td align="left" rowspan="1" colspan="1">720</td><td align="left" rowspan="1" colspan="1">726</td></tr><tr><td align="left" rowspan="1" colspan="1">304. SARGIIFTKTRQSAYALSQWIT</td><td align="left" rowspan="1" colspan="1">720</td><td align="left" rowspan="1" colspan="1">741</td></tr><tr><td align="left" rowspan="1" colspan="1">305. IIFTKTRQSAYALS</td><td align="left" rowspan="1" colspan="1">724</td><td align="left" rowspan="1" colspan="1">737</td></tr><tr><td align="left" rowspan="1" colspan="1">306. TKTRQSAYAL</td><td align="left" rowspan="1" colspan="1">727</td><td align="left" rowspan="1" colspan="1">736</td></tr><tr><td align="left" rowspan="1" colspan="1">307. TKTRQSAYALSQ</td><td align="left" rowspan="1" colspan="1">727</td><td align="left" rowspan="1" colspan="1">738</td></tr><tr><td align="left" rowspan="1" colspan="1">308. QSAYALSQWI</td><td align="left" rowspan="1" colspan="1">731</td><td align="left" rowspan="1" colspan="1">740</td></tr><tr><td align="left" rowspan="1" colspan="1">309. YALSQW</td><td align="left" rowspan="1" colspan="1">734</td><td align="left" rowspan="1" colspan="1">739</td></tr><tr><td align="left" rowspan="1" colspan="1">310. ITENEKFAEVGV</td><td align="left" rowspan="1" colspan="1">740</td><td align="left" rowspan="1" colspan="1">751</td></tr><tr><td align="left" rowspan="1" colspan="1">311. TENEKF</td><td align="left" rowspan="1" colspan="1">741</td><td align="left" rowspan="1" colspan="1">746</td></tr><tr><td align="left" rowspan="1" colspan="1">312. TENEKFAEVG</td><td align="left" rowspan="1" colspan="1">741</td><td align="left" rowspan="1" colspan="1">750</td></tr><tr><td align="left" rowspan="1" colspan="1">313. KFAEVGVKAHHLIGAG</td><td align="left" rowspan="1" colspan="1">745</td><td align="left" rowspan="1" colspan="1">760</td></tr><tr><td align="left" rowspan="1" colspan="1">314. AEVGVKAHHL</td><td align="left" rowspan="1" colspan="1">747</td><td align="left" rowspan="1" colspan="1">756</td></tr><tr><td align="left" rowspan="1" colspan="1">315. AEVGVKAHHLIGAGHSSE</td><td align="left" rowspan="1" colspan="1">747</td><td align="left" rowspan="1" colspan="1">764</td></tr><tr><td align="left" rowspan="1" colspan="1">316. AEVGVKAHHLIGAGHSSEF</td><td align="left" rowspan="1" colspan="1">747</td><td align="left" rowspan="1" colspan="1">765</td></tr><tr><td align="left" rowspan="1" colspan="1">317. EVGVKAHHLIGAGHSSE</td><td align="left" rowspan="1" colspan="1">748</td><td align="left" rowspan="1" colspan="1">764</td></tr><tr><td align="left" rowspan="1" colspan="1">318. VGVKAH</td><td align="left" rowspan="1" colspan="1">749</td><td align="left" rowspan="1" colspan="1">754</td></tr><tr><td align="left" rowspan="1" colspan="1">319. VGVKAHHLIGAGHSSE</td><td align="left" rowspan="1" colspan="1">749</td><td align="left" rowspan="1" colspan="1">764</td></tr><tr><td align="left" rowspan="1" colspan="1">320. GVKAHHLIGAGHS</td><td align="left" rowspan="1" colspan="1">750</td><td align="left" rowspan="1" colspan="1">762</td></tr><tr><td align="left" rowspan="1" colspan="1">321. GVKAHHLIGAGHSS</td><td align="left" rowspan="1" colspan="1">750</td><td align="left" rowspan="1" colspan="1">763</td></tr><tr><td align="left" rowspan="1" colspan="1">322. GVKAHHLIGAGHSSE</td><td align="left" rowspan="1" colspan="1">750</td><td align="left" rowspan="1" colspan="1">764</td></tr><tr><td align="left" rowspan="1" colspan="1">323. GVKAHHLIGAGHSSEFKPM</td><td align="left" rowspan="1" colspan="1">750</td><td align="left" rowspan="1" colspan="1">768</td></tr><tr><td align="left" rowspan="1" colspan="1">324. HLIGAG</td><td align="left" rowspan="1" colspan="1">755</td><td align="left" rowspan="1" colspan="1">760</td></tr><tr><td align="left" rowspan="1" colspan="1">325. IGAGHS</td><td align="left" rowspan="1" colspan="1">757</td><td align="left" rowspan="1" colspan="1">762</td></tr><tr><td align="left" rowspan="1" colspan="1">326. FKPMTQN</td><td align="left" rowspan="1" colspan="1">765</td><td align="left" rowspan="1" colspan="1">771</td></tr><tr><td align="left" rowspan="1" colspan="1">327. NEQKEVISKF</td><td align="left" rowspan="1" colspan="1">771</td><td align="left" rowspan="1" colspan="1">780</td></tr><tr><td align="left" rowspan="1" colspan="1">328. QKEVISKFRT</td><td align="left" rowspan="1" colspan="1">773</td><td align="left" rowspan="1" colspan="1">782</td></tr><tr><td align="left" rowspan="1" colspan="1">329. QKEVISKFRTGKINL</td><td align="left" rowspan="1" colspan="1">773</td><td align="left" rowspan="1" colspan="1">787</td></tr><tr><td align="left" rowspan="1" colspan="1">330. SKFRTGKINLLIATTVAEEGLDIKEC</td><td align="left" rowspan="1" colspan="1">778</td><td align="left" rowspan="1" colspan="1">803</td></tr><tr><td align="left" rowspan="1" colspan="1">331. KFRTGK</td><td align="left" rowspan="1" colspan="1">779</td><td align="left" rowspan="1" colspan="1">784</td></tr><tr><td align="left" rowspan="1" colspan="1">332. KFRTGKINLLIATTVAE</td><td align="left" rowspan="1" colspan="1">779</td><td align="left" rowspan="1" colspan="1">795</td></tr><tr><td align="left" rowspan="1" colspan="1">333. RTGKINLL</td><td align="left" rowspan="1" colspan="1">781</td><td align="left" rowspan="1" colspan="1">788</td></tr><tr><td align="left" rowspan="1" colspan="1">334. TGKINL</td><td align="left" rowspan="1" colspan="1">782</td><td align="left" rowspan="1" colspan="1">787</td></tr><tr><td align="left" rowspan="1" colspan="1">335. LLIATT</td><td align="left" rowspan="1" colspan="1">787</td><td align="left" rowspan="1" colspan="1">792</td></tr><tr><td align="left" rowspan="1" colspan="1">336. LIATTV</td><td align="left" rowspan="1" colspan="1">788</td><td align="left" rowspan="1" colspan="1">793</td></tr><tr><td align="left" rowspan="1" colspan="1">337. ATTVAE</td><td align="left" rowspan="1" colspan="1">790</td><td align="left" rowspan="1" colspan="1">795</td></tr><tr><td align="left" rowspan="1" colspan="1">338. ATTVAEEGLD</td><td align="left" rowspan="1" colspan="1">790</td><td align="left" rowspan="1" colspan="1">799</td></tr><tr><td align="left" rowspan="1" colspan="1">339. ATTVAEEGLDIKE</td><td align="left" rowspan="1" colspan="1">790</td><td align="left" rowspan="1" colspan="1">802</td></tr><tr><td align="left" rowspan="1" colspan="1">340. VAEEGLD</td><td align="left" rowspan="1" colspan="1">793</td><td align="left" rowspan="1" colspan="1">799</td></tr><tr><td align="left" rowspan="1" colspan="1">341. EEGLDIKECNIVIR</td><td align="left" rowspan="1" colspan="1">795</td><td align="left" rowspan="1" colspan="1">808</td></tr><tr><td align="left" rowspan="1" colspan="1">342. EEGLDIKECNIVIRYG</td><td align="left" rowspan="1" colspan="1">795</td><td align="left" rowspan="1" colspan="1">810</td></tr><tr><td align="left" rowspan="1" colspan="1">343. ECNIVIRYGLVTNEI</td><td align="left" rowspan="1" colspan="1">802</td><td align="left" rowspan="1" colspan="1">816</td></tr><tr><td align="left" rowspan="1" colspan="1">344. IVIRYGL</td><td align="left" rowspan="1" colspan="1">805</td><td align="left" rowspan="1" colspan="1">811</td></tr><tr><td align="left" rowspan="1" colspan="1">345. IVIRYGLVTNE</td><td align="left" rowspan="1" colspan="1">805</td><td align="left" rowspan="1" colspan="1">815</td></tr><tr><td align="left" rowspan="1" colspan="1">346. IVIRYGLVTNEIAMVQ</td><td align="left" rowspan="1" colspan="1">805</td><td align="left" rowspan="1" colspan="1">820</td></tr><tr><td align="left" rowspan="1" colspan="1">347. TNEIAMVQARGRA</td><td align="left" rowspan="1" colspan="1">813</td><td align="left" rowspan="1" colspan="1">825</td></tr><tr><td align="left" rowspan="1" colspan="1">348. TNEIAMVQARGRAR</td><td align="left" rowspan="1" colspan="1">813</td><td align="left" rowspan="1" colspan="1">826</td></tr><tr><td align="left" rowspan="1" colspan="1">349. ARGRARADESTYV</td><td align="left" rowspan="1" colspan="1">821</td><td align="left" rowspan="1" colspan="1">833</td></tr><tr><td align="left" rowspan="1" colspan="1">350. RARADESTYVLVAHSGSGVIEHETVN</td><td align="left" rowspan="1" colspan="1">824</td><td align="left" rowspan="1" colspan="1">849</td></tr><tr><td align="left" rowspan="1" colspan="1">351. RADESTYVLV</td><td align="left" rowspan="1" colspan="1">826</td><td align="left" rowspan="1" colspan="1">835</td></tr><tr><td align="left" rowspan="1" colspan="1">352. RADESTYVLVAHSG</td><td align="left" rowspan="1" colspan="1">826</td><td align="left" rowspan="1" colspan="1">839</td></tr><tr><td align="left" rowspan="1" colspan="1">353. ADESTYVLVAHSGSGV</td><td align="left" rowspan="1" colspan="1">827</td><td align="left" rowspan="1" colspan="1">842</td></tr><tr><td align="left" rowspan="1" colspan="1">354. ESTYVLVAHSGSGVIEHE</td><td align="left" rowspan="1" colspan="1">829</td><td align="left" rowspan="1" colspan="1">846</td></tr><tr><td align="left" rowspan="1" colspan="1">355. YVLVAHSGSGVIEHETVND</td><td align="left" rowspan="1" colspan="1">832</td><td align="left" rowspan="1" colspan="1">850</td></tr><tr><td align="left" rowspan="1" colspan="1">356. VLVAHSGSGV</td><td align="left" rowspan="1" colspan="1">833</td><td align="left" rowspan="1" colspan="1">842</td></tr><tr><td align="left" rowspan="1" colspan="1">357. VAHSGSGVI</td><td align="left" rowspan="1" colspan="1">835</td><td align="left" rowspan="1" colspan="1">843</td></tr><tr><td align="left" rowspan="1" colspan="1">358. VAHSGSGVIEHETVND</td><td align="left" rowspan="1" colspan="1">835</td><td align="left" rowspan="1" colspan="1">850</td></tr><tr><td align="left" rowspan="1" colspan="1">359. AHSGSGVIEH</td><td align="left" rowspan="1" colspan="1">836</td><td align="left" rowspan="1" colspan="1">845</td></tr><tr><td align="left" rowspan="1" colspan="1">360. AHSGSGVIEHETVND</td><td align="left" rowspan="1" colspan="1">836</td><td align="left" rowspan="1" colspan="1">850</td></tr><tr><td align="left" rowspan="1" colspan="1">361. HSGSGVIEHE</td><td align="left" rowspan="1" colspan="1">837</td><td align="left" rowspan="1" colspan="1">846</td></tr><tr><td align="left" rowspan="1" colspan="1">362. SGSGVIEHETVNDFRE</td><td align="left" rowspan="1" colspan="1">838</td><td align="left" rowspan="1" colspan="1">853</td></tr><tr><td align="left" rowspan="1" colspan="1">363. GSGVIEHETV</td><td align="left" rowspan="1" colspan="1">839</td><td align="left" rowspan="1" colspan="1">848</td></tr><tr><td align="left" rowspan="1" colspan="1">364. SGVIEH</td><td align="left" rowspan="1" colspan="1">840</td><td align="left" rowspan="1" colspan="1">845</td></tr><tr><td align="left" rowspan="1" colspan="1">365. SGVIEHETVND</td><td align="left" rowspan="1" colspan="1">840</td><td align="left" rowspan="1" colspan="1">850</td></tr><tr><td align="left" rowspan="1" colspan="1">366. GVIEHETVND</td><td align="left" rowspan="1" colspan="1">841</td><td align="left" rowspan="1" colspan="1">850</td></tr><tr><td align="left" rowspan="1" colspan="1">367. NDFREKMMYKAIHCVQNMK</td><td align="left" rowspan="1" colspan="1">849</td><td align="left" rowspan="1" colspan="1">867</td></tr><tr><td align="left" rowspan="1" colspan="1">368. DFREKMMYKAIHCVQNMKP</td><td align="left" rowspan="1" colspan="1">850</td><td align="left" rowspan="1" colspan="1">868</td></tr><tr><td align="left" rowspan="1" colspan="1">369. FREKMMYKAIHCVQ</td><td align="left" rowspan="1" colspan="1">851</td><td align="left" rowspan="1" colspan="1">864</td></tr><tr><td align="left" rowspan="1" colspan="1">370. FREKMMYKAIHCVQNMKPEE</td><td align="left" rowspan="1" colspan="1">851</td><td align="left" rowspan="1" colspan="1">870</td></tr><tr><td align="left" rowspan="1" colspan="1">371. YKAIHCVQNMKPEE</td><td align="left" rowspan="1" colspan="1">857</td><td align="left" rowspan="1" colspan="1">870</td></tr><tr><td align="left" rowspan="1" colspan="1">372. KAIHCVQNMKPEE</td><td align="left" rowspan="1" colspan="1">858</td><td align="left" rowspan="1" colspan="1">870</td></tr><tr><td align="left" rowspan="1" colspan="1">373. YAHKILE</td><td align="left" rowspan="1" colspan="1">871</td><td align="left" rowspan="1" colspan="1">877</td></tr><tr><td align="left" rowspan="1" colspan="1">374. YAHKILEL</td><td align="left" rowspan="1" colspan="1">871</td><td align="left" rowspan="1" colspan="1">878</td></tr><tr><td align="left" rowspan="1" colspan="1">375. AHKILELQMQSIMEKKMKTK</td><td align="left" rowspan="1" colspan="1">872</td><td align="left" rowspan="1" colspan="1">891</td></tr><tr><td align="left" rowspan="1" colspan="1">376. AHKILELQMQSIMEKKMKTKRNIAKHYK</td><td align="left" rowspan="1" colspan="1">872</td><td align="left" rowspan="1" colspan="1">899</td></tr><tr><td align="left" rowspan="1" colspan="1">377. LQMQSIMEKK</td><td align="left" rowspan="1" colspan="1">878</td><td align="left" rowspan="1" colspan="1">887</td></tr><tr><td align="left" rowspan="1" colspan="1">378. MQSIMEKKMKTK</td><td align="left" rowspan="1" colspan="1">880</td><td align="left" rowspan="1" colspan="1">891</td></tr><tr><td align="left" rowspan="1" colspan="1">379. SIMEKKM</td><td align="left" rowspan="1" colspan="1">882</td><td align="left" rowspan="1" colspan="1">888</td></tr><tr><td align="left" rowspan="1" colspan="1">380. NIAKHYKNNPSL</td><td align="left" rowspan="1" colspan="1">893</td><td align="left" rowspan="1" colspan="1">904</td></tr><tr><td align="left" rowspan="1" colspan="1">381. PSLITF</td><td align="left" rowspan="1" colspan="1">902</td><td align="left" rowspan="1" colspan="1">907</td></tr><tr><td align="left" rowspan="1" colspan="1">382. SLITFLCKNCSVL</td><td align="left" rowspan="1" colspan="1">903</td><td align="left" rowspan="1" colspan="1">915</td></tr><tr><td align="left" rowspan="1" colspan="1">383. SLITFLCKNCSVLACSG</td><td align="left" rowspan="1" colspan="1">903</td><td align="left" rowspan="1" colspan="1">919</td></tr><tr><td align="left" rowspan="1" colspan="1">384. LITFLCKNCSV</td><td align="left" rowspan="1" colspan="1">904</td><td align="left" rowspan="1" colspan="1">914</td></tr><tr><td align="left" rowspan="1" colspan="1">385. ITFLCKNCSVL</td><td align="left" rowspan="1" colspan="1">905</td><td align="left" rowspan="1" colspan="1">915</td></tr><tr><td align="left" rowspan="1" colspan="1">386. ITFLCKNCSVLA</td><td align="left" rowspan="1" colspan="1">905</td><td align="left" rowspan="1" colspan="1">916</td></tr><tr><td align="left" rowspan="1" colspan="1">387. FLCKNCSVLACSGE</td><td align="left" rowspan="1" colspan="1">907</td><td align="left" rowspan="1" colspan="1">920</td></tr><tr><td align="left" rowspan="1" colspan="1">388. LCKNCSVL</td><td align="left" rowspan="1" colspan="1">908</td><td align="left" rowspan="1" colspan="1">915</td></tr><tr><td align="left" rowspan="1" colspan="1">389. LCKNCSVLACSG</td><td align="left" rowspan="1" colspan="1">908</td><td align="left" rowspan="1" colspan="1">919</td></tr><tr><td align="left" rowspan="1" colspan="1">390. CKNCSVL</td><td align="left" rowspan="1" colspan="1">909</td><td align="left" rowspan="1" colspan="1">915</td></tr><tr><td align="left" rowspan="1" colspan="1">391. KNCSVLACSG</td><td align="left" rowspan="1" colspan="1">910</td><td align="left" rowspan="1" colspan="1">919</td></tr><tr><td align="left" rowspan="1" colspan="1">392. VLACSGEDIHVIEK</td><td align="left" rowspan="1" colspan="1">914</td><td align="left" rowspan="1" colspan="1">927</td></tr><tr><td align="left" rowspan="1" colspan="1">393. LACSGED</td><td align="left" rowspan="1" colspan="1">915</td><td align="left" rowspan="1" colspan="1">921</td></tr><tr><td align="left" rowspan="1" colspan="1">394. ACSGEDIHVIE</td><td align="left" rowspan="1" colspan="1">916</td><td align="left" rowspan="1" colspan="1">926</td></tr><tr><td align="left" rowspan="1" colspan="1">395. DIHVIE</td><td align="left" rowspan="1" colspan="1">921</td><td align="left" rowspan="1" colspan="1">926</td></tr><tr><td align="left" rowspan="1" colspan="1">396. DIHVIEKMHHVNMT</td><td align="left" rowspan="1" colspan="1">921</td><td align="left" rowspan="1" colspan="1">934</td></tr><tr><td align="left" rowspan="1" colspan="1">397. IHVIEKMHHVNM</td><td align="left" rowspan="1" colspan="1">922</td><td align="left" rowspan="1" colspan="1">933</td></tr><tr><td align="left" rowspan="1" colspan="1">398. IHVIEKMHHVNMTPEF</td><td align="left" rowspan="1" colspan="1">922</td><td align="left" rowspan="1" colspan="1">937</td></tr><tr><td align="left" rowspan="1" colspan="1">399. KMHHVNMTPEF</td><td align="left" rowspan="1" colspan="1">927</td><td align="left" rowspan="1" colspan="1">937</td></tr><tr><td align="left" rowspan="1" colspan="1">400. FKELYI</td><td align="left" rowspan="1" colspan="1">937</td><td align="left" rowspan="1" colspan="1">942</td></tr><tr><td align="left" rowspan="1" colspan="1">401. YIVRENKALQKKCAD</td><td align="left" rowspan="1" colspan="1">941</td><td align="left" rowspan="1" colspan="1">955</td></tr><tr><td align="left" rowspan="1" colspan="1">402. VRENKALQKKCAD</td><td align="left" rowspan="1" colspan="1">943</td><td align="left" rowspan="1" colspan="1">955</td></tr><tr><td align="left" rowspan="1" colspan="1">403. ENKALQKKCADYQ</td><td align="left" rowspan="1" colspan="1">945</td><td align="left" rowspan="1" colspan="1">957</td></tr><tr><td align="left" rowspan="1" colspan="1">404. ALQKKCADYQINGEIICKCGQAWGTMMV</td><td align="left" rowspan="1" colspan="1">948</td><td align="left" rowspan="1" colspan="1">975</td></tr><tr><td align="left" rowspan="1" colspan="1">405. ADYQINGEIICKCGQ</td><td align="left" rowspan="1" colspan="1">954</td><td align="left" rowspan="1" colspan="1">968</td></tr><tr><td align="left" rowspan="1" colspan="1">406. INGEIIC</td><td align="left" rowspan="1" colspan="1">958</td><td align="left" rowspan="1" colspan="1">964</td></tr><tr><td align="left" rowspan="1" colspan="1">407. IICKCGQAWGTM</td><td align="left" rowspan="1" colspan="1">962</td><td align="left" rowspan="1" colspan="1">973</td></tr><tr><td align="left" rowspan="1" colspan="1">408. GTMMVHKGLDLPCLKIRNFVVVFKNNS</td><td align="left" rowspan="1" colspan="1">971</td><td align="left" rowspan="1" colspan="1">997</td></tr><tr><td align="left" rowspan="1" colspan="1">409. MVHKGLDL</td><td align="left" rowspan="1" colspan="1">974</td><td align="left" rowspan="1" colspan="1">981</td></tr><tr><td align="left" rowspan="1" colspan="1">410. MVHKGLDLPCL</td><td align="left" rowspan="1" colspan="1">974</td><td align="left" rowspan="1" colspan="1">984</td></tr><tr><td align="left" rowspan="1" colspan="1">411. MVHKGLDLPCLKIRN</td><td align="left" rowspan="1" colspan="1">974</td><td align="left" rowspan="1" colspan="1">988</td></tr><tr><td align="left" rowspan="1" colspan="1">412. VHKGLDLPCL</td><td align="left" rowspan="1" colspan="1">975</td><td align="left" rowspan="1" colspan="1">984</td></tr><tr><td align="left" rowspan="1" colspan="1">413. HKGLDL</td><td align="left" rowspan="1" colspan="1">976</td><td align="left" rowspan="1" colspan="1">981</td></tr><tr><td align="left" rowspan="1" colspan="1">414. HKGLDLPCLK</td><td align="left" rowspan="1" colspan="1">976</td><td align="left" rowspan="1" colspan="1">985</td></tr><tr><td align="left" rowspan="1" colspan="1">415. NFVVVF</td><td align="left" rowspan="1" colspan="1">988</td><td align="left" rowspan="1" colspan="1">993</td></tr><tr><td align="left" rowspan="1" colspan="1">416. VVVFKNNSTKKQYKKWVEL</td><td align="left" rowspan="1" colspan="1">990</td><td align="left" rowspan="1" colspan="1">1008</td></tr><tr><td align="left" rowspan="1" colspan="1">417. VVFKNNSTKKQYKKWVEL</td><td align="left" rowspan="1" colspan="1">991</td><td align="left" rowspan="1" colspan="1">1008</td></tr><tr><td align="left" rowspan="1" colspan="1">418. VFKNNSTKKQYKKWVEL</td><td align="left" rowspan="1" colspan="1">992</td><td align="left" rowspan="1" colspan="1">1008</td></tr><tr><td align="left" rowspan="1" colspan="1">419. FKNNST</td><td align="left" rowspan="1" colspan="1">993</td><td align="left" rowspan="1" colspan="1">998</td></tr><tr><td align="left" rowspan="1" colspan="1">420. KNNSTKKQYKKWVEL</td><td align="left" rowspan="1" colspan="1">994</td><td align="left" rowspan="1" colspan="1">1008</td></tr><tr><td align="left" rowspan="1" colspan="1">421. STKKQY</td><td align="left" rowspan="1" colspan="1">997</td><td align="left" rowspan="1" colspan="1">1002</td></tr><tr><td align="left" rowspan="1" colspan="1">422. QYKKWVELPITFPN</td><td align="left" rowspan="1" colspan="1">1001</td><td align="left" rowspan="1" colspan="1">1014</td></tr><tr><td align="left" rowspan="1" colspan="1">423. PITFPNL</td><td align="left" rowspan="1" colspan="1">1009</td><td align="left" rowspan="1" colspan="1">1015</td></tr><tr><td align="left" rowspan="1" colspan="1">424. PITFPNLD</td><td align="left" rowspan="1" colspan="1">1009</td><td align="left" rowspan="1" colspan="1">1016</td></tr><tr><td align="left" rowspan="1" colspan="1">425. PITFPNLDY</td><td align="left" rowspan="1" colspan="1">1009</td><td align="left" rowspan="1" colspan="1">1017</td></tr></tbody></table></div><div class="largeobj-link align_right" id="largeobj_idm139914615669648"><a target="object" rel="noopener" href="/pmc/articles/PMC11153190/table/tbl1/?report=objectonly">Open in a separate window</a></div></div><!--fig ft0--><!--fig mode=article f1--><div class="fig iconblock whole_rhythm" id="fig2" co-legend-rid="lgnd_fig2"><a href="/pmc/articles/PMC11153190/figure/fig2/" target="figure" rid-figpopup="fig2" rid-ob="ob-fig2"><!--fig/graphic|fig/alternatives/graphic mode="anchored" m1--><div class="figure" data-largeobj="" data-largeobj-link-rid="largeobj_idm139914619328976"><a class="inline_block ts_canvas" href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=11153190_gr2.jpg" target="tileshopwindow" rel="noopener"><div class="ts_bar small" title="Click on image to zoom"></div><img loading="lazy" alt="Fig. 2" title="Click on image to zoom" class="tileshop" src="/pmc/articles/PMC11153190/bin/gr2.jpg" /></a></div><div class="largeobj-link align_right" id="largeobj_idm139914619328976"><a target="object" rel="noopener" href="/pmc/articles/PMC11153190/figure/fig2/?report=objectonly">Open in a separate window</a></div></a><div class="icnblk_cntnt" id="lgnd_fig2"><div><a class="figpopup" href="/pmc/articles/PMC11153190/figure/fig2/" target="figure" rid-figpopup="fig2" rid-ob="ob-fig2">Fig. 2</a></div><!--caption a7--><div class="caption"><p>Volcano plot showing the mass difference in hydrogen-deuterium exchange (&#x00394;<em>HX</em>) and <em>p</em>-value at each deuterium exchange time for peptides detected by hydrogen deuterium exchange mass spectrometry experiments. Five plots in the region enclosed by the red dotted line (&#x00394;HX&#x000a0;&#x0003c;&#x000a0;&#x02212;0.4978 or &#x00394;HX&#x0003c;0.4978 and p-value &#x0003c;0.01) are those with significant differences at the 99&#x000a0;% confidence interval.</p></div></div></div><!--table ft1--><!--table-wrap mode="anchored" t5--><div class="table-wrap anchored whole_rhythm" id="tbl2"><h3>Table 2</h3><!--caption a7--><div class="caption"><p>Start and end points and deuterium exchange times of 5 peptides with significant differences in the analysis by Volcano plot and the difference of their deuterium exchange degree and p-value at the 99&#x000a0;% confidence interval.</p></div><div class="xtable"><table frame="hsides" rules="groups" class="rendered small default_table"><thead><tr><th rowspan="1" colspan="1">Peptide<br />No.</th><th rowspan="1" colspan="1">Start</th><th rowspan="1" colspan="1">End</th><th rowspan="1" colspan="1">Exchange time (min.)</th><th rowspan="1" colspan="1">&#x00394;<em>HX</em> (Da)</th><th rowspan="1" colspan="1"><em>p</em>-value</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1">417</td><td align="left" rowspan="1" colspan="1">426</td><td align="left" rowspan="1" colspan="1">0.5</td><td align="left" rowspan="1" colspan="1">0.6458</td><td align="left" rowspan="1" colspan="1">0.002</td></tr><tr><td align="left" rowspan="1" colspan="1">2</td><td align="left" rowspan="1" colspan="1">417</td><td align="left" rowspan="1" colspan="1">426</td><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1">1.318</td><td align="left" rowspan="1" colspan="1">0.002</td></tr><tr><td align="left" rowspan="1" colspan="1">3</td><td align="left" rowspan="1" colspan="1">417</td><td align="left" rowspan="1" colspan="1">426</td><td align="left" rowspan="1" colspan="1">10</td><td align="left" rowspan="1" colspan="1">1.847</td><td align="left" rowspan="1" colspan="1">0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">4</td><td align="left" rowspan="1" colspan="1">417</td><td align="left" rowspan="1" colspan="1">426</td><td align="left" rowspan="1" colspan="1">60</td><td align="left" rowspan="1" colspan="1">1.9857</td><td align="left" rowspan="1" colspan="1">0.002</td></tr><tr><td align="left" rowspan="1" colspan="1">5</td><td align="left" rowspan="1" colspan="1">417</td><td align="left" rowspan="1" colspan="1">426</td><td align="left" rowspan="1" colspan="1">240</td><td align="left" rowspan="1" colspan="1">2.1403</td><td align="left" rowspan="1" colspan="1">0.001</td></tr></tbody></table></div><div class="largeobj-link align_right" id="largeobj_idm139914619325584"><a target="object" rel="noopener" href="/pmc/articles/PMC11153190/table/tbl2/?report=objectonly">Open in a separate window</a></div></div></div><div id="sec3.2" class="sec"><h3 id="sec3.2title">3.2. Characteristics of MDA5 expression in human tissues</h3><p id="p0205" class="p p-first">To study mRNA levels of MDA5 in normal human tissues. Repeated analyses revealed that MDA5 mRNA was constitutively expressed in the lung, spleen, pancreas, and placenta, and was weakly expressed in the muscle. The relative mRNA expression of MDA5 per &#x003b2;-actin in various tissues in the two RT-qPCR experiments is shown in <a href="/pmc/articles/PMC11153190/figure/fig3/" target="figure" class="fig-table-link figpopup" rid-figpopup="fig3" rid-ob="ob-fig3" co-legend-rid="lgnd_fig3"><span>Fig. 3</span></a>A. We performed western blotting to evaluate MDA5 protein expression using an MDA5 mAb (clone H27). Normal lung and lung cancer tissues were obtained from two patients (Patients 1 and 2) with squamous lung cancer. Western blot analysis showed that PBMCs, normal lung tissues, and lung cancer tissues expressed MDA5. The molecular size of human MDA5 is approximately 120&#x000a0;kDa, as previously reported [<a href="#bib33" rid="bib33" class=" bibr popnode">33</a>]. Three cancer cell lines, 293T, A549, and HeLa, have also expressed MDA5 at approximately 120&#x000a0;kDa (data not shown). Moreover, we found a weak band of MDA5 protein of approximately 60&#x000a0;kDa in PBMCs and normal and cancerous lung tissues. Representative Western blot analysis results are shown in <a href="/pmc/articles/PMC11153190/figure/fig3/" target="figure" class="fig-table-link figpopup" rid-figpopup="fig3" rid-ob="ob-fig3" co-legend-rid="lgnd_fig3"><span>Fig. 3</span></a>B.</p><!--fig ft0--><!--fig mode=article f1--><div class="fig iconblock whole_rhythm" id="fig3" co-legend-rid="lgnd_fig3"><a href="/pmc/articles/PMC11153190/figure/fig3/" target="figure" rid-figpopup="fig3" rid-ob="ob-fig3"><!--fig/graphic|fig/alternatives/graphic mode="anchored" m1--><div class="figure" data-largeobj="" data-largeobj-link-rid="largeobj_idm139914624830400"><a class="inline_block ts_canvas" href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=11153190_gr3.jpg" target="tileshopwindow" rel="noopener"><div class="ts_bar small" title="Click on image to zoom"></div><img loading="lazy" alt="Fig. 3" title="Click on image to zoom" class="tileshop" src="/pmc/articles/PMC11153190/bin/gr3.jpg" /></a></div><div class="largeobj-link align_right" id="largeobj_idm139914624830400"><a target="object" rel="noopener" href="/pmc/articles/PMC11153190/figure/fig3/?report=objectonly">Open in a separate window</a></div></a><div class="icnblk_cntnt" id="lgnd_fig3"><div><a class="figpopup" href="/pmc/articles/PMC11153190/figure/fig3/" target="figure" rid-figpopup="fig3" rid-ob="ob-fig3">Fig. 3</a></div><!--caption a7--><div class="caption"><p>MDA5 mRNA and protein expression in the human lungs. (A) Complementary DNAs (cDNAs) isolated from normal human tissues (lung, spleen, pancreas, muscle, and placenta). Two different real-time quantitative PCRs (RT-qPCR) were performed. Mean relative expression was calculated using the comparative threshold cycle method. Relative mRNA expression of MDA5 per &#x003b2;-actin is shown in Y-axis. (B) PBMCs were obtained from a healthy donor. Normal lungs and cancerous lungs were obtained from a 67-year-old male patient (patient 1) with squamous cell carcinoma (SCC) of the lung. Western blot analysis of PBMCs, normal lungs, and cancerous lungs using mouse anti-human MDA5 mAb (H27) and anti-&#x003b2;-actin mAb.</p><p>1. PBMCs (100 ng/lane). 2. Normal lung (left lung, S6, 100 ng/lane) (patient 1). 3. Normal lung (left lung, S8, 100 ng/lane) (patient 1). 4. Normal lungs (left lung S10, 100 ng/lane) (patient 1). 5. Lung cancer (100 ng/lane) (patient 1).</p></div></div></div><p id="p0210" class="p p-last">Next, we analyzed the MDA5 protein expression in normal lungs. Immunohistochemical analysis using an in-house anti-MDA5 mAb (clone H27) also showed that epithelial and vascular endothelial cells weakly expressed MDA5. Interestingly, alveolar macrophages moderately expressed MDA5 protein (upper panel, <a href="/pmc/articles/PMC11153190/figure/fig4/" target="figure" class="fig-table-link figpopup" rid-figpopup="fig4" rid-ob="ob-fig4" co-legend-rid="lgnd_fig4"><span>Fig. 4</span></a>). We obtained normal tonsil and pancreatic tissues and performed immunohistochemical analysis of MDA5 protein expression. MDA5 protein was strongly expressed in the cytoplasm of lymphoid cells in the tonsils (lower right panel, <a href="/pmc/articles/PMC11153190/figure/fig4/" target="figure" class="fig-table-link figpopup" rid-figpopup="fig4" rid-ob="ob-fig4" co-legend-rid="lgnd_fig4"><span>Fig. 4</span></a>) and acinar cells of the pancreas (lower left panel, <a href="/pmc/articles/PMC11153190/figure/fig4/" target="figure" class="fig-table-link figpopup" rid-figpopup="fig4" rid-ob="ob-fig4" co-legend-rid="lgnd_fig4"><span>Fig. 4</span></a>).</p><!--fig ft0--><!--fig mode=article f1--><div class="fig iconblock whole_rhythm" id="fig4" co-legend-rid="lgnd_fig4"><a href="/pmc/articles/PMC11153190/figure/fig4/" target="figure" rid-figpopup="fig4" rid-ob="ob-fig4"><!--fig/graphic|fig/alternatives/graphic mode="anchored" m1--><div class="figure" data-largeobj="" data-largeobj-link-rid="largeobj_idm139914624822400"><a class="inline_block ts_canvas" href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=11153190_gr4.jpg" target="tileshopwindow" rel="noopener"><div class="ts_bar small" title="Click on image to zoom"></div><img loading="lazy" alt="Fig. 4" title="Click on image to zoom" class="tileshop" src="/pmc/articles/PMC11153190/bin/gr4.jpg" /></a></div><div class="largeobj-link align_right" id="largeobj_idm139914624822400"><a target="object" rel="noopener" href="/pmc/articles/PMC11153190/figure/fig4/?report=objectonly">Open in a separate window</a></div></a><div class="icnblk_cntnt" id="lgnd_fig4"><div><a class="figpopup" href="/pmc/articles/PMC11153190/figure/fig4/" target="figure" rid-figpopup="fig4" rid-ob="ob-fig4">Fig. 4</a></div><!--caption a7--><div class="caption"><p>Immunohistochemical analysis of MDA5 expression in tissues. Immunohistochemical analysis with our established mouse anti-human MDA5 mAb (clone H27) in the normal lung (upper panel), normal tonsil (lower left), and pancreas (lower right) was performed with mouse anti-human MDA5 mAb (clone H27).</p><p>Green arrowhead: Macrophages. Blue arrowhead: Alveolar epithelial cells. Red arrowhead: Vascular endothelial cells.</p></div></div></div></div><div id="sec3.3" class="sec"><h3 id="sec3.3title">3.3. Soluble MDA5 protein in sera</h3><p id="p0215" class="p p-first-last">We tested MDA5 protein in the sera of 32 healthy donors using two human MDA5 mAbs (clones H27 and H46). Using electrochemiluminescence in a MESOSCALE DISCOVERY&#x000ae; assay system, the dynamic range of this assay system ranges approximately from 100&#x000a0;pg/mL through 250&#x000a0;ng/mL. We found that soluble MDA5 protein was detectable in sera from 14 of the 32 healthy donors (3314&#x000a0;&#x000b1;&#x000a0;7215&#x000a0;pg/mL, <a href="/pmc/articles/PMC11153190/figure/fig5/" target="figure" class="fig-table-link figpopup" rid-figpopup="fig5" rid-ob="ob-fig5" co-legend-rid="lgnd_fig5"><span>Fig. 5</span></a>). Moreover, the level of soluble MDA5 protein in the sera of the three donors was &#x0003e;10&#x000a0;ng/ml. In contrast, soluble MDA5 was not detected in the urine of six donors; however, soluble MDA5 protein was detectable in the serum of two of these six urine donors. Next, we tested the MDA5 protein levels in the sera of 31 patients with DM. We found that soluble MDA5 protein was detectable in sera from 26 of the 31 DM patients (635&#x000a0;&#x000b1;&#x000a0;791&#x000a0;pg/mL, <a href="/pmc/articles/PMC11153190/figure/fig5/" target="figure" class="fig-table-link figpopup" rid-figpopup="fig5" rid-ob="ob-fig5" co-legend-rid="lgnd_fig5"><span>Fig. 5</span></a>). The mean levels of soluble MDA5 protein in the sera of 32 healthy donors were higher than those in the sera of 31 patients with DM; however, the difference was not significant.</p><!--fig ft0--><!--fig mode=article f1--><div class="fig iconblock whole_rhythm" id="fig5" co-legend-rid="lgnd_fig5"><a href="/pmc/articles/PMC11153190/figure/fig5/" target="figure" rid-figpopup="fig5" rid-ob="ob-fig5"><!--fig/graphic|fig/alternatives/graphic mode="anchored" m1--><div class="figure" data-largeobj="" data-largeobj-link-rid="largeobj_idm139914630015216"><a class="inline_block ts_canvas" href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=11153190_gr5.jpg" target="tileshopwindow" rel="noopener"><div class="ts_bar small" title="Click on image to zoom"></div><img loading="lazy" alt="Fig. 5" title="Click on image to zoom" class="tileshop" src="/pmc/articles/PMC11153190/bin/gr5.jpg" /></a></div><div class="largeobj-link align_right" id="largeobj_idm139914630015216"><a target="object" rel="noopener" href="/pmc/articles/PMC11153190/figure/fig5/?report=objectonly">Open in a separate window</a></div></a><div class="icnblk_cntnt" id="lgnd_fig5"><div><a class="figpopup" href="/pmc/articles/PMC11153190/figure/fig5/" target="figure" rid-figpopup="fig5" rid-ob="ob-fig5">Fig. 5</a></div><!--caption a7--><div class="caption"><p>Serum levels of soluble MDA5 protein. Serum levels of soluble MDA5 were analyzed in 32 healthy donors (left) and 31 patients with DM (right) using an in-house highly sensitive sandwich immunoassay system. Values for MDA 5 protein (pg/mL) are shown on the Y-axis. The sensitivity limit of the assay was 80&#x000a0;pg/mL.</p></div></div></div></div><div id="sec3.4" class="sec sec-last"><h3 id="sec3.4title">3.4. Characteristics of soluble MDA5 protein</h3><p id="p0220" class="p p-first-last">As MDA5 is a viral receptor, we hypothesized that soluble MDA5 could be obtained through the stimulation of immune cells. We hypothesized that PBMCs would produce soluble MDA5. Subsequently, PBMCs were isolated from four healthy donors, suspended in cold PBS at 2&#x000a0;&#x000d7;&#x000a0;10<sup>6</sup>&#x000a0;cells/mL, and stimulated with 250&#x000a0;&#x003bc;g/mL poly I:C at 37&#x000a0;&#x000b0;C to activate MDA5 [<a href="#bib2" rid="bib2" class=" bibr popnode">2</a>]. Five experiments were conducted. Supernatants were harvested at various time points (0, 15, 1, and 2h). The levels of MDA5 protein in the supernatants of PBMCs without poly I:C were 0&#x000a0;&#x000b1;&#x000a0;0&#x000a0;pg/mL at 0&#x000a0;min, 493&#x000a0;&#x000b1;&#x000a0;486&#x000a0;pg/mL at 15&#x000a0;min, 262&#x000a0;&#x000b1;&#x000a0;224&#x000a0;pg/mL at 1&#x000a0;h, and 111&#x000a0;&#x000b1;&#x000a0;166&#x000a0;pg/mL at 2&#x000a0;h. The levels of MDA5 protein in the supernatants of PBMCs with poly I:C were 0&#x000a0;&#x000b1;&#x000a0;0&#x000a0;pg/mL at 0&#x000a0;min, 731&#x000a0;&#x000b1;&#x000a0;593&#x000a0;pg/mL at 15&#x000a0;min, 175&#x000a0;&#x000b1;&#x000a0;141&#x000a0;pg/mL at 1&#x000a0;h, and 111&#x000a0;&#x000b1;&#x000a0;157&#x000a0;pg/mL at 2&#x000a0;h. Sandwich immunoassay revealed that MDA5 protein levels increased in the supernatant of PMBCs within 15&#x000a0;min of poly I:C stimulation. However, they were barely detectable after 2&#x000a0;h. Representative data are shown in <a href="/pmc/articles/PMC11153190/figure/fig6/" target="figure" class="fig-table-link figpopup" rid-figpopup="fig6" rid-ob="ob-fig6" co-legend-rid="lgnd_fig6"><span>Fig. 6</span></a>A. Western blotting showed the same results; MDA5 protein increased in the supernatant of PMBCs within 15&#x000a0;min after poly I:C stimulation but was hardly detectable after 2&#x000a0;h. The molecular size of soluble MDA5 was approximately 60&#x000a0;kDa. As described above (<a href="/pmc/articles/PMC11153190/figure/fig3/" target="figure" class="fig-table-link figpopup" rid-figpopup="fig3" rid-ob="ob-fig3" co-legend-rid="lgnd_fig3"><span>Fig. 3</span></a>B), PBMCs expressed MDA5 protein with molecular weights of approximately 60 and 120&#x000a0;kDa, respectively (<a href="/pmc/articles/PMC11153190/figure/fig6/" target="figure" class="fig-table-link figpopup" rid-figpopup="fig6" rid-ob="ob-fig6" co-legend-rid="lgnd_fig6"><span>Fig. 6</span></a>B).</p><!--fig ft0--><!--fig mode=article f1--><div class="fig iconblock whole_rhythm" id="fig6" co-legend-rid="lgnd_fig6"><a href="/pmc/articles/PMC11153190/figure/fig6/" target="figure" rid-figpopup="fig6" rid-ob="ob-fig6"><!--fig/graphic|fig/alternatives/graphic mode="anchored" m1--><div class="figure" data-largeobj="" data-largeobj-link-rid="largeobj_idm139914615950000"><a class="inline_block ts_canvas" href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=11153190_gr6.jpg" target="tileshopwindow" rel="noopener"><div class="ts_bar small" title="Click on image to zoom"></div><img loading="lazy" alt="Fig. 6" title="Click on image to zoom" class="tileshop" src="/pmc/articles/PMC11153190/bin/gr6.jpg" /></a></div><div class="largeobj-link align_right" id="largeobj_idm139914615950000"><a target="object" rel="noopener" href="/pmc/articles/PMC11153190/figure/fig6/?report=objectonly">Open in a separate window</a></div></a><div class="icnblk_cntnt" id="lgnd_fig6"><div><a class="figpopup" href="/pmc/articles/PMC11153190/figure/fig6/" target="figure" rid-figpopup="fig6" rid-ob="ob-fig6">Fig. 6</a></div><!--caption a7--><div class="caption"><p>Characteristics of soluble human MDA5 protein (A) Peripheral blood nuclear cells (PBMCs) were isolated from peripheral blood. Cells (2&#x000a0;&#x000d7;&#x000a0;10<sup>6</sup>&#x000a0;cells/mL in PBS) were stimulated with or without 250&#x000a0;mg/mL polyinosinic-polycytidylic acid sodium salt (poly I:C) at 37&#x000a0;&#x000b0;C. The level of soluble MDA5 in the supernatants was analyzed. The vales of MDA 5 protein (pg/mL) were shown in the Y-axis. (B) Western blot analysis for the MDA5 protein was perform with mouse anti-human MDA5 mAb (clone H27). 1. Whole PBMC. 2. Supernatant at 0&#x000a0;min. 3. Supernatant at 15&#x000a0;min without stimulation. 4. Supernatant at 15&#x000a0;min with stimulation by poly I:C. 5. Supernatant at 1&#x000a0;h without stimulation. 6. Supernatant at 1&#x000a0;h with stimulation by poly I:C. 7. Supernatant at 2&#x000a0;h without stimulation. 8. Supernatant at 2&#x000a0;h stimulation by poly I:C.</p></div></div></div></div></div><div id="sec4" class="tsec sec"><h2 class="head no_bottom_margin" id="sec4title">4. Discussion</h2><p id="p0225" class="p p-first">In our study, we demonstrated that the MDA5 protein is present in the serum in a soluble form. Our RT-qPCR study showed that MDA5 mRNA was expressed in various organs of healthy humans, indicating that MDA5 was present in all cells, as previously reported [<a href="#bib1" rid="bib1" class=" bibr popnode">1</a>]. However, immunohistochemical staining revealed that MDA5 was more strongly expressed in alveolar macrophages than in the alveolar epithelium or vascular endothelium of the lungs. This may be due to phagocytosis of exudate-soluble MDA5 in the alveolar space by alveolar macrophages. Furthermore, we demonstrated that the stimulation of PBMCs elevated soluble MDA5 levels, indicating the strong involvement of immune cells in the formation of soluble MDA5.</p><p id="p0230">The full-length MDA5 (<em>IFIH1</em>) cDNA encodes 1025 amino acids [<a href="#bib33" rid="bib33" class=" bibr popnode">33</a>] with a predicted molecular weight of 116,686.83. Using the newly developed mAbs, we observed two immunoreactive bands of the MDA5 protein with molecular weights of 60 and 120&#x000a0;kDa in PBMCs, normal lungs, and cancerous lung tissues. Here, we showed that the 60&#x000a0;kDa MDA5 protein increased in the supernatant of PBMCs within 15&#x000a0;min of synthetic MDA5 agonist/dsRNA stimulation. Hydrogen/deuterium exchange Mass Spectrometry (HDX-MS) was used to analyze the structural features and dynamic properties of proteins. HDX-MS revealed that an anti-human MDA5 mAb (clone H46) bound to an epitope (415QILENSLLNL424) derived from the helicase domain of the MDA5 protein<strong>.</strong> These results suggest that soluble MDA5 proteins containing a helicase domain can be generated by alternative splicing of MDA5 mRNA or digestion of MDA5 protein by proteases in some tissues.</p><p id="p0235">In RNA viruses, dsRNA is generated as a replication intermediate during viral infections. TLR3, which localizes to the endosomal membrane, recognizes viral dsRNA and synthetic dsRNA analogs [<a href="#bib34" rid="bib34" class=" bibr popnode">34</a>]. As described above, the cytoplasmic proteins RIG-I and MDA5 recognize viral dsRNAs and synthetic dsRNA analogs [<a href="#bib2" rid="bib2" class=" bibr popnode">2</a>]. Although it is unknown whether soluble MDA5 can bind to dsRNA and/or ssRNA viruses, soluble MDA5 can interfere with the recognition of RNA viruses by TLR3, RIG-I, and MDA5. We are currently investigating this issue to better define the roles of soluble MDA5 proteins.</p><p id="p0240">A multicenter retrospective cohort study of Japanese patients with myositis-associated ILD (JAMI) at 44 centers in Japan showed that the presence of anti-MDA5 antibody is an independent risk factor for DM-ILD mortality, as well as, old age, high CRP, and low peripheral capillary oxygen saturation [<a href="#bib35" rid="bib35" class=" bibr popnode">35</a>]. Increased levels of Coxsackie B virus antibodies in patients with juvenile DM have been reported previously [<a href="#bib36" rid="bib36" class=" bibr popnode">36</a>]. Another study reported regional differences in the incidence of anti-MDA5 antibodies in Japanese patients with DM [<a href="#bib37" rid="bib37" class=" bibr popnode">37</a>]. Therefore, viral infections and environmental factors may contribute to the production of autoantibodies against MDA5. We have recently reported that MDA5 was moderately or strongly expressed in the lungs of patients with DM [<a href="#bib22" rid="bib22" class=" bibr popnode">22</a>]. In this study, we measured serum levels of MDA5 protein in patients with DM. MDA5 protein was detected in the sera of patients with DM. However, the molecular mechanisms underlying anti-MDA5 antibody production in patients are still unknown.</p><p id="p0245">We examined the subset of cells that expressed MDA5 after stimulation with poly (I: C). We isolated from healthy donors. PBMCs were stimulated with or without poly I:C for 15, 30, 1, or 2&#x000a0;h. We, then, performed surface and intra-cellular staining (ICS) on different subpopulations of cells (CD4<sup>+</sup> T cells, CD8<sup>+</sup> T cells, CD16<sup>+</sup> cells, CD19<sup>+</sup> B cells, and CD56<sup>+</sup> NK cells) using flow cytometry. In freshly isolated PBMCs, not all cell populations expressed MDA5 on their surfaces, but highly expressed MDA5 protein in the cell cytoplasm. After stimulation with poly I:C, the expression of MDA5 was not altered on the surface or in the cytoplasm (data not shown). These results suggest that the 60&#x000a0;kDa form of MDA5 is present in the cytoplasm.</p><p id="p0250" class="p p-last">We found that soluble MDA5 protein was detectable in some sera, but not in the urine of healthy donors. Soluble MDA5 protein was rapidly released from the cytoplasm of the tissues after dsRNA poly I:C stimulation. MDA5 was also detected in the supernatant of PBMCs that were not stimulated with poly I:C. These results suggest 1) RNA viral infection increases the levels of soluble MDA5 protein in sera. 2) PBMCs constitutively release soluble MDA5 from the cytoplasm. 3) Soluble MDA5 protein is released from dying cells. Nonetheless, further analyses are required to confirm these hypotheses. The present study can help understand the role of MDA5 in the recognition of RNA viruses and the development of autoimmune diseases.</p></div><div id="sec5" class="tsec sec"><h2 class="head no_bottom_margin" id="sec5title">Data availability statement</h2><p id="p0255" class="p p-first-last">The authors declare that the data supporting the findings of this study are available within the paper. A request for more detailed data should be sent to the corresponding authors with the permission of all authors.</p></div><div id="sec6" class="tsec sec"><h2 class="head no_bottom_margin" id="sec6title">Funding</h2><p id="p0260" class="p p-first-last">This work was supported by a Grant-in-Aid for Scientific Research (C) (no. 19K08637, T.H.) from the Ministry of Education, Science, and Sports (Japan) and the Kakihara Science Technology Foundation (Fukuoka, Japan). It was also funded by the Deutsche Forschungsgemeinschaft (German Research Foundation) under Germany's Excellence Strategy-EXC2151-390873048 and TRR237 and by the Deutsche Forschungsgemeinschaft (German Research Foundation) Grant No. 369799452 and Project No. 404459591.</p></div><div id="sec7" class="tsec sec"><h2 class="head no_bottom_margin" id="sec7title">CRediT authorship contribution statement</h2><p id="p0265" class="p p-first-last"><strong>Masaki Okamoto:</strong> Writing &#x02013; original draft, Conceptualization. <strong>Yoshiaki Zaizen:</strong> Writing &#x02013; original draft, Validation, Formal analysis, Data curation. <strong>Shinjiro Kaieda:</strong> Data curation. <strong>Takashi Nouno:</strong> Data curation. <strong>Takuma Koga:</strong> Data curation. <strong>Goushi Matama:</strong> Data curation. <strong>Masahiro Mitsuoka:</strong> Data curation. <strong>Jun Akiba:</strong> Data curation. <strong>Shintaro Yamada:</strong> Data curation. <strong>Hiroki Kato:</strong> Funding acquisition, Data curation. <strong>Tomoaki Hoshino:</strong> Writing &#x02013; original draft, Investigation, Funding acquisition, Conceptualization.</p></div><div id="sec-a.q.i" class="tsec sec"><h2 class="head no_bottom_margin" id="sec-a.q.ititle">Declaration of competing interest</h2><p id="p0270" class="p p-first-last">The authors declare the following financial interests/personal relationships which may be considered as potential competing interests:Tomoaki Hoshino has patent pending to Detecting soluble form of MDA5.</p></div><div id="ack0010" class="tsec sec"><h2 class="head no_bottom_margin" id="ack0010title">Acknowledgments</h2><div class="sec"><p id="p0275">The authors are grateful to Dr. Howard A. Young (National Cancer Institute-Frederick) and Dr. Takeshi Kawabe (Tohoku University, Sendai, Japan) for editing our manuscript and Dr. Shigekazu Nagata (Osaka University, Suita, Japan) for providing the pEF-BOS-EX vector.</p></div></div><div id="fn-group-a.r.d" class="tsec sec"><h2 class="head no_bottom_margin" id="fn-group-a.r.dtitle">Footnotes</h2><!--back/fn-group--><div class="fm-sec half_rhythm small"><p class="fn sec" id="appsec2"><sup>Appendix A</sup>Supplementary data to this article can be found online at <a href="https://doi.org/10.1016/j.heliyon.2024.e31727" data-ga-action="click_feat_suppl" ref="reftype=extlink&amp;article-id=11153190&amp;issue-id=463821&amp;journal-id=2992&amp;FROM=Article%7CBody&amp;TO=External%7CLink%7CURI" target="_blank">https://doi.org/10.1016/j.heliyon.2024.e31727</a>.</p></div></div><div id="appsec1" class="tsec bk-sec"><a id="supplementary-material-sec"></a><h2 class="head no_bottom_margin" id="appsec1title">Appendix A. Supplementary data</h2><!--/article/back/sec/--><p id="p0280" class="p p-first-last">The following are the Supplementary data to this article:<!--fig ft0--><!--fig @position="anchor" mode=article f4--><!--fig mode="anchored" f5--></p><div class="fig  iconblock anchored whole_rhythm" id="dfig1"><h3>figs1</h3><!--fig/graphic|fig/alternatives/graphic mode="anchored" m1--><div class="figure" data-largeobj="" data-largeobj-link-rid="largeobj_idm139914615738496"><img loading="lazy" class="fig-image" alt="figs1" title="figs1" src="/pmc/articles/PMC11153190/bin/mmcfigs1.jpg" /></div><div class="largeobj-link align_right" id="largeobj_idm139914615738496"><a target="object" rel="noopener" href="/pmc/articles/PMC11153190/figure/dfig1/?report=objectonly">Open in a separate window</a></div></div><p><!--fig ft0--><!--fig @position="anchor" mode=article f4--><!--fig mode="anchored" f5--></p><div class="fig  iconblock anchored whole_rhythm" id="dfig2"><h3>figs2</h3><!--fig/graphic|fig/alternatives/graphic mode="anchored" m1--><div class="figure" data-largeobj="" data-largeobj-link-rid="largeobj_idm139914615735696"><img loading="lazy" class="fig-image" alt="figs2" title="figs2" src="/pmc/articles/PMC11153190/bin/mmcfigs2.jpg" /></div><div class="largeobj-link align_right" id="largeobj_idm139914615735696"><a target="object" rel="noopener" href="/pmc/articles/PMC11153190/figure/dfig2/?report=objectonly">Open in a separate window</a></div></div><p><!--fig ft0--><!--fig @position="anchor" mode=article f4--><!--fig mode="anchored" f5--></p><div class="fig  iconblock anchored whole_rhythm" id="dfig3"><h3>figs3</h3><!--fig/graphic|fig/alternatives/graphic mode="anchored" m1--><div class="figure" data-largeobj="" data-largeobj-link-rid="largeobj_idm139914615732896"><img loading="lazy" class="fig-image" alt="figs3" title="figs3" src="/pmc/articles/PMC11153190/bin/mmcfigs3.jpg" /></div><div class="largeobj-link align_right" id="largeobj_idm139914615732896"><a target="object" rel="noopener" href="/pmc/articles/PMC11153190/figure/dfig3/?report=objectonly">Open in a separate window</a></div></div><p><!--fig ft0--><!--fig @position="anchor" mode=article f4--><!--fig mode="anchored" f5--></p><div class="fig  iconblock anchored whole_rhythm" id="dfig4"><h3>figs4</h3><!--fig/graphic|fig/alternatives/graphic mode="anchored" m1--><div class="figure" data-largeobj="" data-largeobj-link-rid="largeobj_idm139914615730096"><img loading="lazy" class="fig-image" alt="figs4" title="figs4" src="/pmc/articles/PMC11153190/bin/mmcfigs4.jpg" /></div><div class="largeobj-link align_right" id="largeobj_idm139914615730096"><a target="object" rel="noopener" href="/pmc/articles/PMC11153190/figure/dfig4/?report=objectonly">Open in a separate window</a></div></div><p><!--fig ft0--><!--fig @position="anchor" mode=article f4--><!--fig mode="anchored" f5--></p><div class="fig  iconblock anchored whole_rhythm" id="dfig5"><h3>figs5</h3><!--fig/graphic|fig/alternatives/graphic mode="anchored" m1--><div class="figure" data-largeobj="" data-largeobj-link-rid="largeobj_idm139914615727296"><img loading="lazy" class="fig-image" alt="figs5" title="figs5" src="/pmc/articles/PMC11153190/bin/mmcfigs5.jpg" /></div><div class="largeobj-link align_right" id="largeobj_idm139914615727296"><a target="object" rel="noopener" href="/pmc/articles/PMC11153190/figure/dfig5/?report=objectonly">Open in a separate window</a></div></div><p></p></div><div id="cebib0010" class="tsec sec"><h2 class="head no_bottom_margin" id="cebib0010title">References</h2><div class="ref-list-sec sec" id="reference-list"><div class="ref-cit-blk half_rhythm" id="bib1">1. <span class="element-citation" id="sref1">Yoneyama M., Onomoto K., Jogi M., et al. Viral RNA detection by RIG-I-like receptors. <span><span class="ref-journal">Curr. Opin. Immunol. </span>2015;<span class="ref-vol">32</span>:48–53.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/25594890" ref="reftype=pubmed&amp;article-id=11153190&amp;issue-id=463821&amp;journal-id=2992&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Curr.+Opin.+Immunol.&amp;title=Viral+RNA+detection+by+RIG-I-like+receptors&amp;author=M.+Yoneyama&amp;author=K.+Onomoto&amp;author=M.+Jogi&amp;volume=32&amp;publication_year=2015&amp;pages=48-53&amp;pmid=25594890&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=11153190&amp;issue-id=463821&amp;journal-id=2992&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="bib2">2. <span class="element-citation" id="sref2">Kato H., Takeuchi O., Sato S., et al. Differential roles of MDA5 and RIG-I helicases in the recognition of RNA viruses. <span><span class="ref-journal">Nature. </span>2006;<span class="ref-vol">441</span>:101–105.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/16625202" ref="reftype=pubmed&amp;article-id=11153190&amp;issue-id=463821&amp;journal-id=2992&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Nature&amp;title=Differential+roles+of+MDA5+and+RIG-I+helicases+in+the+recognition+of+RNA+viruses&amp;author=H.+Kato&amp;author=O.+Takeuchi&amp;author=S.+Sato&amp;volume=441&amp;publication_year=2006&amp;pages=101-105&amp;pmid=16625202&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=11153190&amp;issue-id=463821&amp;journal-id=2992&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="bib3">3. <span class="element-citation" id="sref3">Zalinger Z.B., Elliott R., Rose K.M., et al. MDA5 is critical to host defense during infection with murine coronavirus. <span><span class="ref-journal">J. Virol. </span>2015;<span class="ref-vol">89</span>:12330–12340.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC4665247/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/26423942" ref="reftype=pubmed&amp;article-id=11153190&amp;issue-id=463821&amp;journal-id=2992&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=J.+Virol.&amp;title=MDA5+is+critical+to+host+defense+during+infection+with+murine+coronavirus&amp;author=Z.B.+Zalinger&amp;author=R.+Elliott&amp;author=K.M.+Rose&amp;volume=89&amp;publication_year=2015&amp;pages=12330-12340&amp;pmid=26423942&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=11153190&amp;issue-id=463821&amp;journal-id=2992&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="bib4">4. <span class="element-citation" id="sref4">Sampaio N.G., Chauveau L., Hertzog J., et al. The RNA sensor MDA5 detects SARS-CoV-2 infection. <span><span class="ref-journal">Sci. Rep. </span>2021;<span class="ref-vol">11</span></span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC8249624/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/34211037" ref="reftype=pubmed&amp;article-id=11153190&amp;issue-id=463821&amp;journal-id=2992&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Sci.+Rep.&amp;title=The+RNA+sensor+MDA5+detects+SARS-CoV-2+infection&amp;author=N.G.+Sampaio&amp;author=L.+Chauveau&amp;author=J.+Hertzog&amp;volume=11&amp;publication_year=2021&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=11153190&amp;issue-id=463821&amp;journal-id=2992&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="bib5">5. <span class="element-citation" id="sref5">Yoneyama M., Fujita T. Function of RIG-I-like receptors in antiviral innate immunity. <span><span class="ref-journal">J. Biol. Chem. </span>2007;<span class="ref-vol">282</span>:15315–15318.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/17395582" ref="reftype=pubmed&amp;article-id=11153190&amp;issue-id=463821&amp;journal-id=2992&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=J.+Biol.+Chem.&amp;title=Function+of+RIG-I-like+receptors+in+antiviral+innate+immunity&amp;author=M.+Yoneyama&amp;author=T.+Fujita&amp;volume=282&amp;publication_year=2007&amp;pages=15315-15318&amp;pmid=17395582&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=11153190&amp;issue-id=463821&amp;journal-id=2992&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="bib6">6. <span class="element-citation" id="sref6">Lamborn I.T., Jing H., Zhang Y., et al. Recurrent rhinovirus infections in a child with inherited MDA5 deficiency. <span><span class="ref-journal">J. Exp. Med. </span>2017;<span class="ref-vol">214</span>:1949–1972.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC5502429/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/28606988" ref="reftype=pubmed&amp;article-id=11153190&amp;issue-id=463821&amp;journal-id=2992&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=J.+Exp.+Med.&amp;title=Recurrent+rhinovirus+infections+in+a+child+with+inherited+MDA5+deficiency&amp;author=I.T.+Lamborn&amp;author=H.+Jing&amp;author=Y.+Zhang&amp;volume=214&amp;publication_year=2017&amp;pages=1949-1972&amp;pmid=28606988&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=11153190&amp;issue-id=463821&amp;journal-id=2992&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="bib7">7. <span class="element-citation" id="sref7">Funabiki M., Kato H., Miyachi Y., et al. Autoimmune disorders associated with gain of function of the intracellular sensor MDA5. <span><span class="ref-journal">Immunity. </span>2014;<span class="ref-vol">40</span>:199–212.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/24530055" ref="reftype=pubmed&amp;article-id=11153190&amp;issue-id=463821&amp;journal-id=2992&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Immunity&amp;title=Autoimmune+disorders+associated+with+gain+of+function+of+the+intracellular+sensor+MDA5&amp;author=M.+Funabiki&amp;author=H.+Kato&amp;author=Y.+Miyachi&amp;volume=40&amp;publication_year=2014&amp;pages=199-212&amp;pmid=24530055&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=11153190&amp;issue-id=463821&amp;journal-id=2992&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="bib8">8. <span class="element-citation" id="sref8">Onizawa H., Kato H., Kimura H., et al. Aicardi-Goutieres syndrome-like encephalitis in mutant mice with constitutively active MDA5. <span><span class="ref-journal">Int. Immunol. </span>2021;<span class="ref-vol">33</span>:225–240.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/33165593" ref="reftype=pubmed&amp;article-id=11153190&amp;issue-id=463821&amp;journal-id=2992&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Int.+Immunol.&amp;title=Aicardi-Goutieres+syndrome-like+encephalitis+in+mutant+mice+with+constitutively+active+MDA5&amp;author=H.+Onizawa&amp;author=H.+Kato&amp;author=H.+Kimura&amp;volume=33&amp;publication_year=2021&amp;pages=225-240&amp;pmid=33165593&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=11153190&amp;issue-id=463821&amp;journal-id=2992&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="bib9">9. <span class="element-citation" id="sref9">Shigemoto T., Kageyama M., Hirai R., et al. Identification of loss of function mutations in human genes encoding RIG-I and MDA5: implications for resistance to type I diabetes. <span><span class="ref-journal">J. Biol. Chem. </span>2009;<span class="ref-vol">284</span>:13348–13354.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC2679434/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/19324880" ref="reftype=pubmed&amp;article-id=11153190&amp;issue-id=463821&amp;journal-id=2992&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=J.+Biol.+Chem.&amp;title=Identification+of+loss+of+function+mutations+in+human+genes+encoding+RIG-I+and+MDA5:+implications+for+resistance+to+type+I+diabetes&amp;author=T.+Shigemoto&amp;author=M.+Kageyama&amp;author=R.+Hirai&amp;volume=284&amp;publication_year=2009&amp;pages=13348-13354&amp;pmid=19324880&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=11153190&amp;issue-id=463821&amp;journal-id=2992&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="bib10">10. <span class="element-citation" id="sref10">Nejentsev S., Walker N., Riches D., et al. Rare variants of IFIH1, a gene implicated in antiviral responses, protect against type 1 diabetes. <span><span class="ref-journal">Science. </span>2009;<span class="ref-vol">324</span>:387–389.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC2707798/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/19264985" ref="reftype=pubmed&amp;article-id=11153190&amp;issue-id=463821&amp;journal-id=2992&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Science&amp;title=Rare+variants+of+IFIH1,+a+gene+implicated+in+antiviral+responses,+protect+against+type+1+diabetes&amp;author=S.+Nejentsev&amp;author=N.+Walker&amp;author=D.+Riches&amp;volume=324&amp;publication_year=2009&amp;pages=387-389&amp;pmid=19264985&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=11153190&amp;issue-id=463821&amp;journal-id=2992&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="bib11">11. <span class="element-citation" id="sref11">Rice G.I., Del Toro Duany Y., Jenkinson E.M., et al. Gain-of-function mutations in IFIH1 cause a spectrum of human disease phenotypes associated with upregulated type I interferon signaling. <span><span class="ref-journal">Nat. Genet. </span>2014;<span class="ref-vol">46</span>:503–509.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC4004585/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/24686847" ref="reftype=pubmed&amp;article-id=11153190&amp;issue-id=463821&amp;journal-id=2992&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Nat.+Genet.&amp;title=Gain-of-function+mutations+in+IFIH1+cause+a+spectrum+of+human+disease+phenotypes+associated+with+upregulated+type+I+interferon+signaling&amp;author=G.I.+Rice&amp;author=Y.+Del+Toro+Duany&amp;author=E.M.+Jenkinson&amp;volume=46&amp;publication_year=2014&amp;pages=503-509&amp;pmid=24686847&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=11153190&amp;issue-id=463821&amp;journal-id=2992&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="bib12">12. <span class="element-citation" id="sref12">Oda H., Nakagawa K., Abe J., et al. Aicardi-Goutieres syndrome is caused by IFIH1 mutations. <span><span class="ref-journal">Am. J. Hum. Genet. </span>2014;<span class="ref-vol">95</span>:121–125.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC4085581/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/24995871" ref="reftype=pubmed&amp;article-id=11153190&amp;issue-id=463821&amp;journal-id=2992&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Am.+J.+Hum.+Genet.&amp;title=Aicardi-Goutieres+syndrome+is+caused+by+IFIH1+mutations&amp;author=H.+Oda&amp;author=K.+Nakagawa&amp;author=J.+Abe&amp;volume=95&amp;publication_year=2014&amp;pages=121-125&amp;pmid=24995871&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=11153190&amp;issue-id=463821&amp;journal-id=2992&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="bib13">13. <span class="element-citation" id="sref13">Sontheimer R.D. Would a new name hasten the acceptance of amyopathic dermatomyositis (dermatomyositis sine myositis) as a distinctive subset within the idiopathic inflammatory dermatomyopathies spectrum of clinical illness? <span><span class="ref-journal">J. Am. Acad. Dermatol. </span>2002;<span class="ref-vol">46</span>:626–636.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/11907524" ref="reftype=pubmed&amp;article-id=11153190&amp;issue-id=463821&amp;journal-id=2992&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=J.+Am.+Acad.+Dermatol.&amp;title=Would+a+new+name+hasten+the+acceptance+of+amyopathic+dermatomyositis+(dermatomyositis+sine+myositis)+as+a+distinctive+subset+within+the+idiopathic+inflammatory+dermatomyopathies+spectrum+of+clinical+illness?&amp;author=R.D.+Sontheimer&amp;volume=46&amp;publication_year=2002&amp;pages=626-636&amp;pmid=11907524&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=11153190&amp;issue-id=463821&amp;journal-id=2992&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="bib14">14. <span class="element-citation" id="sref14">Marie I., Hatron P.Y., Dominique S., et al. Short-term and long-term outcomes of interstitial lung disease in polymyositis and dermatomyositis: a series of 107 patients. <span><span class="ref-journal">Arthritis Rheum. </span>2011;<span class="ref-vol">63</span>:3439–3447.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/21702020" ref="reftype=pubmed&amp;article-id=11153190&amp;issue-id=463821&amp;journal-id=2992&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Arthritis+Rheum.&amp;title=Short-term+and+long-term+outcomes+of+interstitial+lung+disease+in+polymyositis+and+dermatomyositis:+a+series+of+107+patients&amp;author=I.+Marie&amp;author=P.Y.+Hatron&amp;author=S.+Dominique&amp;volume=63&amp;publication_year=2011&amp;pages=3439-3447&amp;pmid=21702020&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=11153190&amp;issue-id=463821&amp;journal-id=2992&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="bib15">15. <span class="element-citation" id="sref15">Sato S., Hirakata M., Kuwana M., et al. Autoantibodies to a 140-kd polypeptide, CADM-140, in Japanese patients with clinically amyopathic dermatomyositis. <span><span class="ref-journal">Arthritis Rheum. </span>2005;<span class="ref-vol">52</span>:1571–1576.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/15880816" ref="reftype=pubmed&amp;article-id=11153190&amp;issue-id=463821&amp;journal-id=2992&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Arthritis+Rheum.&amp;title=Autoantibodies+to+a+140-kd+polypeptide,+CADM-140,+in+Japanese+patients+with+clinically+amyopathic+dermatomyositis&amp;author=S.+Sato&amp;author=M.+Hirakata&amp;author=M.+Kuwana&amp;volume=52&amp;publication_year=2005&amp;pages=1571-1576&amp;pmid=15880816&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=11153190&amp;issue-id=463821&amp;journal-id=2992&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="bib16">16. <span class="element-citation" id="sref16">Yoshida N., Okamoto M., Kaieda S., et al. Association of anti-aminoacyl-transfer RNA synthetase antibody and anti-melanoma differentiation-associated gene 5 antibody with the therapeutic response of polymyositis/dermatomyositis-associated interstitial lung disease. <span><span class="ref-journal">Respiratory investigation. </span>2017;<span class="ref-vol">55</span>:24–32.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/28012490" ref="reftype=pubmed&amp;article-id=11153190&amp;issue-id=463821&amp;journal-id=2992&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Respiratory+investigation&amp;title=Association+of+anti-aminoacyl-transfer+RNA+synthetase+antibody+and+anti-melanoma+differentiation-associated+gene+5+antibody+with+the+therapeutic+response+of+polymyositis/dermatomyositis-associated+interstitial+lung+disease&amp;author=N.+Yoshida&amp;author=M.+Okamoto&amp;author=S.+Kaieda&amp;volume=55&amp;publication_year=2017&amp;pages=24-32&amp;pmid=28012490&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=11153190&amp;issue-id=463821&amp;journal-id=2992&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="bib17">17. <span class="element-citation" id="sref17">Sakamoto S., Okamoto M., Kaieda S., et al. Low positive titer of anti-melanoma differentiation-associated gene 5 antibody is not associated with a poor long-term outcome of interstitial lung disease in patients with dermatomyositis. <span><span class="ref-journal">Respiratory investigation. </span>2018;<span class="ref-vol">56</span>:464–472.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/30150008" ref="reftype=pubmed&amp;article-id=11153190&amp;issue-id=463821&amp;journal-id=2992&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Respiratory+investigation&amp;title=Low+positive+titer+of+anti-melanoma+differentiation-associated+gene+5+antibody+is+not+associated+with+a+poor+long-term+outcome+of+interstitial+lung+disease+in+patients+with+dermatomyositis&amp;author=S.+Sakamoto&amp;author=M.+Okamoto&amp;author=S.+Kaieda&amp;volume=56&amp;publication_year=2018&amp;pages=464-472&amp;pmid=30150008&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=11153190&amp;issue-id=463821&amp;journal-id=2992&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="bib18">18. <span class="element-citation" id="sref18">Li L., Wang Q., Yang F., et al. Anti-MDA5 antibody as a potential diagnostic and prognostic biomarker in patients with dermatomyositis. <span><span class="ref-journal">Oncotarget. </span>2017;<span class="ref-vol">8</span>:26552–26564.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC5432278/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/28460448" ref="reftype=pubmed&amp;article-id=11153190&amp;issue-id=463821&amp;journal-id=2992&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Oncotarget&amp;title=Anti-MDA5+antibody+as+a+potential+diagnostic+and+prognostic+biomarker+in+patients+with+dermatomyositis&amp;author=L.+Li&amp;author=Q.+Wang&amp;author=F.+Yang&amp;volume=8&amp;publication_year=2017&amp;pages=26552-26564&amp;pmid=28460448&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=11153190&amp;issue-id=463821&amp;journal-id=2992&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="bib19">19. <span class="element-citation" id="sref19">Zunt S.L., Burton L.V., Goldblatt L.I., et al. Soluble forms of Toll-like receptor 4 are present in human saliva and modulate tumour necrosis factor-alpha secretion by macrophage-like cells. <span><span class="ref-journal">Clin. Exp. Immunol. </span>2009;<span class="ref-vol">156</span>:285–293.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC2759477/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/19292767" ref="reftype=pubmed&amp;article-id=11153190&amp;issue-id=463821&amp;journal-id=2992&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Clin.+Exp.+Immunol.&amp;title=Soluble+forms+of+Toll-like+receptor+4+are+present+in+human+saliva+and+modulate+tumour+necrosis+factor-alpha+secretion+by+macrophage-like+cells&amp;author=S.L.+Zunt&amp;author=L.V.+Burton&amp;author=L.I.+Goldblatt&amp;volume=156&amp;publication_year=2009&amp;pages=285-293&amp;pmid=19292767&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=11153190&amp;issue-id=463821&amp;journal-id=2992&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="bib20">20. <span class="element-citation" id="sref20">Hossain M.J., Morandi E., Tanasescu R., et al. The soluble form of toll-like receptor 2 is elevated in serum of multiple sclerosis patients: a novel potential disease biomarker. <span><span class="ref-journal">Front. Immunol. </span>2018;<span class="ref-vol">9</span>:457.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC5861194/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/29593720" ref="reftype=pubmed&amp;article-id=11153190&amp;issue-id=463821&amp;journal-id=2992&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Front.+Immunol.&amp;title=The+soluble+form+of+toll-like+receptor+2+is+elevated+in+serum+of+multiple+sclerosis+patients:+a+novel+potential+disease+biomarker&amp;author=M.J.+Hossain&amp;author=E.+Morandi&amp;author=R.+Tanasescu&amp;volume=9&amp;publication_year=2018&amp;pages=457&amp;pmid=29593720&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=11153190&amp;issue-id=463821&amp;journal-id=2992&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="bib21">21. <span class="element-citation" id="sref21">Bohan A., Peter J.B. Polymyositis and dermatomyositis (first of two parts) <span><span class="ref-journal">N. Engl. J. Med. </span>1975;<span class="ref-vol">292</span>:344–347.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/1090839" ref="reftype=pubmed&amp;article-id=11153190&amp;issue-id=463821&amp;journal-id=2992&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=N.+Engl.+J.+Med.&amp;title=Polymyositis+and+dermatomyositis+(first+of+two+parts)&amp;author=A.+Bohan&amp;author=J.B.+Peter&amp;volume=292&amp;publication_year=1975&amp;pages=344-347&amp;pmid=1090839&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=11153190&amp;issue-id=463821&amp;journal-id=2992&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="bib22">22. <span class="element-citation" id="sref22">Zaizen Y., Okamoto M., Azuma K., et al. Enhanced immune complex formation in the lungs of patients with dermatomyositis. <span><span class="ref-journal">Respir. Res. </span>2023;<span class="ref-vol">24</span>:86.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC10024827/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/36934274" ref="reftype=pubmed&amp;article-id=11153190&amp;issue-id=463821&amp;journal-id=2992&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Respir.+Res.&amp;title=Enhanced+immune+complex+formation+in+the+lungs+of+patients+with+dermatomyositis&amp;author=Y.+Zaizen&amp;author=M.+Okamoto&amp;author=K.+Azuma&amp;volume=24&amp;publication_year=2023&amp;pages=86&amp;pmid=36934274&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=11153190&amp;issue-id=463821&amp;journal-id=2992&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="bib23">23. <span class="element-citation" id="sref23">Takenaka S.I., Kaieda S., Kawayama T., et al. IL-38: a new factor in rheumatoid arthritis. <span><span class="ref-journal">Biochemistry and biophysics reports. </span>2015;<span class="ref-vol">4</span>:386–391.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC5669445/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/29124228" ref="reftype=pubmed&amp;article-id=11153190&amp;issue-id=463821&amp;journal-id=2992&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Biochemistry+and+biophysics+reports&amp;title=IL-38:+a+new+factor+in+rheumatoid+arthritis&amp;author=S.I.+Takenaka&amp;author=S.+Kaieda&amp;author=T.+Kawayama&amp;volume=4&amp;publication_year=2015&amp;pages=386-391&amp;pmid=29124228&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=11153190&amp;issue-id=463821&amp;journal-id=2992&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="bib24">24. <span class="element-citation" id="sref24">Kitasato Y., Hoshino T., Okamoto M., et al. Enhanced expression of interleukin-18 and its receptor in idiopathic pulmonary fibrosis. <span><span class="ref-journal">Am. J. Respir. Cell Mol. Biol. </span>2004;<span class="ref-vol">31</span>:619–625.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/15308504" ref="reftype=pubmed&amp;article-id=11153190&amp;issue-id=463821&amp;journal-id=2992&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Am.+J.+Respir.+Cell+Mol.+Biol.&amp;title=Enhanced+expression+of+interleukin-18+and+its+receptor+in+idiopathic+pulmonary+fibrosis&amp;author=Y.+Kitasato&amp;author=T.+Hoshino&amp;author=M.+Okamoto&amp;volume=31&amp;publication_year=2004&amp;pages=619-625&amp;pmid=15308504&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=11153190&amp;issue-id=463821&amp;journal-id=2992&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="bib25">25. <span class="element-citation" id="sref25">Mizushima S., Nagata S. pEF-BOS, a powerful mammalian expression vector. <span><span class="ref-journal">Nucleic Acids Res. </span>1990;<span class="ref-vol">18</span>:5322.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC332193/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/1698283" ref="reftype=pubmed&amp;article-id=11153190&amp;issue-id=463821&amp;journal-id=2992&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Nucleic+Acids+Res.&amp;title=pEF-BOS,+a+powerful+mammalian+expression+vector&amp;author=S.+Mizushima&amp;author=S.+Nagata&amp;volume=18&amp;publication_year=1990&amp;pages=5322&amp;pmid=1698283&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=11153190&amp;issue-id=463821&amp;journal-id=2992&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="bib26">26. <span class="element-citation" id="sref26">Yoneyama M., Kikuchi M., Matsumoto K., et al. Shared and unique functions of the DExD/H-box helicases RIG-I, MDA5, and LGP2 in antiviral innate immunity. <span><span class="ref-journal">J. Immunol. </span>2005;<span class="ref-vol">175</span>:2851–2858.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/16116171" ref="reftype=pubmed&amp;article-id=11153190&amp;issue-id=463821&amp;journal-id=2992&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=J.+Immunol.&amp;title=Shared+and+unique+functions+of+the+DExD/H-box+helicases+RIG-I,+MDA5,+and+LGP2+in+antiviral+innate+immunity&amp;author=M.+Yoneyama&amp;author=M.+Kikuchi&amp;author=K.+Matsumoto&amp;volume=175&amp;publication_year=2005&amp;pages=2851-2858&amp;pmid=16116171&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=11153190&amp;issue-id=463821&amp;journal-id=2992&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="bib27">27. <span class="element-citation" id="sref27">Takenaka S., Kawayama T., Imaoka H., et al. The progression of comorbidity in IL-18 transgenic chronic obstructive pulmonary disease mice model. <span><span class="ref-journal">Biochem. Biophys. Res. Commun. </span>2014;<span class="ref-vol">445</span>:597–601.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/24565845" ref="reftype=pubmed&amp;article-id=11153190&amp;issue-id=463821&amp;journal-id=2992&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Biochem.+Biophys.+Res.+Commun.&amp;title=The+progression+of+comorbidity+in+IL-18+transgenic+chronic+obstructive+pulmonary+disease+mice+model&amp;author=S.+Takenaka&amp;author=T.+Kawayama&amp;author=H.+Imaoka&amp;volume=445&amp;publication_year=2014&amp;pages=597-601&amp;pmid=24565845&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=11153190&amp;issue-id=463821&amp;journal-id=2992&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="bib28">28. <span class="element-citation" id="sref28">Tominaga M., Okamoto M., Kawayama T., et al. Overexpression of IL-38 protein in anticancer drug-induced lung injury and acute exacerbation of idiopathic pulmonary fibrosis. <span><span class="ref-journal">Respiratory investigation. </span>2017;<span class="ref-vol">55</span>:293–299.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/28942884" ref="reftype=pubmed&amp;article-id=11153190&amp;issue-id=463821&amp;journal-id=2992&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Respiratory+investigation&amp;title=Overexpression+of+IL-38+protein+in+anticancer+drug-induced+lung+injury+and+acute+exacerbation+of+idiopathic+pulmonary+fibrosis&amp;author=M.+Tominaga&amp;author=M.+Okamoto&amp;author=T.+Kawayama&amp;volume=55&amp;publication_year=2017&amp;pages=293-299&amp;pmid=28942884&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=11153190&amp;issue-id=463821&amp;journal-id=2992&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="bib29">29. <span class="element-citation" id="sref29">Nouno T., Okamoto M., Ohnishi K., et al. Elevation of pulmonary CD163(+) and CD204(+) macrophages is associated with the clinical course of idiopathic pulmonary fibrosis patients. <span><span class="ref-journal">J. Thorac. Dis. </span>2019;<span class="ref-vol">11</span>:4005–4017.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC6790423/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/31656675" ref="reftype=pubmed&amp;article-id=11153190&amp;issue-id=463821&amp;journal-id=2992&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=J.+Thorac.+Dis.&amp;title=Elevation+of+pulmonary+CD163(+)+and+CD204(+)+macrophages+is+associated+with+the+clinical+course+of+idiopathic+pulmonary+fibrosis+patients&amp;author=T.+Nouno&amp;author=M.+Okamoto&amp;author=K.+Ohnishi&amp;volume=11&amp;publication_year=2019&amp;pages=4005-4017&amp;pmid=31656675&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=11153190&amp;issue-id=463821&amp;journal-id=2992&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="bib30">30. <span class="element-citation" id="sref30">Hageman T.S., Weis D.D. Reliable identification of significant differences in differential hydrogen exchange-mass spectrometry measurements using a hybrid significance testing approach. <span><span class="ref-journal">Anal. Chem. </span>2019;<span class="ref-vol">91</span>:8008–8016.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/31099554" ref="reftype=pubmed&amp;article-id=11153190&amp;issue-id=463821&amp;journal-id=2992&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Anal.+Chem.&amp;title=Reliable+identification+of+significant+differences+in+differential+hydrogen+exchange-mass+spectrometry+measurements+using+a+hybrid+significance+testing+approach&amp;author=T.S.+Hageman&amp;author=D.D.+Weis&amp;volume=91&amp;publication_year=2019&amp;pages=8008-8016&amp;pmid=31099554&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=11153190&amp;issue-id=463821&amp;journal-id=2992&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="bib31">31. <span class="element-citation" id="sref31">Sawada M., Kawayama T., Imaoka H., et al. IL-18 induces airway hyperresponsiveness and pulmonary inflammation via CD4+ T cell and IL-13. <span><span class="ref-journal">PLoS One. </span>2013;<span class="ref-vol">8</span></span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC3558507/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/23382928" ref="reftype=pubmed&amp;article-id=11153190&amp;issue-id=463821&amp;journal-id=2992&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=PLoS+One&amp;title=IL-18+induces+airway+hyperresponsiveness+and+pulmonary+inflammation+via+CD4++T+cell+and+IL-13&amp;author=M.+Sawada&amp;author=T.+Kawayama&amp;author=H.+Imaoka&amp;volume=8&amp;publication_year=2013&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=11153190&amp;issue-id=463821&amp;journal-id=2992&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="bib32">32. <span class="element-citation" id="sref32">Hoshino T., Winkler-Pickett R.T., Mason A.T., et al. IL-13 production by NK cells: IL-13-producing NK and T cells are present in vivo in the absence of IFN-gamma. <span><span class="ref-journal">J. Immunol. </span>1999;<span class="ref-vol">162</span>:51–59.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/9886369" ref="reftype=pubmed&amp;article-id=11153190&amp;issue-id=463821&amp;journal-id=2992&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=J.+Immunol.&amp;title=IL-13+production+by+NK+cells:+IL-13-producing+NK+and+T+cells+are+present+in+vivo+in+the+absence+of+IFN-gamma&amp;author=T.+Hoshino&amp;author=R.T.+Winkler-Pickett&amp;author=A.T.+Mason&amp;volume=162&amp;publication_year=1999&amp;pages=51-59&amp;pmid=9886369&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=11153190&amp;issue-id=463821&amp;journal-id=2992&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="bib33">33. <span class="element-citation" id="sref33">Kang D.C., Gopalkrishnan R.V., Wu Q., et al. mda-5: an interferon-inducible putative RNA helicase with double-stranded RNA-dependent ATPase activity and melanoma growth-suppressive properties. <span><span class="ref-journal">Proc. Natl. Acad. Sci. U. S. A. </span>2002;<span class="ref-vol">99</span>:637–642.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC117358/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/11805321" ref="reftype=pubmed&amp;article-id=11153190&amp;issue-id=463821&amp;journal-id=2992&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Proc.+Natl.+Acad.+Sci.+U.+S.+A.&amp;title=mda-5:+an+interferon-inducible+putative+RNA+helicase+with+double-stranded+RNA-dependent+ATPase+activity+and+melanoma+growth-suppressive+properties&amp;author=D.C.+Kang&amp;author=R.V.+Gopalkrishnan&amp;author=Q.+Wu&amp;volume=99&amp;publication_year=2002&amp;pages=637-642&amp;pmid=11805321&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=11153190&amp;issue-id=463821&amp;journal-id=2992&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="bib34">34. <span class="element-citation" id="sref34">Alexopoulou L., Holt A.C., Medzhitov R., et al. Recognition of double-stranded RNA and activation of NF-kappaB by Toll-like receptor 3. <span><span class="ref-journal">Nature. </span>2001;<span class="ref-vol">413</span>:732–738.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/11607032" ref="reftype=pubmed&amp;article-id=11153190&amp;issue-id=463821&amp;journal-id=2992&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Nature&amp;title=Recognition+of+double-stranded+RNA+and+activation+of+NF-kappaB+by+Toll-like+receptor+3&amp;author=L.+Alexopoulou&amp;author=A.C.+Holt&amp;author=R.+Medzhitov&amp;volume=413&amp;publication_year=2001&amp;pages=732-738&amp;pmid=11607032&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=11153190&amp;issue-id=463821&amp;journal-id=2992&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="bib35">35. <span class="element-citation" id="sref35">Sato S., Masui K., Nishina N., et al. Initial predictors of poor survival in myositis-associated interstitial lung disease: a multicentre cohort of 497 patients. <span><span class="ref-journal">Rheumatology. </span>2018;<span class="ref-vol">57</span>:1212–1221.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/29596687" ref="reftype=pubmed&amp;article-id=11153190&amp;issue-id=463821&amp;journal-id=2992&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Rheumatology&amp;title=Initial+predictors+of+poor+survival+in+myositis-associated+interstitial+lung+disease:+a+multicentre+cohort+of+497+patients&amp;author=S.+Sato&amp;author=K.+Masui&amp;author=N.+Nishina&amp;volume=57&amp;publication_year=2018&amp;pages=1212-1221&amp;pmid=29596687&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=11153190&amp;issue-id=463821&amp;journal-id=2992&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="bib36">36. <span class="element-citation" id="sref36">Christensen M.L., Pachman L.M., Schneiderman R., et al. Prevalence of Coxsackie B virus antibodies in patients with juvenile dermatomyositis. <span><span class="ref-journal">Arthritis Rheum. </span>1986;<span class="ref-vol">29</span>:1365–1370.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/3022759" ref="reftype=pubmed&amp;article-id=11153190&amp;issue-id=463821&amp;journal-id=2992&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Arthritis+Rheum.&amp;title=Prevalence+of+Coxsackie+B+virus+antibodies+in+patients+with+juvenile+dermatomyositis&amp;author=M.L.+Christensen&amp;author=L.M.+Pachman&amp;author=R.+Schneiderman&amp;volume=29&amp;publication_year=1986&amp;pages=1365-1370&amp;pmid=3022759&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=11153190&amp;issue-id=463821&amp;journal-id=2992&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="bib37">37. <span class="element-citation" id="sref37">Muro Y., Sugiura K., Hoshino K., et al. Epidemiologic study of clinically amyopathic dermatomyositis and anti-melanoma differentiation-associated gene 5 antibodies in central Japan. <span><span class="ref-journal">Arthritis Res. Ther. </span>2011;<span class="ref-vol">13</span>:R214.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC3334667/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/22192091" ref="reftype=pubmed&amp;article-id=11153190&amp;issue-id=463821&amp;journal-id=2992&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Arthritis+Res.+Ther.&amp;title=Epidemiologic+study+of+clinically+amyopathic+dermatomyositis+and+anti-melanoma+differentiation-associated+gene+5+antibodies+in+central+Japan&amp;author=Y.+Muro&amp;author=K.+Sugiura&amp;author=K.+Hoshino&amp;volume=13&amp;publication_year=2011&amp;pages=R214&amp;pmid=22192091&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=11153190&amp;issue-id=463821&amp;journal-id=2992&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div></div></div></div><!--post-content--><div class="courtesy-note whole_rhythm small"><hr /><div class="half_rhythm">Articles from <span class="acknowledgment-journal-title">Heliyon</span> are provided here courtesy of <strong>Elsevier</strong></div><hr /></div><div id="body-link-poppers"><span></span></div></div>
            
        </section>
    </article>
    <aside class="usa-width-one-fourth usa-layout-docs-sidenav pmc-sidebar">
         
  

<div class="scroller">

    
        <section>
                <h6>Other Formats</h6>
                <ul class="pmc-sidebar__formats">
                  <li class="pdf-link other_item"><a href="/pmc/articles/PMC11153190/pdf/main.pdf" class="int-view">PDF (2.4M)</a></li>
                </ul>
        </section>
    
    <section>
        <h6>Actions</h6>
        <ul class="pmc-sidebar__actions">
            <li>
                <button role="button" class="citation-button citation-dialog-trigger ctxp"
                        aria-label="Open dialog with citation text in different styles" data-ga-category="save_share" data-ga-action="cite" data-ga-label="open"
                        data-all-citations-url="/pmc/resources/citations/11153190/"
                        data-citation-style="nlm"
                        data-download-format-link="/pmc/resources/citations/11153190/export/"
                >
                    <span class="button-label">Cite</span>
                </button>
            </li>
            <li>
                
                    

<link type="text/css" href="ncbi-overlay-block/src/overlay-block.css">
<div class="collections-button-container" data-article-id="11153190" data-article-db="pmc">
  <button class="collections-button collections-dialog-trigger"
          aria-label="Save article in MyNCBI collections."
          data-ga-category="collections_button"
          data-ga-action="click"
          data-ga-label="collections_button"
          data-collections-open-dialog-enabled="false"
          data-collections-open-dialog-url="https://www.ncbi.nlm.nih.gov/account?back_url=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC11153190%2F%23open-collections-dialog"
          data-in-collections="false">
      <span class="button-label">Collections</span>
  </button>
  <div class="overlay" role="dialog">
  <div id="collections-action-dialog"
       class="dialog collections-dialog"
       aria-hidden="true">
    <div class="title">Add to Collections</div>
    <div class="collections-action-panel action-panel">
      


<form id="collections-action-dialog-form"
      class="collections-action-panel-form action-panel-content action-form action-panel-smaller-selectors"
      data-existing-collections-url="/pmc/list-existing-collections/"
      data-add-to-existing-collection-url="/pmc/add-to-existing-collection/"
      data-create-and-add-to-new-collection-url="/pmc/create-and-add-to-new-collection/"
      data-myncbi-max-collection-name-length="100"
      data-collections-root-url="https://www.ncbi.nlm.nih.gov/myncbi/collections/">

  <input type="hidden" name="csrfmiddlewaretoken" value="Laczk6AT4j30cAiQ07AQK7KgStPTVzUHWkgtA8DZWPNUBOJn4IZi9UvdKwpf3sXw">

  

  <div class="choice-group" role="radiogroup">
    <ul class="radio-group-items">
      <li>
        <input type="radio"
               id="collections-action-dialog-new-aside "
               class="collections-new"
               name="collections"
               value="new"
               data-ga-category="collections_button"
               data-ga-action="click"
               data-ga-label="collections_radio_new">
        <label for="collections-action-dialog-new-aside ">Create a new collection</label>
      </li>
      <li>
        <input type="radio"
               id="collections-action-dialog-existing-aside "
               class="collections-existing"
               name="collections"
               value="existing"
               checked="true"
               data-ga-category="collections_button"
               data-ga-action="click"
               data-ga-label="collections_radio_existing">
        <label for="collections-action-dialog-existing-aside ">Add to an existing collection</label>
      </li>
    </ul>
  </div>

  <div class="controls-wrapper">
    <div class="action-panel-control-wrap new-collections-controls">
      <label for="collections-action-dialog-add-to-new" class="action-panel-label required-field-asterisk">
        Name your collection:
      </label>
      <input
        type="text"
        name="add-to-new-collection"
        id="collections-action-dialog-add-to-new"
        class="collections-action-add-to-new"
        pattern="[^&quot;&amp;=&lt;&gt;/]*" title="The following characters are not allowed in the Name field: &quot;&amp;=&lt;&gt;/"
        maxlength=""
        data-ga-category="collections_button"
        data-ga-action="create_collection"
        data-ga-label="non_favorties_collection">
      <div class="collections-new-name-too-long usa-input-error-message selection-validation-message">
        Name must be less than  characters
      </div>
    </div>
    <div class="action-panel-control-wrap existing-collections-controls">
      <label for="collections-action-dialog-add-to-existing" class="action-panel-label">
        Choose a collection:
      </label>
      <select id="collections-action-dialog-add-to-existing"
              class="action-panel-selector collections-action-add-to-existing"
              data-ga-category="collections_button"
              data-ga-action="select_collection"
              data-ga-label="($('.collections-action-add-to-existing').val() === 'Favorites') ? 'Favorites' : 'non_favorites_collection'">
      </select>
      <div class="collections-retry-load-on-error usa-input-error-message selection-validation-message">
        Unable to load your collection due to an error<br>
        <a href="#">Please try again</a>
      </div>
    </div>
  </div>

  <div class="action-panel-actions">
    <button class="action-panel-submit"
            type="submit"
            data-loading-label="Adding..."
            data-pinger-ignore
            data-ga-category="collections_button"
            data-ga-action="click"
            data-ga-label="add">
      Add
    </button>
    <button class="action-panel-cancel"
            aria-label="Close 'Add to Collections' panel"
            ref="linksrc=close_collections_panel"
            aria-controls="collections-action-panel"
            aria-expanded="false"
            data-ga-category="collections_button"
            data-ga-action="click"
            data-ga-label="cancel">
      Cancel
    </button>
  </div>
</form>
    </div>
  </div>
</div>
</div>
                
            </li>

        </ul>
    </section>
    
        <section class="social-sharing">
            <h6>Share</h6>
            <ul class="pmc-sidebar__share">
                <li><a class="fa-stack fa-lg" target="_blank" rel="noopener noreferrer" role="button" href="https://twitter.com/intent/tweet?url=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC11153190%2F&amp;text=Soluble%20form%20of%20the%20MDA5%20protein%20in%20human%20sera" alt="Share on Twitter"><i class="fa fa-twitter fa-stack-1x">&#160;</i></a></li> 
<li><a class="fa-stack fa-lg" target="_blank" rel="noopener noreferrer" role="button" href="https://www.facebook.com/sharer/sharer.php?u=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC11153190%2F" alt="Share on Facebook"><i class="fa fa-facebook fa-stack-1x">&#160;</i></a></li>
                <li>
                    <div class="share-permalink">
                        <button class="trigger"  alt="Show article permalink" aria-expanded="false" aria-haspopup="true">
                            <i class="fa-stack fa-lg" >
                                <i class="fa fa-link fa-stack-1x">&nbsp;</i>
                            </i>
                        </button>
                        <div class="dropdown dropdown-container" hidden>
                              <div class="title">
                                Permalink
                              </div>
                              <div class="content">
                                  <input type="text" class="permalink-text" value="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11153190/" aria-label="Article permalink"><button class="permalink-copy-button usa-button-primary" title="Copy article permalink" data-ga-category="save_share" data-ga-action="link" data-ga-label="copy_link">
                                      <span class="button-title">Copy</span>
                                  </button>
                              </div>
                        </div>
                    </div>
                </li>
            </ul>
        </section>
    
    <section>
        <h6>RESOURCES</h6>
        <ul class="pmc-sidebar__resources">
        
            <li>
                <div class="usa-accordion">
                    <button
                            data-ga-category="resources_accordion"
                            data-ga-action="open_similar_articles"
                            data-ga-label="/pmc/articles/PMC11153190/"
                            class="usa-accordion-button"
                            aria-controls="similar-articles-accordion-aside"
                            aria-expanded="false"
                            data-action-open="open_similar_articles"
                            data-action-close="close_similar_articles"
                    >
                        Similar articles
                    </button>
                    <div
                            
                                data-source-url="/pmc/resources/similar-article-links/38845920/"
                            

                         class="usa-accordion-content pmc-sidebar__resources--citations" id="similar-articles-accordion-aside" aria-hidden="true">
                        
                    </div>
                </div>
            </li>
            <li>
                <div class="usa-accordion">
                    <button
                            data-ga-category="resources_accordion"
                            data-ga-action="open_cited_by"
                            data-ga-label="/pmc/articles/PMC11153190/"
                            class="usa-accordion-button"
                            aria-controls="cited-by-accordion-aside"
                            aria-expanded="false"
                            data-action-open="open_cited_by"
                            data-action-close="close_cited_by"
                    >
                        Cited by other articles
                    </button>
                    <div
                            
                                data-source-url="/pmc/resources/cited-by-links/38845920/"
                            
                            class="usa-accordion-content pmc-sidebar__resources--citations"
                            id="cited-by-accordion-aside"
                            aria-hidden="true"
                    >
                        
                    </div>
                </div>
            </li>
            <li>
                <div class="usa-accordion">
                    <button
                            data-ga-category="resources_accordion"
                            data-ga-action="open_NCBI_links"
                            data-ga-label="/pmc/articles/PMC11153190/"
                            class="usa-accordion-button"
                            aria-controls="links-accordion-aside"
                            aria-expanded="false"
                            data-action-open="open_NCBI_links"
                            data-action-close="close_NCBI_link"
                    >
                        Links to NCBI Databases
                    </button>
                    <div data-source-url="/pmc/resources/db-links/11153190/" class="usa-accordion-content" id="links-accordion-aside" aria-hidden="true"></div>
                </div>
            </li>

            
        
        </ul>
    </section>

 </div>

    </aside>
</main>

    <div class="overlay" role="dialog" aria-label="Citation Dialog">
  <div class="dialog citation-dialog">
    <button class="close-overlay" tabindex="1">[x]</button>
    <div class="title">Cite</div>
    <div class="citation-text-block">
  <div class="citation-text"></div>
  <div class="citation-actions">
    <button
      class="copy-button dialog-focus"
      data-ga-category="save_share"
      data-ga-action="cite"
      data-ga-label="copy"
      tabindex="2">
      Copy
    </button>

      <a href="#"
              class="export-button"
              data-ga-category="save_share"
              data-ga-action="cite"
              data-ga-label="download"
              title="Download a file for external citation management software"
              tabindex="3">
          <span class="title">Download .nbib</span>
          <span class="title-mobile">.nbib</span>
      </a>


    

<div class="citation-style-selector-wrapper">
  <label class="selector-label">Format:</label>
  <select aria-label="Format" class="citation-style-selector" tabindex="4" >
    
      <option data-style-url-name="ama"
              value="AMA"
              >
        AMA
      </option>
    
      <option data-style-url-name="apa"
              value="APA"
              >
        APA
      </option>
    
      <option data-style-url-name="mla"
              value="MLA"
              >
        MLA
      </option>
    
      <option data-style-url-name="nlm"
              value="NLM"
              selected="selected">
        NLM
      </option>
    
  </select>
</div>
  </div>
</div>
  </div>
</div>

     <!-- ========== BEGIN FOOTER ========== -->
 <footer>
      <section class="icon-section">
        <div id="icon-section-header" class="icon-section_header">Follow NCBI</div>
        <div class="grid-container container">
          <div class="icon-section_container">
            <a class="footer-icon" id="footer_twitter" href="https://twitter.com/ncbi" aria-label="Twitter"><svg
                data-name="Layer 1" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 300 300">
                <defs>
                  <style>
                    .cls-11 {
                      fill: #737373;
                    }
                  </style>
                </defs>
                <title>Twitter</title>
                <path class="cls-11"
                  d="M250.11,105.48c-7,3.14-13,3.25-19.27.14,8.12-4.86,8.49-8.27,11.43-17.46a78.8,78.8,0,0,1-25,9.55,39.35,39.35,0,0,0-67,35.85,111.6,111.6,0,0,1-81-41.08A39.37,39.37,0,0,0,81.47,145a39.08,39.08,0,0,1-17.8-4.92c0,.17,0,.33,0,.5a39.32,39.32,0,0,0,31.53,38.54,39.26,39.26,0,0,1-17.75.68,39.37,39.37,0,0,0,36.72,27.3A79.07,79.07,0,0,1,56,223.34,111.31,111.31,0,0,0,116.22,241c72.3,0,111.83-59.9,111.83-111.84,0-1.71,0-3.4-.1-5.09C235.62,118.54,244.84,113.37,250.11,105.48Z">
                </path>
              </svg></a>
            <a class="footer-icon" id="footer_facebook" href="https://www.facebook.com/ncbi.nlm" aria-label="Facebook"><svg
                data-name="Layer 1" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 300 300">
                <title>Facebook</title>
                <path class="cls-11"
                  d="M210.5,115.12H171.74V97.82c0-8.14,5.39-10,9.19-10h27.14V52l-39.32-.12c-35.66,0-42.42,26.68-42.42,43.77v19.48H99.09v36.32h27.24v109h45.41v-109h35Z">
                </path>
              </svg></a>
            <a class="footer-icon" id="footer_linkedin"
              href="https://www.linkedin.com/company/ncbinlm"
              aria-label="LinkedIn"><svg data-name="Layer 1" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 300 300">
                <title>LinkedIn</title>
                <path class="cls-11"
                  d="M101.64,243.37H57.79v-114h43.85Zm-22-131.54h-.26c-13.25,0-21.82-10.36-21.82-21.76,0-11.65,8.84-21.15,22.33-21.15S101.7,78.72,102,90.38C102,101.77,93.4,111.83,79.63,111.83Zm100.93,52.61A17.54,17.54,0,0,0,163,182v61.39H119.18s.51-105.23,0-114H163v13a54.33,54.33,0,0,1,34.54-12.66c26,0,44.39,18.8,44.39,55.29v58.35H198.1V182A17.54,17.54,0,0,0,180.56,164.44Z">
                </path>
              </svg></a>
            <a class="footer-icon" id="footer_github" href="https://github.com/ncbi" aria-label="GitHub"><svg
                data-name="Layer 1" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 300 300">
                <defs>
                  <style>
                    .cls-11,
                    .cls-12 {
                      fill: #737373;
                    }

                    .cls-11 {
                      fill-rule: evenodd;
                    }
                  </style>
                </defs>
                <title>GitHub</title>
                <path class="cls-11"
                  d="M151.36,47.28a105.76,105.76,0,0,0-33.43,206.1c5.28,1,7.22-2.3,7.22-5.09,0-2.52-.09-10.85-.14-19.69-29.42,6.4-35.63-12.48-35.63-12.48-4.81-12.22-11.74-15.47-11.74-15.47-9.59-6.56.73-6.43.73-6.43,10.61.75,16.21,10.9,16.21,10.9,9.43,16.17,24.73,11.49,30.77,8.79,1-6.83,3.69-11.5,6.71-14.14C108.57,197.1,83.88,188,83.88,147.51a40.92,40.92,0,0,1,10.9-28.39c-1.1-2.66-4.72-13.42,1-28,0,0,8.88-2.84,29.09,10.84a100.26,100.26,0,0,1,53,0C198,88.3,206.9,91.14,206.9,91.14c5.76,14.56,2.14,25.32,1,28a40.87,40.87,0,0,1,10.89,28.39c0,40.62-24.74,49.56-48.29,52.18,3.79,3.28,7.17,9.71,7.17,19.58,0,14.15-.12,25.54-.12,29,0,2.82,1.9,6.11,7.26,5.07A105.76,105.76,0,0,0,151.36,47.28Z">
                </path>
                <path class="cls-12"
                  d="M85.66,199.12c-.23.52-1.06.68-1.81.32s-1.2-1.06-.95-1.59,1.06-.69,1.82-.33,1.21,1.07.94,1.6Zm-1.3-1">
                </path>
                <path class="cls-12"
                  d="M90,203.89c-.51.47-1.49.25-2.16-.49a1.61,1.61,0,0,1-.31-2.19c.52-.47,1.47-.25,2.17.49s.82,1.72.3,2.19Zm-1-1.08">
                </path>
                <path class="cls-12"
                  d="M94.12,210c-.65.46-1.71,0-2.37-.91s-.64-2.07,0-2.52,1.7,0,2.36.89.65,2.08,0,2.54Zm0,0"></path>
                <path class="cls-12"
                  d="M99.83,215.87c-.58.64-1.82.47-2.72-.41s-1.18-2.06-.6-2.7,1.83-.46,2.74.41,1.2,2.07.58,2.7Zm0,0">
                </path>
                <path class="cls-12"
                  d="M107.71,219.29c-.26.82-1.45,1.2-2.64.85s-2-1.34-1.74-2.17,1.44-1.23,2.65-.85,2,1.32,1.73,2.17Zm0,0">
                </path>
                <path class="cls-12"
                  d="M116.36,219.92c0,.87-1,1.59-2.24,1.61s-2.29-.68-2.3-1.54,1-1.59,2.26-1.61,2.28.67,2.28,1.54Zm0,0">
                </path>
                <path class="cls-12"
                  d="M124.42,218.55c.15.85-.73,1.72-2,1.95s-2.37-.3-2.52-1.14.73-1.75,2-2,2.37.29,2.53,1.16Zm0,0"></path>
              </svg></a>
            <a class="footer-icon" id="footer_blog" href="https://ncbiinsights.ncbi.nlm.nih.gov/" aria-label="Blog">
              <svg id="Layer_1" data-name="Layer 1" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 40 40"><defs><style>.cls-1{fill:#737373;}</style></defs><path class="cls-1" d="M14,30a4,4,0,1,1-4-4,4,4,0,0,1,4,4Zm11,3A19,19,0,0,0,7.05,15a1,1,0,0,0-1,1v3a1,1,0,0,0,.93,1A14,14,0,0,1,20,33.07,1,1,0,0,0,21,34h3a1,1,0,0,0,1-1Zm9,0A28,28,0,0,0,7,6,1,1,0,0,0,6,7v3a1,1,0,0,0,1,1A23,23,0,0,1,29,33a1,1,0,0,0,1,1h3A1,1,0,0,0,34,33Z"/></svg>
            </a>
          </div>
        </div>
      </section>

      <section class="container-fluid bg-primary">
        <div class="container pt-5">
          <div class="row mt-3">
            <div class="col-lg-3 col-12">
              <p><a class="text-white" href="https://www.nlm.nih.gov/socialmedia/index.html">Connect with NLM</a></p>
              <ul class="list-inline social_media">
                <li class="list-inline-item"><a href="https://twitter.com/NLM_NIH" aria-label="Twitter"
                    target="_blank" rel="noopener noreferrer"><svg version="1.1" xmlns="http://www.w3.org/2000/svg"
                      xmlns:xlink="http://www.w3.org/1999/xlink" x="0px" y="0px" viewBox="0 0 249 249"
                      style="enable-background:new 0 0 249 249;" xml:space="preserve">
                      <style type="text/css">
                        .st20 {
                          fill: #FFFFFF;
                        }

                        .st30 {
                          fill: none;
                          stroke: #FFFFFF;
                          stroke-width: 8;
                          stroke-miterlimit: 10;
                        }
                      </style>
                      <title>SM-Twitter</title>
                      <g>
                        <g>
                          <g>
                            <path class="st20" d="M192.9,88.1c-5,2.2-9.2,2.3-13.6,0.1c5.7-3.4,6-5.8,8.1-12.3c-5.4,3.2-11.4,5.5-17.6,6.7
                                                c-10.5-11.2-28.1-11.7-39.2-1.2c-7.2,6.8-10.2,16.9-8,26.5c-22.3-1.1-43.1-11.7-57.2-29C58,91.6,61.8,107.9,74,116
                                                c-4.4-0.1-8.7-1.3-12.6-3.4c0,0.1,0,0.2,0,0.4c0,13.2,9.3,24.6,22.3,27.2c-4.1,1.1-8.4,1.3-12.5,0.5c3.6,11.3,14,19,25.9,19.3
                                                c-11.6,9.1-26.4,13.2-41.1,11.5c12.7,8.1,27.4,12.5,42.5,12.5c51,0,78.9-42.2,78.9-78.9c0-1.2,0-2.4-0.1-3.6
                                                C182.7,97.4,189.2,93.7,192.9,88.1z"></path>
                          </g>
                        </g>
                        <circle class="st30" cx="124.4" cy="128.8" r="108.2"></circle>
                      </g>
                    </svg></a></li>
                <li class="list-inline-item"><a href="https://www.facebook.com/nationallibraryofmedicine"
                    aria-label="Facebook" rel="noopener noreferrer" target="_blank">
                    <svg version="1.1" xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink" x="0px"
                      y="0px" viewBox="0 0 249 249" style="enable-background:new 0 0 249 249;" xml:space="preserve">
                      <style type="text/css">
                        .st10 {
                          fill: #FFFFFF;
                        }

                        .st110 {
                          fill: none;
                          stroke: #FFFFFF;
                          stroke-width: 8;
                          stroke-miterlimit: 10;
                        }
                      </style>
                      <title>SM-Facebook</title>
                      <g>
                        <g>
                          <path class="st10" d="M159,99.1h-24V88.4c0-5,3.3-6.2,5.7-6.2h16.8V60l-24.4-0.1c-22.1,0-26.2,16.5-26.2,27.1v12.1H90v22.5h16.9
                                                      v67.5H135v-67.5h21.7L159,99.1z"></path>
                        </g>
                      </g>
                      <circle class="st110" cx="123.6" cy="123.2" r="108.2"></circle>
                    </svg>
                  </a></li>
                <li class="list-inline-item"><a href="https://www.youtube.com/user/NLMNIH" aria-label="Youtube"
                    target="_blank" rel="noopener noreferrer"><svg version="1.1" xmlns="http://www.w3.org/2000/svg"
                      xmlns:xlink="http://www.w3.org/1999/xlink" x="0px" y="0px" viewBox="0 0 249 249"
                      style="enable-background:new 0 0 249 249;" xml:space="preserve">
                      <title>SM-Youtube</title>
                      <style type="text/css">
                        .st4 {
                          fill: none;
                          stroke: #FFFFFF;
                          stroke-width: 8;
                          stroke-miterlimit: 10;
                        }

                        .st5 {
                          fill: #FFFFFF;
                        }
                      </style>
                      <circle class="st4" cx="124.2" cy="123.4" r="108.2"></circle>
                      <g transform="translate(0,-952.36218)">
                        <path class="st5"
                          d="M88.4,1037.4c-10.4,0-18.7,8.3-18.7,18.7v40.1c0,10.4,8.3,18.7,18.7,18.7h72.1c10.4,0,18.7-8.3,18.7-18.7
                                            v-40.1c0-10.4-8.3-18.7-18.7-18.7H88.4z M115.2,1058.8l29.4,17.4l-29.4,17.4V1058.8z"></path>
                      </g>
                    </svg></a></li>
              </ul>
            </div>
            <div class="col-lg-3 col-12">
              <p class="address_footer text-white">National Library of Medicine<br>
                <a href="https://www.google.com/maps/place/8600+Rockville+Pike,+Bethesda,+MD+20894/@38.9959508,-77.101021,17z/data=!3m1!4b1!4m5!3m4!1s0x89b7c95e25765ddb:0x19156f88b27635b8!8m2!3d38.9959508!4d-77.0988323"
                  class="text-white" target="_blank" rel="noopener noreferrer">8600 Rockville Pike<br>
                  Bethesda, MD 20894</a></p>
            </div>
            <div class="col-lg-3 col-12 centered-lg">
              <p><a href="https://www.nlm.nih.gov/web_policies.html" class="text-white">Web Policies</a><br>
                <a href="https://www.nih.gov/institutes-nih/nih-office-director/office-communications-public-liaison/freedom-information-act-office"
                  class="text-white">FOIA</a><br>
                <a href="https://www.hhs.gov/vulnerability-disclosure-policy/index.html" class="text-white" id="vdp">HHS Vulnerability Disclosure</a></p>
            </div>
            <div class="col-lg-3 col-12 centered-lg">
              <p><a class="supportLink text-white" href="https://support.nlm.nih.gov/">Help</a><br>
                <a href="https://www.nlm.nih.gov/accessibility.html" class="text-white">Accessibility</a><br>
                <a href="https://www.nlm.nih.gov/careers/careers.html" class="text-white">Careers</a></p>
            </div>
          </div>
          <div class="row">
            <div class="col-lg-12 centered-lg">
              <nav class="bottom-links">
                <ul class="mt-3">
                  <li>
                    <a class="text-white" href="//www.nlm.nih.gov/">NLM</a>
                  </li>
                  <li>
                    <a class="text-white"
                  href="https://www.nih.gov/">NIH</a>
                  </li>
                  <li>
                    <a class="text-white" href="https://www.hhs.gov/">HHS</a>
                  </li>
                  <li>
                    <a
                  class="text-white" href="https://www.usa.gov/">USA.gov</a>
                  </li>
                </ul>
              </nav>
            </div>
          </div>
        </div>
      </section>
    </footer>
 <!-- ========== END FOOTER ========== -->
  <!-- javascript to inject NWDS meta tags. Note: value of nwds_version is updated by "npm version" command -->
 
  <script type="text/javascript">
    var nwds_version = "1.1.9-2";

    var meta_nwds_ver = document.createElement('meta');
    meta_nwds_ver.name = 'ncbi_nwds_ver';
    meta_nwds_ver.content = nwds_version;
    document.getElementsByTagName('head')[0].appendChild(meta_nwds_ver);

    var meta_nwds = document.createElement('meta');
    meta_nwds.name = 'ncbi_nwds';
    meta_nwds.content = 'yes';
    document.getElementsByTagName('head')[0].appendChild(meta_nwds);

	var alertsUrl = "/core/alerts/alerts.js";
	if (typeof ncbiBaseUrl !== 'undefined') {
		alertsUrl = ncbiBaseUrl + alertsUrl;
	}
  </script>



  
    <!-- JavaScript -->
    <script src="/pmc/static/CACHE/js/output.0f72d6a64937.js"></script>
  
  
    <script src="https://code.jquery.com/jquery-3.5.0.min.js"
          integrity="sha256-xNzN2a4ltkB44Mc/Jz3pT4iU1cmeR0FkXs4pru/JxaQ="
          crossorigin="anonymous">
    </script>
    <script>
        var fallbackJquery = "/pmc/static/base/js/jquery-3.5.0.min.js";
        window.jQuery || document.write("<script src=" + fallbackJquery + ">\x3C/script>")
    </script>
  

  <script src="/pmc/static/CACHE/js/output.a212a9fcf845.js"></script>
<script src="/pmc/static/CACHE/js/output.7999321d1aac.js"></script>
<script src="/pmc/static/CACHE/js/output.7ca436b2ea51.js"></script>
<script src="/pmc/static/CACHE/js/output.f8422046fbe0.js"></script>
<script src="/pmc/static/CACHE/js/output.ff40c7d85ff8.js"></script>
<script src="/pmc/static/CACHE/js/output.a6a84a0ad361.js"></script>

<script type="text/javascript" src="/pmc/static/bundles/base/base.038d36e4e31104b40a19.js" ></script>

    <script type="text/javascript">
        if(typeof jQuery !=='undefined') {
            jQuery.migrateMute = true;
        }
    </script>
    <script type="text/javascript" src="https://code.jquery.com/jquery-migrate-1.4.1.js"></script>
    <script type="text/javascript" src="/core/jig/1.15.2/js/jig.nojquery.min.js">//</script><script type="text/javascript" src="/corehtml/pmc/js/common.min.js?_=3.18">//</script><script type="text/javascript" src="/corehtml/pmc/js/NcbiTagServer.min.js?_=3.18">//</script><script type="text/javascript" src="/corehtml/pmc/js/crb.min.js?_=3.18">//</script><script type="text/javascript" src="/corehtml/pmc/js/jactions.min.js?_=3.18">//</script><script type="text/javascript" src="/core/mathjax/2.7.9/MathJax.js?config=/corehtml/pmc/js/mathjax-config-classic.3.4.js"></script><script type="text/javascript">window.name="mainwindow";</script>

    <script type="text/javascript">var exports = {};</script>
    <script src="/pmc/static/CACHE/js/output.340a3b9cce7f.js"></script>
<script src="/pmc/static/CACHE/js/output.228f96f3298e.js"></script>
    <script type="text/javascript" src="/pmc/static/bundles/article/article.b7dd20e527283dd68f45.js" ></script>
    <script type="text/javascript">
        window.ncbi.pmc.articlePage.init({ pageURL: '/pmc/articles/PMC11153190/', citeCookieName: 'pmc-cf'});
    </script>


  
  
  <script  type="text/javascript" src="https://www.ncbi.nlm.nih.gov/core/pinger/pinger.js"> </script>


  
      
  

</body>
</html>
